Annual report 2021  
Allergy solutions  
for life  
ALK-Abelló A/S  
Bøge Allé 6-8  
DK-2970 Hørsholm  
Denmark  
CVR no. 63 71 79 16  
 
Management’s review  
Annual report 2021  
ALK  
2
Table of contents  
Management’s review  
Financial statements  
Introduction  
Statements  
4
7
8
9
Letter from the Chairman and CEO  
ALK at a glance  
2021: Highlights of the year  
2022 outlook  
46 Statement by Management  
on the annual report  
47 Independent auditor’s report  
Consolidated financial statements  
52 Income statement  
Performance  
13 Financial highlights and key ratios  
14 Sales and market trends  
16 Financial review of 2021  
18 Q4 review  
52 Statement of comprehensive income  
53 Cash flow statement  
54 Balance sheet  
55 Statement of changes in equity  
56 Notes  
20 Sustainability  
Tablet sales up  
Strategy  
Parent company financial statements  
92 Income statement  
93 Balance sheet  
94 Statement of changes in equity  
95 Notes  
29%  
24 Strategy progress  
30 ALK’s business model  
Tablet sales grew by 29%  
in 2021  
Corporate matters  
32 Governance and ownership  
40 Risk management  
42 Board of Directors  
Revenue up  
103 Financial highlights by quarter  
Cover picture: ALK has begun  
developing an allergy immunotherapy  
tablet for potentially life-threatening  
peanut allergy.  
12%  
44 Board of Management  
Revenue grew by 12%  
to DKKm 3,916 in 2021  
 
 
Management’s review  
Annual report 2021  
ALK  
3
At the start of a complex  
manufacturing process,  
ALK turns peanut kernels  
into a powder to be used  
as a source material for the  
peanut tablets.  
Introduction  
4 Letter from the Chairman and CEO  
7 ALK at a glance  
8 2021: Highlights of the year  
9 2022 outlook  
   
 
Management’s review  
Annual report 2021  
ALK  
4
Letter from the Chairman and CEO  
ALK is growing fast and is  
on course to deliver long-  
currency to DKK 534 million, driven by  
higher sales, margin improvements, and  
efficiencies.  
8-12% organically, and increased  
operating profit (EBITDA). This is expected  
despite extraordinarily high R&D costs,  
and the support for new, short-term  
growth initiatives, such as ramping up in  
China and digital consumer activities, plus  
longer-term growth initiatives such as an  
entry into food allergy, developing a new  
adrenaline auto-injector, and the pursuit  
of paediatric indications for the tablets.  
COVID, unfortunately, will most likely  
remain a factor in the year ahead, and  
may cause short-term fluctuations in sales  
in some markets, but overall, we expect  
to continue to withstand this ongoing  
challenge.  
term, continuous growth with  
improving profitability, while also  
investing in, and executing, new  
projects and activities to deliver  
an EBIT in the range of 25% while  
safeguarding, and potentially  
accelerating growth, from 2025  
onwards.  
Throughout the year, COVID still impacted  
the lives of millions around the world,  
and ALK continued to prioritise the safety  
and well-being of its staff, as well as the  
supply of products for doctors and their  
patients. Despite some challenges – for  
example, schedules for certain clinical  
trials had to be revised – the pandemic  
proved manageable for ALK, not least due  
to the hard work of our employees and  
their flexibility in accommodating changes  
in working practices. Thanks in part to  
these efforts, our supply chain, inventories  
and distribution remained resilient to the  
raw materials and logistical challenges  
reported by multiple industries.  
ALK maintained its  
progress towards  
continuous growth and  
improved profitability as we  
In 2021, ALK maintained its progress  
towards continuous growth and improved  
profitability as we successfully executed  
on our strategic priorities. Revenue grew  
by 12% on broad-based growth across  
all three sales regions, with tablets being  
the key driver of growth. Operating profit  
(EBITDA) increased by 35% in reported  
successfully executed on our  
strategic priorities.  
Employee engagement and retention  
remain important areas of focus for us.  
Over the past year, ALK has implemented  
programmes to support engagement and  
retention, promote talent identification  
and development, and to develop our  
Continues  
Anders Hedegaard,  
Chairman of the Board  
In 2022, we expect continued progress  
with full-year revenue forecast to grow  
 
 
Management’s review  
Annual report 2021  
ALK  
5
depth and breadth in existing and new  
markets – via consumer engagement and  
new digital models, new channels, market  
share gains and additional registrations.  
At the same time, we will manage our  
legacy portfolio of SCIT and SLIT-drops  
products to further support overall growth.  
Europe and North America. To illustrate  
the importance of this, the vast majority  
of SLIT-tablet patients in the fast-growing  
market of Japan are currently under 18  
years. That’s probably because parents,  
who may play down their own allergies and  
suffer in silence, are much more proactive  
when it comes to seeking treatment for  
their children.  
leaders. The 2021 employee engagement  
survey registered scores that were above  
the healthcare industry average and  
we are striving to further improve the  
attractiveness of working at ALK, using the  
valuable input from our employees, so we  
can continue to recruit and retain skilled  
employees.  
In the process, we expect gross margins  
to gradually improve, while capacity costs  
relative to revenue will decrease from  
2023, once we have completed large-  
scale clinical development work on the  
respiratory tablets.  
In addition, we continued to take steps on  
our sustainability journey, by ensuring that  
this priority becomes an integrated part of  
our overall business strategy.  
The second opportunity is China, which  
is already one of the world’s largest  
markets for house dust mite allergy  
immunotherapy (AIT) and has the potential  
to become significantly larger. Right now,  
we are expanding our salesforce and  
strengthening market access activities  
with the aim of speeding up the adoption  
of our existing AIT offering. This is so we  
can build the allergy treatment market  
ahead of a planned introduction of  
Maintaining growth and improving  
profitability  
Safeguarding and, potentially,  
accelerating growth  
e pandemic proved  
manageable for ALK,  
Our ambition remains to deliver organic  
growth of 10% or more annually, and to  
ramp up profitability to an EBIT-margin of  
around 25% in 2025. We believe that these  
are realistic ambitions given the market  
potential, the business transformation  
we have delivered, and the unwavering  
commitment of everyone at ALK to deliver  
on the promises we have made.  
While we remain committed to delivering  
on our promises, we are also, as previously  
mentioned, investing to accelerate growth  
beyond 2025. That’s why we are already  
funding a number of high potential growth  
accelerators, which look many years  
beyond 2025.  
not least due to the hard work  
of our employees.  
ACARIZAX® which, subject to approval,  
is targeted for 2025. Meanwhile, our new  
Jext® partnership with Grandpharma will  
further widen our footprint in China.  
Carsten Hellmann,  
President & CEO  
The first of these is children. In 2023,  
we expect to complete our paediatric  
clinical trials in house dust mite and tree  
pollen allergic rhinitis, which should open  
the door to full paediatric coverage in  
Thirdly, we want to enter the market for  
adrenaline auto-injectors in the USA  
with an affordable, competitive, next-  
Continues  
Tablets, which already account for 45% of  
ALK’s total revenue, will still be the main  
growth engine, and we aim to continue  
their momentum by expanding prescriber  
 
Management’s review  
Annual report 2021  
ALK  
6
generation product. To achieve this, we  
have two development programmes – an  
external project with Windgap Medical  
and an in-house project, with the aim of  
submitting a regulatory filing to the FDA by  
2024.  
Dedicated to allergy solutions for life  
In closing, we would like to thank ALK’s  
employees for their continuing efforts and  
their tireless commitment to providing  
allergy solutions for life. Their dedication  
and discipline are what allow us to deliver  
on the ambitious targets we have set,  
and to help as many allergy sufferers as  
possible. Special thanks are also due to  
our partners, without whom we could  
not succeed, and to the patients and  
prescribers who place their trust in us – a  
trust we never take for granted and work  
hard every day to maintain.  
Finally, we want to develop a new,  
mainstream treatment for food allergy.  
In 2021, we completed a feasibility  
study confirming that ALK’s current  
tablet technology is suitable for this  
project, and we plan to start Phase I  
clinical development in 2022 with an  
initial project for peanut allergy. With  
very limited treatment options available  
for this potentially life-threatening  
allergic condition, we believe this move  
is an important step towards fulfilling our  
promise of becoming the allergy company.  
Last, but not least, we would like to thank  
our shareholders. As ALK’s financial  
performance continues to improve  
towards our targets, we look forward to  
rewarding them through continued, long-  
term value creation.  
Each of these potential accelerators is  
being pursued at full speed and, if we can  
repeat our recent successes, they will help  
to establish a much larger and stronger  
ALK, capable of continuously generating  
attractive shareholder returns for many  
years to come.  
Anders Hedegaard  
Chairman of the Board  
Peanut drug substance samples are analysed in  
our state-of-the-art laboratories using high-  
performance liquid chromatography, whereby  
chromatograms show visualisations of the peanut  
drug substance alongside other allergens.  
Carsten Hellmann  
President & CEO  
 
Management’s review  
Annual report 2021  
ALK  
7
ALK at a glance  
ALK key figures  
Global presence  
ALK is a global allergy solutions company with a wide range of  
treatments, products and services to meet the unique needs  
of allergy sufferers, their families and doctors. Headquartered  
in Hørsholm, Denmark, the company is listed on Nasdaq  
Copenhagen (ALKB:DC/OMX: ALK B)  
North America  
Revenue  
17%  
Europe  
Revenue  
72%  
11%  
International  
markets  
Revenue  
Established:  
Employees:  
1923  
~2,600  
Markets with  
ALK presence:  
Patients in treatment  
with ALK products*:  
Development in revenue (DKKbn)  
SLIT-tablets (% growth in local currencies)  
SCIT/SLIT-drops  
Production sites  
ALK’s unique manufacturing  
processes ensure its products  
meet required quality  
standards and represent a  
significant barrier to potential  
competitors, making them  
an important factor in  
maintaining ALK’s market  
position  
3.9  
3.5  
47  
~2.1m  
3.3  
Other  
2.9  
2.9  
+29%  
+42%  
+45%  
+8%  
+28%  
Number of most common  
respiratory allergies  
Participated in clinical  
trials for the tablets:  
covered by ALK's tablets:  
>24,000  
5
2017  
2018  
2019  
2020  
2021  
* Covering AIT and/or adrenaline  
 
 
Management’s review  
Annual report 2021  
ALK  
8
2021: Highlights of the year  
Sustainability  
highlights 2021  
July  
ALK and  
Grandpharma team  
up to market the first  
adrenaline auto-  
injector in China  
April  
November  
Approval for  
paediatric use of the  
ragweed-tablet in  
the USA  
Diagnostics, allergy immunotherapy  
and/or adrenaline products made  
accessible to +100,000 additional  
patients  
Q3: Revenue up  
20% with tablet  
sales up 41%  
December  
Data from ALK’s real-world  
evidence activities published  
in The Lancet Regional  
Health – Europe  
February  
October  
ALK completes its  
three-year transformation  
and updates its strategy,  
including decision to enter  
food allergy  
Key approval in  
Europe for SCIT  
manufacturing  
June  
Employee  
engagement score  
above industry  
benchmark based on  
93% participation  
CO2 emissions from production  
reduced by 42% compared to the  
2019 baseline  
November  
Formulation  
feasibility study  
optimisation effort  
completed for peanut  
allergy product  
August  
December  
Q2: Revenue up  
13% with tablet  
sales up 23%  
Full-year 2021:  
Revenue up 12%,  
tablet sales up 29%,  
EBITDA up 35% in  
reported currency  
May  
First recyclable packaging solution  
for OSIRIS®, has a carbon footprint  
19 times lower than before  
Q1: Revenue up  
9% with tablet  
sales up 32%  
50% of waste reused or recycled,  
up from 38%  
Women made up 49%  
of all managers, up from 46%  
 
 
Management’s review  
Annual report 2021  
ALK  
9
2022 outlook  
2022 targets  
ALK expects growth across  
all sales regions in 2022, with  
revenue projected to increase  
by 8-12% organically in local  
currencies, and the tablet portfolio  
expected to remain the key growth  
driver.  
(2021: 534), reflecting revenue growth  
and an improved gross margin, both  
attributable to tablet sales growth, as well  
as efficiencies.  
sales in Europe will increase in single digits  
whereas sales growth in North America  
is expected at around 10% and growth  
in International markets is expected to  
exceed 10%. However, in absolute terms,  
the majority of growth is expected to come  
from Europe.  
Revenue  
8-12%  
growth  
Growth across all sales regions  
The COVID pandemic continues to cause a  
degree of uncertainty regarding capacity  
at allergy clinics and patients’ behaviour,  
which may lead to some volatility in the  
quarterly results.  
(2021: DKK 3,916 million)  
Tablets, ALK’s single largest product  
category, will remain key to growth in  
2022. ALK plans for strong tablet sales  
growth across its regions and estimates  
global tablet sales growth of around 20%  
in 2022, with double-digit growth across  
all three sales regions, led by market share  
Continues  
EBITDA  
DKK  
(Revenue growth rates are stated in local  
currencies, unless otherwise indicated)  
Revenue  
The growth, projected at 8-12% in local  
currencies, is expected to be broad-based  
across all sales regions. The mid-point of  
the projected revenue range assumes that  
625-725  
million  
Operating profit (EBITDA) is expected  
to increase to DKK 625-725 million  
Operating profit (EBITDA)  
DKK ~50 million increase in R&D costs  
(2021: DKK 534 million)  
Forward-looking statements  
This report contains forward-looking statements, including forecasts of future revenue, operating profit and cash flow, as well as expected business-related  
events. Such statements are, by their very nature, subject to risks and uncertainties, as various factors, some of which are beyond the control of ALK, may cause  
actual results and performance to differ materially from the forecasts made in this report. Without being exhaustive, such factors include, e.g., consequences of  
the global COVID pandemic, general economic and business-related conditions, including: legal issues, uncertainty relating to demand, pricing, reimbursement  
rules, partners’ plans and forecasts, fluctuations in exchange rates, competitive factors and reliance on suppliers. Additional factors include the risks associated  
with the sourcing and manufacturing of ALK’s products, as well as the potential for side effects from the use of ALK’s existing and future products, as allergy  
immunotherapy may be associated with allergic reactions of differing extents, durations and severities.  
 
 
Management’s review  
Annual report 2021  
ALK  
10  
gains and market expansion, particularly  
in central and northern Europe, and Japan.  
with the increased sales and efficiencies  
that come from utilising higher-volume  
production lines – are expected to lead to  
long-term margin improvements.  
In addition, ALK expects low single-digit  
sales growth from the remaining, non-  
tablet portfolio, mainly driven by SCIT  
products and the adrenaline auto-injector,  
Jext®.  
Operating profit  
As previously stated, capacity costs will  
be influenced by a planned increase in  
R&D expenses in order to complete the  
clinical development of the respiratory  
tablet portfolio, gather further evidence  
for the tablets’ use in children, secure  
tablet registrations in new geographies  
and progress the food AIT programme into  
clinical development. R&D costs for 2022  
are estimated at around DKK 650-700  
million, roughly a DKK 50 million increase  
over 2021. The increase mainly relates to  
activities that were originally scheduled for  
2020-21 but were postponed due to the  
impact of COVID on patient recruitment for  
clinical trials.  
The higher end of the projected revenue  
range assumes accelerated sales growth  
across all regions with tablets leading  
the way and faster market share gains,  
supported by continuing regulatory  
impetus towards evidence-based allergy  
immunotherapy (AIT) products in key  
markets. The lower end of the revenue  
range incorporates pricing pressures,  
particularly in selected markets in Europe,  
and/or more pronounced, negative effects  
from COVID.  
Our industry-leading project  
teams meet regularly to  
brainstorm, share ideas, and  
discuss results – an essential  
part of the peanut tablet  
development project.  
Margins  
The gross margin is expected to improve  
by 1-2 percentage points on 61% in 2021,  
driven by efficiencies and higher sales  
– especially from tablets, with higher  
volumes absorbed by existing capacity.  
ALK will continue to allocate resources  
to the execution of its product and site  
strategy. These activities – in combination  
Sales and marketing costs are expected  
to increase, although the ratio to revenue  
is expected to improve slightly versus  
2021. The expected increase reflects  
investments in current and future growth  
drivers, including additional investments  
to expand in China, further consumer-to-  
Continues  
 
Management’s review  
Annual report 2021  
ALK  
11  
patient initiatives and early preparations  
for future paediatric tablet launches. ALK  
will continue to seek to leverage its existing  
sales and marketing platforms to drive  
underlying margin improvement.  
projected at around DKK 400 million,  
with investments focused on supporting  
long-term growth ambitions relating  
to tablets and adrenaline auto-  
injectors, the further streamlining and  
specialisation of production facilities,  
as well as IT upgrades. Free cash flow  
is expected to be negative, mainly due  
to changes in working capital, including  
a one-off repayment of up to DKK 175  
million in accrued rebates, originally  
anticipated as due for payment in 2021.  
On this basis, ALK expects the operating  
profit (EBITDA) to be in the range of DKK  
625-725 million, exceeding the level of  
2021 and in line with ALK’s long-term  
earnings ambitions of achieving a ~25%  
EBIT margin in 2025.  
Ramping up in China  
Assumptions  
The outlook does not include any revenue  
from acquisitions, new partnerships or  
the in-licensing of adjacent products and  
services, nor does it include any sizeable  
payments related to M&As or in-licensing  
activities.  
ALK has had a presence in China’s  
rapidly growing allergy treatment  
In anticipation of this, ALK will ramp up  
its local presence over the next three  
The outlook assumes that COVID will not  
affect home-based tablet treatments,  
and that patients in general will remain  
able and willing to visit healthcare  
professionals without significant  
limitations, although fluctuations may  
occur in some markets.  
market for nearly 20 years. New allergy  
immunotherapy products must be  
documented and registered before they  
can be sold in China, and there are just  
three players in the market, including  
ALK, with a competitor’s SLIT-drops  
products the current leaders in a market  
worth around DKK 800 million annually.  
years, increasing the size of its salesforce  
significantly, supporting education and  
training for allergy specialists, and  
recruiting back-office staff for essential  
disciplines such as management,  
medical and legal affairs, compliance,  
and sales and marketing.  
The outlook is based on current  
exchange rates, resulting in a positive  
effect of approximately 1 percentage  
point on reported revenue growth  
and an immaterial effect on reported  
EBITDA.  
Alongside this build-up, ALK has teamed  
up with local partner Grandpharma  
in an exclusive licensing agreement  
that will see ALK’s adrenaline auto-  
injector Jext® registered and launched  
in China. In addition, it is in the process  
of establishing a partner-based  
digitalisation strategy, to ensure an  
engagement platform for its future  
ambitions.  
The outlook assumes that COVID  
will not significantly impact planned  
clinical activities, sales and marketing  
activities or investments. CAPEX is  
ALK enjoys a strong reputation locally for  
offering high-quality products which are  
prescribed via selected hospital-based  
clinics in key locations. The current range  
is focused on the SCIT product Alutard®  
for the treatment of house dust mite  
allergy, plus an associated diagnostic  
product, and these are building ALK’s  
reputation and market presence ahead of  
the introduction of ALK’s house dust mite  
tablet which, subject to approval, could  
be on the market from 2025 onwards.  
 
Management’s review  
Annual report 2021  
ALK  
12  
Performance  
The peanut drug substance  
is carefully analysed via the  
electrophoretic SDS-PAGE  
method. The blue bands  
reveal proteins of different  
molecular weights.  
13 Financial highlights and key ratios  
14 Sales and market trends  
16 Financial review of 2021  
18 Q4 review  
20 Sustainability  
 
 
Management’s review  
Annual report 2021  
ALK  
13  
Financial highlights and key ratios  
for the ALK Group*  
DKK  
2021  
DKK  
2020  
DKK  
2019  
DKK  
2018  
DKK  
2017  
EUR  
2021  
EUR  
2020  
DKK  
2021  
DKK  
2020  
DKK  
2019  
DKK  
2018  
DKK  
2017  
EUR  
2021  
EUR  
2020  
Amounts in DKKm/EURm**  
Amounts in DKKm/EURm**  
Income statement  
Revenue  
EBITDA  
Information on shares  
Proposed dividend  
Share capital  
3,916  
534  
3,491  
395  
3,274  
241  
2,915  
136  
2,910  
253  
527  
72  
469  
53  
-
-
-
-
-
-
-
14.9  
111  
111  
111  
111  
111  
14.9  
Operating profit (EBIT)  
Net financial items  
Profit before tax (EBT)  
Net profit  
292  
(13)  
279  
219  
2,492  
150  
(49)  
101  
25  
2,419  
(14)  
(17)  
(31)  
(50)  
2,385  
(96)  
(7)  
(103)  
(170)  
2,341  
(80)  
(42)  
(122)  
(158)  
2,213  
39  
(2)  
38  
29  
20  
(7)  
14  
3
Shares in thousands of DKK 10 each  
Share price, at year end  
Net asset value per share  
11,141 11,141 11,141 11,141 11,141 11,141  
11,141  
336.1  
38.0  
3,430  
312  
2,500  
283  
1,635  
285  
960  
285  
740  
295  
461.2  
42.0  
Key figures  
Gross margin – %  
EBITDA margin – %  
Average number of employees (FTE)  
2,492  
2,419  
61.2  
13.6  
6.6  
10.2  
-
58.1  
11.3  
0.8  
5.5  
-
57.8  
7.4  
(1.6)  
(0.5)  
-
56.0  
4.7  
(5.3)  
(3.3)  
-
56.4  
8.7  
(5.1)  
(3.1)  
-
61.2  
13.6  
6.6  
10.2  
-
58.1  
11.3  
0.8  
5.5  
-
0.3  
0.3  
3.7  
1,092  
8.8  
Balance sheet  
Total assets  
Invested capital  
Equity  
Return on equity (ROE) – %  
ROIC incl. goodwill – %  
Pay-out ratio – %  
Earnings per share (EPS)  
Earnings per share (DEPS), diluted  
Cash flow per share (CFPS)  
Price earnings ratio (PE)  
Share price/Net asset value  
5,830  
2,931  
3,480  
5,563  
2,807  
3,153  
5,495  
2,759  
3,176  
4,865  
2,968  
3,179  
4,958  
2,864  
3,290  
784  
394  
468  
748  
377  
424  
20.0  
19.8  
42.7  
172  
11.0  
2.3  
2.3  
27.6  
1,092  
8.8  
(4.6)  
(4.6)  
12.1  
(356)  
5.7  
(15.6)  
(15.6)  
(8.7)  
(61)  
3.4  
(15.9)  
(15.9)  
(39.0)  
(46)  
2.5  
2.7  
2.7  
5.7  
172  
11.0  
Cash flow and investments  
Depreciation, amortisation  
and impairment  
Cash flow from operating activities  
Cash flow from investing activities  
– of which investment in intangible assets  
– of which investment in tangible assetss  
– of which acquisitions of  
242  
468  
(266)  
(45)  
245  
301  
(245)  
(26)  
255  
132  
(157)  
(20)  
232  
(95)  
(199)  
(52)  
333  
(387)  
(358)  
(27)  
33  
63  
(36)  
(6)  
33  
40  
(33)  
(3)  
Revenue growth – %  
Organic growth  
Exchange rate differences  
Acquisitions/divestments  
Total growth revenue  
12  
-
-
8
(1)  
-
11  
1
-
1
(1)  
-
(6)  
(1)  
4
12  
-
-
8
(1)  
-
7
(218)  
(196)  
(147)  
(126)  
(240)  
(29)  
(26)  
companies and operations  
Free cash flow  
-
-
56  
(20)  
(25)  
(21)  
(294)  
(94)  
(745)  
-
27  
-
8
12  
7
12  
-
(3)  
12  
202  
*
Management’s review comprises pages 1-44 as well as ‘Financial highlights and key ratios by quarter for the ALK Group’ on page  
103  
**Financial highlights and key ratios stated in EUR constitute supplementary information to the Management’s review. The exchange  
rate used in translating from DKK to EUR is the exchange rate prevailing on 31 December 2021 (EUR 100 = DKK 744) (31 December  
2020: EUR 100 = DKK 744)  
Read the ESG key figures overview here  
For definitions and reconciliation of alternative performance measures, see page 90  
 
 
Management’s review  
Annual report 2021  
ALK  
14  
Sales and market trends  
ALK’s full-year revenue for 2021  
increased 12% to DKK 3,916  
million (3,491), in line with the  
improved outlook, issued on 11  
November 2021, and reflecting  
strong performances in all sales  
regions.  
the shift of patients to SLIT-tablets. Sales  
of other products increased 10% as lower  
Jext® sales were outweighed by a recovery  
in sales for the wider portfolio.  
Revenue by geography  
Revenue by product line  
Growth  
(l.c.)  
Growth  
(l.c.)  
DKKm  
2021  
2020  
DKKm  
2021  
2020  
Europe  
North America  
Int'l markets  
2,809  
683  
424  
10%  
23%  
15%  
2,550  
573  
368  
SCIT/SLIT-drops  
SLIT-tablets  
Other products  
1,655  
1,774  
487  
(1)%  
29%  
10%  
1,673  
1,370  
448  
Europe  
European revenue was up 10% at DKK  
2,809 million (2,550), despite occasional  
constraints caused by resurgences of  
COVID.  
Overall revenue  
3,916  
12%  
3,491  
Overall revenue  
3,916  
12%  
3,491  
(Comparative figures for 2020 are shown  
in brackets. Revenue growth rates are  
stated in local currencies, unless otherwise  
indicated)  
Sales growth was largely fuelled by  
tablets, revenue from which increased by  
31% on market share gains and market  
expansion – predominantly on the take-  
up of ITULAZAX® and the halo effect this  
created for GRAZAX®. Furthermore, the  
convenience of tablets as a home-based  
treatment made them a useful option  
for patients unable to continue with their  
usual treatments due to COVID-related  
constraints. Sales of legacy allergy  
immunotherapy (AIT) products declined  
4%, influenced by planned product  
discontinuations which reduced growth  
Continues  
Revenue by geography  
Revenue by product line  
Europe  
North America  
SCIT/SLIT-drops  
Other  
SLIT-tablets  
International markets  
11% (11%)  
17% (16%)  
13% (13%)  
Revenue growth was driven by ALK’s tablet  
portfolio, sales of which grew 29% overall,  
continuing the strong positive trajectory  
of recent years. Sales of legacy products  
were largely unchanged as sales mostly  
recovered for SCIT products previously  
impacted by COVID, which had prevented  
or discouraged visits to allergy clinics.  
Meanwhile, sales of SLIT-drops declined  
on planned product discontinuations and  
72% (73%)  
42% (48%)  
2021  
(2020)  
2021  
(2020)  
45% (39%)  
 
 
Management’s review  
Annual report 2021  
ALK  
15  
5-year total revenue by geography  
5-year total revenue by product line  
COVID-aside, market conditions were  
largely stable across Europe in 2021, and  
there were no notable changes affecting  
the pricing and reimbursement of AIT  
products, although the risk of pressure in  
selected markets remains.  
International markets  
Revenue from International markets  
increased 15% in local currencies to DKK  
424 million (368). Growth was largely  
attributable to a strong performance from  
ALK’s largest market in the region – Japan  
– although there was sales growth in  
almost all International markets.  
Europe  
North America  
SCIT/SLIT-drops  
Other  
SLIT-tablets  
International markets  
DKKm  
DKKm  
4,000  
3,000  
2,000  
1,000  
0
4,000  
3,000  
2,000  
1,000  
0
North America  
Revenue in North America recovered  
from the 2020 impact of COVID, growing  
by 23% in local currencies to DKK 683  
million (573). Tablet sales increased 42%  
in the region to DKK 120 million (85) on  
increased uptake among key prescribers,  
improved sales margins in the USA, and  
easing of COVID-related restrictions,  
allowing patients to visit clinics more freely  
once again. Growth was further supported  
by the strong early performance of  
Quarterly revenue figures for Japan and  
China continued to be distorted by the  
phasing of shipments to these markets.  
However, in both cases, in-market sales  
growth remained very strong throughout  
the year.  
2017 2018 2019 2020 2021  
2017 2018 2019 2020 2021  
by 3 percentage points, however, this  
effect is expected to be negligible from  
2022 onwards. Sales of other products fell  
back 8% due to lower Jext® sales, mainly  
influenced by fewer prescription renewals  
because of COVID. These figures reflect the  
fact that, at an individual market level, the  
European picture differs from country to  
country.  
guidelines reinforced recommendations  
that only documented, registered AIT  
products should be prescribed for new  
allergy patients. Meanwhile, in the  
Nordic countries, ALK saw solid growth  
resulting from its work to expand the  
overall AIT market. In France, sales were  
down slightly as tablet sales growth  
was counterbalanced by lost sales from  
patients shifting from legacy products  
to tablets. Continuing concerns and  
restrictions related to COVID impacted  
selected allergy markets somewhat  
towards the end of the year.  
TM in Canada.  
ITULATEK  
Sales of bulk allergen extracts and other  
products – particularly those that are  
primarily used in hospital settings – also  
recovered well, up 14% at DKK 302 million  
(275), and up 27% at DKK 261 million  
(213), respectively.  
In ALK’s largest market, Germany, sales  
grew strongly on increased market share,  
and ALK’s market position strengthened  
as updated national prescription  
 
Management’s review  
Annual report 2021  
ALK  
16  
Financial review of 2021  
ALK’s full-year operating profit  
(EBITDA) increased 35% in  
reported currency to DKK 534  
million (395), in line with the  
improved outlook, issued on 11  
November 2021, and reflected  
higher sales and improved gross  
margin.  
Cost of sales increased 5% in local  
currencies to DKK 1,520 million (1,463). The  
gross profit of DKK 2,396 million (2,028)  
yielded a gross margin of 61% (58%)  
which exceeded the orginal goal of a 1-2  
percentage point improvement and mainly  
reflected increased sales – especially  
from tablets in Europe – although this was  
somewhat reduced by increased shipments  
to Torii in Japan, which yield lower gross  
margins. ALK continues to see significant  
costs for compliance efforts to secure  
robustness in product supply, as well as  
the implementation of the product and site  
strategy.  
2021 guidance history  
2021E  
2021E  
2021E  
2021E  
2021  
DKK  
5 Feb. outlook 5 May outlook 9 Aug. outlook 11 Nov. outlook  
Actual  
+12% (l.c.)  
534m  
Revenue  
EBITDA  
+8-12% (l.c)  
325-425m  
+9-12% (l.c.) +10-12% (l.c.) +11-12% (l.c.)  
375-425m  
~(200)m  
450-500m  
~(100)m  
500-550m  
~ +200m  
Free cash flow  
~(200-300)m  
+202m  
(Comparative figures for 2020 are shown  
in brackets)  
Revenue  
Gross margin  
Revenue  
Revenue  
Gross profit  
Cost of sales  
2021 revenue increased by 12% in  
local currencies to DKK 3,916 million  
(3,491). Exchange rate fluctuations did  
not materially impact reported revenue  
growth. Planned product discontinuations,  
which mostly involved SCIT/SLIT-drops  
products in Europe during Q1, impacted  
overall growth negatively by ~1 percentage  
point. The effect was negligible in the  
remaining nine months of the year.  
Revenue growth  
Gross margin  
Capacity costs increased 13% in  
local currencies to DKK 2,105 million  
(1,877). R&D expenses increased by  
23% in local currencies to DKK 631 million  
(515) in support of a planned increase  
in clinical trial activities. Sales and  
marketing expenses increased by 10%  
in local currencies, reflecting a gradual  
Continues  
DKKm  
%
DKKm  
%
4,000  
20  
4,000  
80  
70  
60  
50  
40  
3,250  
2,500  
1,750  
1,000  
10  
0
3,250  
2,500  
1,750  
1,000  
-10  
-20  
2017 2018 2019 2020 2021  
2017 2018 2019 2020 2021  
 
 
Management’s review  
Annual report 2021  
ALK  
17  
normalisation of activity levels following  
the 2020 impact of COVID on business  
activities, but also operational leverage of  
ALK’s commercial activities. Administrative  
expenses increased 3% in local currencies.  
Net financials were a loss of DKK 13  
million (loss of 49) mainly relating to  
interest payments and loan fees. Tax on  
the profit totalled DKK 60 million (76) and  
net profit was DKK 219 million (25).  
mainly on upgrades to legacy production  
and the build-up of capacity for SLIT-  
tablets production.  
to the settlement of incentive programmes  
and a refinancing of ALK’s loan and credit  
facilities. Currently, ALK has DKK 1.5 billion  
in credit facilities running until the end of  
2024, of which, DKK 1.3 billion is currently  
unused.  
Free cash flow was positive at DKK  
202 million (56), which was better than  
originally expected due to higher earnings  
and the timing of repayment of accrued  
rebates. This result was in line with the  
improved outlook issued on 11 November  
2021.  
EBITDA (operating profit before  
depreciation and amortisation)  
increased 35% in reported currency to  
DKK 534 million (395) and was better  
than originally expected, driven by the  
higher sales and improving gross margin.  
Exchange rates had only a minor effect on  
operating profit.  
Cash flow from operating activities  
improved to DKK 468 million (301) driven  
by higher earnings and receipt of a  
milestone payment related to the recently  
established Jext® partnership for China.  
Equity totalled DKK 3,480 million (3,153)  
at the end of the year, and the equity ratio  
was 60% (57%).  
At the end of 2021, ALK held 148,528 of its  
own shares or 1.3% (1.9%) of the share  
capital.  
Cash flow from investment activities  
was DKK minus 266 million (minus 245),  
Cash flow from financing activities was  
DKK minus 311 million (minus 62), relating  
Research and development  
Sales, marketing and administration  
EBITDA  
Research and development expenses  
Percentage of revenue  
Administrative expenses  
Sales and marketing expenses  
Percentage of revenue  
EBITDA  
EBITDA margin  
DKKm  
%
DKKm  
%
DKKm  
%
800  
20  
16  
12  
8
1,600  
60  
50  
40  
30  
20  
800  
20  
15  
10  
5
600  
400  
200  
0
1,200  
800  
400  
0
600  
400  
200  
0
4
0
2017 2018 2019 2020 2021  
2017 2018 2019 2020 2021  
2017 2018 2019 2020 2021  
 
Management’s review  
Annual report 2021  
ALK  
18  
Q4 review  
(Comparative figures for 2020 are shown  
in brackets. Revenue growth rates are  
stated in local currencies, unless otherwise  
indicated)  
influenced by 2 percentage points due  
to exchange rate fluctuations.  
Revenue by geography  
Revenue by product line  
Q4 Growth  
Q4  
2020  
Q4 Growth  
Q4  
2020  
DKKm  
2021  
(l.c.)  
DKKm  
2021  
(l.c.)  
Tablet sales grew by 23% to DKK 509  
million (409), with double-digit growth  
in Europe and North America, whereas  
sales in International markets were  
impacted by the phasing of shipments  
to ALK’s partner in Japan.  
Europe  
North America  
Int'l markets  
795  
193  
111  
7%  
20%  
6%  
734  
155  
102  
SCIT/SLIT-drops  
SLIT-tablets  
Other products  
483  
509  
107  
0%  
23%  
(2)%  
477  
409  
105  
Strong Q4 delivers results in line with  
latest outlook  
Overall revenue  
1,099  
9%  
991  
Overall revenue  
1,099  
9%  
991  
ALK delivered 2021 full-year results in  
line with expectations following a Q4  
which saw revenue growth of 9%. Growth  
was fuelled by continued strong tablet  
sales growth of 23%, during what is  
traditionally the peak season for allergy  
immunotherapy (AIT) treatment initiations.  
This compares with a Q4 2020 that saw  
extraordinarily high revenue growth of  
16%, with tablet sales growth of 55%  
which was, in part, fuelled by a high  
number of shipments to ALK’s partner in  
Japan.  
Combined SCIT and SLIT-drops sales  
were largely unchanged at DKK 483  
million (477).  
Revenue by geography  
Revenue by product line  
Europe  
North America  
SCIT/SLIT-drops  
Other  
SLIT-tablets  
International markets  
Sales of other products declined 2% to  
DKK 107 million (105).  
10% (10%)  
18% (16%)  
10% (11%)  
72% (74%)  
44% (48%)  
The overall impact of COVID on ALK’s  
business continued to be modest and  
ALK’s supply chain, inventory levels and  
distribution channels remained robust.  
2021  
(2020)  
2021  
(2020)  
46% (41%)  
Q4 highlights  
Total revenue was up 9% in local  
currencies at DKK 1,099 million (991).  
Reported growth was positively  
In Europe, revenue was up 7%, driven  
by strong uptake of the tablets. Tablet  
sales increased 31%, fuelled in particular  
Continues  
 
 
Management’s review  
Annual report 2021  
ALK  
19  
in central and northern Europe by the  
uptake of ITULAZAX® and the halo effect  
this had on GRAZAX®. Combined sales  
of SCIT and SLIT-drops were down 7%,  
reflecting COVID-related constraints in  
some countries and the ongoing transition  
of patients to tablets, while sales of other  
products declined 33% on low sales of the  
Jext® adrenaline auto-injector, influenced  
by fewer prescription renewals because  
of COVID and a Q4 2020 extension to its  
shelf life. Another factor was an industry-  
wide adjustment of rebates in the UK under  
the agreed rebate scheme, announced in  
December. Also in Q4, ALK downsized its  
commercial activities in Spain and Turkey  
to reflect the current market conditions for  
evidence-based AIT treatments.  
to China. Revenue from Japan was, as  
planned, slightly below the high level of  
2020, and impacted by fluctuations in the  
timing of shipments.  
Income statement  
Amounts in DKKm  
Q4 2021  
Q4 2020  
Revenue  
Cost of sales  
1,099  
398  
991  
412  
Gross margin improved to 64% (58%),  
reflecting higher sales – especially  
from tablets in Europe – but also the  
cost of compliance efforts to solidify  
robustness in product supply, as well as  
the implementation of the product and site  
strategy.  
Gross profit  
Gross margin  
Research and development expenses  
Sales and marketing expenses  
Administrative expenses  
701  
64%  
179  
372  
71  
579  
58%  
178  
338  
72  
Operating profit/(loss) (EBIT)  
Net financial items  
79  
(5)  
(9)  
(5)  
Profit/(loss) before tax (EBT)  
Tax on profit  
74  
(2)  
(14)  
17  
Net profit/(loss)  
76  
(31)  
Capacity costs increased 5% to DKK  
622 million (588), largely due to higher  
sales and marketing expenses, related to  
restructuring costs for changes to ALK’s  
setup in Spain and Turkey. R&D expenses  
were level with 2020.  
Operating profit before depreciation  
and amortisation (EBITDA)  
136  
64  
In North America, revenue increased  
20%, driven by the ongoing recovery in  
sales across the portfolio after the very  
challenging market conditions resulting  
from COVID in 2020. Tablet sales in the  
region were up 40%, while sales of bulk  
allergen extracts (SCIT) increased 11%.  
Sales of other products and services  
increased 24%.  
EBITDA of DKK 136 million (64) was in line  
with the most recent outlook, reflecting  
higher sales, as well as improved gross  
margins.  
Growth was fuelled by continued  
strong tablet sales growth of 23%,  
during what is traditionally the peak  
season for AIT treatment initiations.  
Revenue from International markets  
grew by 6%, fuelled by product shipments  
 
Management’s review  
Annual report 2021  
ALK  
20  
Sustainability
After forming a new, internal
Sustainability Committee in
2021, ALK continued integrating
sustainability into its overall
business strategy. ALK remains
a committed signatory of the UN
Global Compact Principles and
supports the UN Sustainable
Development Goals.
also considers employee diversity and
inclusion, responsible business practices,
and environmental impact across the
company’s value chain.
the ambition of securing registrations in
new geographies and patient segments.
In addition, ALK entered a partnership with
Grandpharma, a Chinese pharmaceutical
company, to expand the availability of its
adrenaline auto-injector, Jext®, which is
used for the emergency treatment of acute
allergic reactions.
healthcare systems to train healthcare
professionals on how to diagnose and
treat allergies. In 2021, this initiative
resulted in approximately 3,800 healthcare
professionals being educated.
Expanding ‘Access to Allergy
Care for All’
Diverse and engaged employees
A skilled, diverse and engaged workforce
is essential to ALK’s success. ALK invests
significantly to ensure all employees
have equal opportunities to realise
their full potential, regardless of age,
gender, race, ethnicity, religion, disability,
sexual orientation, or any other unique
characteristic. In addition, ALK’s Cultural
Beliefs: Do the right thing, Pursue growth,
and Build bridges, are designed to inspire
and empower employees to reach their
‘Access to Allergy Care for All’ aims
to make ALK products and solutions
universally accessible, while growing
an ethical and sustainable business. In
2021, ALK made allergy diagnosis, allergy
immunotherapy (AIT) treatment, and
adrenaline products available to more
than 100,000 additional patients, bringing
the total number of patients served to
approximately 2.1 million.
Furthermore, ALK’s digital channels
mobilised more than 375,000 people
to take action on their allergies and
ALK tested several concepts in various
countries to eliminate friction points
on the path to prescriptions for the
many untreated patients eligible for AIT
treatment.
The driving force behind ALK’s
sustainability efforts is ensuring ‘Access
to Allergy Care for All’. This strategy
includes expanding ALK products into new
geographical markets directly or through
partnerships, and into new segments such
as children and adolescents. ALK ensures
a comprehensive portfolio of quality allergy
solutions through innovative research and
development. ALK’s sustainability strategy
ALK introduced tablet-based AIT to
The availability of medicines is just one
factor in broadening access to allergy
care. A significant barrier to allergy
treatment is the lack of access to specialist
doctors. Therefore, ALK is partnering with
two new countries, while extending the
children and adolescent indications of the
existing tablet portfolio to 10 additional
countries. ALK also ran clinical trials with
Continues  
Find out more  
in ALK’s sustainability report,  
https://www.alk.net/  
sustainability  
 
 
Management’s review  
Annual report 2021  
ALK  
21  
full potential, in the pursuit of advancing
allergy care for all.
on track for approximately 50%, with
53% women and 47% men. The number
of women at vice president and senior
director levels is expected to increase
over the coming years, supported by
ALK’s talent, mentoring and sponsorship
programmes.
ESG key figures overview
Unit
2021
2020
2019
In 2021, ALK continued to take all
Environmental data
Total CO2 emissions
(Scope 1, Scope 2, refrigerants)
CO2 emissions (less renewables)
Energy consumption
Energy intensity
Renewable energy share
Water consumption
necessary measures to protect employees
from the various resurgences of COVID,
while maintaining the pursuit of its
strategic growth ambitions. This required
a degree of flexibility to accommodate
new ways of working. Nevertheless,
ALK’s 2021 employee engagement
survey confirmed that employees felt the
company had prioritised their well-being
and communicated effectively throughout
this period. The survey had a participation
rate of 93% and resulted in an overall
engagement score of 8.2, which was 0.6
above the benchmark for the healthcare
industry.
Tonnes
Tonnes
MWh
Ratio
%
11,258
7,130
45,686
30
45
127,520
50
11,263
12,2131
9,644
46,7621
33
20
122,4611
381
7,391
45,441
31
38
110,530
38
At the end of 2021, ALK’s Board of
m3
%
Directors consisted of nine members. Of
the six shareholder-elected members, two
were women, meeting the target of 30%.
Furthermore, women accounted for 67% of
employee-elected Board members.
Waste recycled from production sites
Social data
Workforce
Headcount
% female
% female
Times
%
2,593
63
2,486
63
46
1.14
10
2,406
62
47
1.13
11
Gender diversity (total)
Gender diversity (all management levels)
Gender pay ratio (men to women)
Employee turnover ratio,
Lost time injury frequency
Absence due to sickness
49
1.18
13
0.32
3.1
Addressing environmental impact
ALK’s journey towards reducing its
environmental impact includes the
optimisation of waste management,
reduction of energy consumption, and
elimination of CO2 emissions across the
value chain. This will involve an increase in
recycling, a transition to renewable energy
sources, and a more circular life-cycle for
ALK’s products and materials. In 2021,
ALK improved waste management and
recycling. The share of waste that was
reused or recycled increased to 50%, up
Continues  
LTIF
%
2.9
3.1
3.5
2.7
Governance data
Gender diversity (Board)
Board meeting attendance rate
CEO pay ratio
%
%
Times
33
94
34
20
98
34
17
97
29
In 2021, the company took further steps
towards increasing gender diversity
among its senior leadership. At the end of
the year, 29% of vice president and senior
director positions were held by women,
which was on track for ALK’s 2025 goal
of at least 35%. The gender balance at
manager and director levels remained
1
Baseline for improvement target
2
LTIF includes all work-related injuries resulting in an individual being physically or mentally unable to work. In 2021,
injuries were only included if diagnosed by a competent medical professional.
Find out more
Read the Financial highlights and
key figures overview here
Please see further information on
the reporting practices for ESG key
figures in ALK’s sustainability report,
https://www.alk.net/sustainability
 
 
Management’s review  
Annual report 2021  
ALK  
22  
from 38% in 2020. In France, switching to
biodegradable packaging materials and
converting to 100% renewable energy at
ALK’s production site in Varennes were
just some of the intiatives taken to reduce
ALK’s impact on climate.
Preparing for Scope 3
ALK set a target to reduce its CO2 emissions by 60%
in 2025, which includes emissions from Scope 1,
Scope 2, transport, business travel, and company
cars.
In addition, ALK will work to secure valid and
robust Scope 3 data as well as investigate
potential material categories to include in its
Scope 3 reporting by 2025.
As a result of the company’s efforts,
energy consumption remained at 2019
levels, despite a significant increase in
production output, while CO2 emissions
from manufacturing operations fell by 42%
compared to the 2019 baseline of total
emissions from non-renewable sources.
Switching from plastic  
to recyclable cardboard  
packaging  
Policies and guidelines
With an increase in awareness and  
concern from its patients and healthcare  
professionals, ALK developed a new  
packaging solution in 2021 for its OSIRIS®  
products in France. Stringent testing  
ensured the quality of the medicines  
would remain uncompromised with this  
new packaging solution.  
In addition to the sustainability benefits,  
the new packaging is also more  
ALK’s sustainability efforts are supported by a wide range of policies and guidelines designed to
ensure everyday activities are aligned with the company’s long-term ambitions. Topics covered by
specific policies include: sustainability as well as the environment, health and safety (EHS), diversity,
remuneration, data ethics, tax, stakeholder communications, investor relations, anti-corruption and
bribery, and whistleblowing. Additionally, ALK’s Code of Conduct details the company’s expectations
on professionalism, honesty and integrity. In 2021, 97% of employees completed and signed off on the
annual online training exercise covering the Code of Conduct.
user-friendly with its colour-coded  
design, which makes it easier to read,  
especially for patients who take multiple  
treatments. ALK intends to evaluate  
similar packaging solutions across the  
entire supply chain.  
The total carbon footprint of the OSIRIS®  
packaging is now 19 times lower than  
before, potentially reducing plastic  
consumption by up to 60 tonnes annually.  
For more information, ALK’s statutory annual report on sustainability, data ethics and gender diversity
(as required by §99a, §99b, §99d and §107d of the Danish Financial Statements Act as well as Article 8 of
the EU Taxonomy) is available at https://www.alk.net/sustainability
 
Management’s review  
Annual report 2021  
ALK  
23  
Strategy  
ALK’s precision  
24 Strategy progress  
extraction processes  
used to make the  
peanut allergy tablets  
is made possible by  
a Dia-Ultra Filtration  
machine.  
30 ALK’s business model  
 
 
Management’s review  
Annual report 2021  
ALK  
24  
Strategy progress  
ALK’s strategic focus areas  
A year ago, ALK updated its  
strategy following the conclusion  
of a three-year strategic  
transformation programme  
designed to stimulate a new  
period of continued growth.  
All of this is underpinned by a company-  
wide ambition to lead the way on  
sustainability, through ALK’s ‘people and  
planet’ commitments.  
b
These strategic priorities map a path  
towards ALK’s financial ambitions for  
2025 and beyond – and will shape an ALK  
capable of delivering continuous, high  
revenue and earnings growth, with annual  
revenue growth of 10% or more, and  
will improve the company’s EBIT margin  
towards around 25% in 2025.  
The priority for the immediate future is to  
build upon that successful transformation  
by targeting continuous growth and  
profitability, as ALK seeks to become ever  
more relevant to people with allergy.  
The strategy is further supported by  
selected longer-term initiatives, which are  
designed to safeguard and potentially  
accelerate ALK’s longer-term growth  
trajectory towards 2030 and beyond.  
This will be achieved by extending the  
company’s leadership in respiratory  
allergy, expanding its position in  
anaphylaxis, establishing a presence in  
food allergy, and pursuing new innovations  
through research. The steps towards  
fulfilling these ambitions fall into four key  
focus areas: succeed in North America,  
complete and commercialise the tablet  
portfolio, consumer engagement and new  
horizons, and optimise for excellence.  
Progress on the strategic priorities  
ALK continued the execution of its strategy  
in 2021, making progress in each of the  
four focus areas despite the impact  
x
Continues  
 
 
Management’s review  
Annual report 2021  
ALK  
25  
of COVID, particularly on the clinical  
development programme:  
Towards ‘25 in 25’ and growth beyond  
In North America, ALK continued its  
efforts to mobilise allergy patients,  
accelerate tablet sales, and to secure  
paediatric and adolescent indications for  
ACARIZAX®/ODACTRA® and RAGWITEK®,  
as well as introducing other prescription  
allergy solutions. Overall, tablets sales  
in the region grew by 42% on increased  
uptake among key prescribers, improved  
sales margins in the USA, and reduced  
COVID-related restrictions, allowing  
Relentless focus on strategy execution in pursuit of ‘allergy care for all’  
25 in 25  
patients to visit clinics more freely once  
again. Growth was further supported by  
the strong early performance of ITULATEKTM  
in Canada. Even so, the long-established  
market barriers to the adoption of the  
tablets in the USA remained a challenge.  
2018-20  
Present  
2025  
2025 and beyond  
37% average tablet sales  
growth  
≥10% organic growth p.a.  
driven by tablets  
Achieve an EBIT margin of  
around 25% in 2025 based  
on continued growth,  
improved gross margin and  
cost efficiencies  
≥10% organic growth p.a.  
Further expand respiratory  
allergy leadership,  
including paediatrics  
Cumulative earnings  
DKK 800m ahead of plan  
Improve efficiency,  
maintain quality, and build  
further tablet capacity  
Work to increase traction in the USA for the  
tablet portfolio included the introduction  
and expansion of a telehealth partnership  
giving patients direct access to an allergy  
health professional, which saw patients  
mobilised to take action on their allergies,  
albeit still in small numbers.  
Past issues cleaned up  
Further expand in China  
and other markets  
Roll out tablets for  
paediatric use  
Initiate clinical  
development of peanut  
AIT, 2024 US filing of  
next-generation adrenline  
product, expand in China  
Strong growth foundations  
Expand in anaphylaxis  
Commercialise food AIT  
Late-stage clinical  
development of food AIT  
60% reduction in CO2  
emissions versus baseline  
Maintain focus on people  
and planet activities  
In 2022, ALK’s goal is to further grow  
its tablets business by increasing  
Continues  
 
Management’s review  
Annual report 2021  
ALK  
26  
prescriber depth among key specialists  
and continuing to pursue partnerships  
in digital health. ALK also aims to drive  
growth in its legacy product sales and to  
obtain approval for the use of ACARIZAX®/  
ODACTRA® in adolescents.  
tablet – progressed as planned, and  
patient recruitment will continue in 2022,  
with both trials expected to complete in  
2023. The trials represent some of the final  
steps towards full paediatric coverage for  
the tablets in Europe and North America,  
which will be an important driver of  
continued double-digit revenue growth for  
ALK.  
Efforts to complete and commercialise  
the tablet portfolio advanced, with  
the aim of securing their use in new  
geographies and additional patient  
groups. In April, ALK received approval  
from the FDA for the use of RAGWITEK® in  
US paediatric patients, while December  
saw the filing of a US application covering  
the use of ODACTRA® in adolescents.  
Also in 2021, ACARIZAX® was approved  
for adult and adolescent use in the UK,  
and for adolescent use in an additional  
nine countries. There were also approvals  
for GRAZAX® in eight countries and  
RAGWIZAX® in two countries, the majority  
of which were in eastern Europe. There  
was also a first UK approval for ITULATEKTM  
for adults and in Russia for adults and  
adolescents.  
COVID continued to impact ALK’s  
Building evidence on AIT in  
allergy and asthma  
paediatric trial in house dust mite-induced  
allergic asthma, in line with previous  
updates. The trial was initiated before  
the start of the pandemic as a regulatory  
commitment to the European Medicines  
Agency’s Paediatric Development  
Committee, to expand the current adult  
asthma indication in Europe by gathering  
equivalent paediatric data. During the  
pandemic, ALK has observed a significant  
reduction in the frequency of asthma  
exacerbations of almost 66% versus pre-  
pandemic levels among patient cohorts  
included in the trial. A reduction of asthma  
exacerbations has also been reported  
for society in general and is believed  
to be the result of virus containment  
measures, such as face masks and social  
distancing. Due to the low number of  
asthma exacerbations observed in the  
Continues  
ALK’s REWEAL programme is designed to  
supplement the current clinical evidence  
base for allergy immunotherapy (AIT)  
by collating ‘real-world’ patient data  
from independent sources in multiple  
countries. In 2021, results from the ALK-  
sponsored REACT study were published  
by The Lancet Regional Health – Europe.  
effect on severe asthma exacerbations  
over the nine years. Finally, patients  
treated with AIT had fewer in-patient stays  
and shorter stays if admitted to hospital.  
REACT is just one example of how our  
understanding of the role of AIT in allergy  
and asthma has advanced significantly  
over recent years. In Europe, ALK’s  
ACARIZAX® is already approved for the  
treatment of both allergic rhinitis and  
allergic asthma, and the Global Initiative  
for Asthma, GINA, now recommends  
sublingual AIT as a treatment option in  
patients with house dust mite-induced  
allergic asthma. ALK will continue to  
invest in generating new data with the  
aim of building on these successes and  
expanding the knowledge base still  
further.  
REACT gathered data from more than  
92,000 patients with both allergic rhinitis  
and asthma. It showed that AIT treatment  
was associated with long-term sustained  
reductions in the use of their existing  
medication for up to nine years after AIT  
treatment initiation. Patients with pre-  
existing asthma who were treated with AIT  
were also more likely to step down their  
asthma treatment regimens, while AIT  
was also associated with a preventative  
ALK’s two paediatric Phase III trials in  
allergic rhinitis – in Europe and North  
America for the house dust mite tablet, and  
in Europe and Canada for the tree pollen  
 
Management’s review  
Annual report 2021  
ALK  
27  
trial, ALK now believes it is unlikely to fulfil  
its objective of demonstrating an effect on  
asthma exacerbations, and the company  
will begin a dialogue with authorities on  
possible next steps. Since house dust mite-  
induced allergic asthma is a comorbidity of  
allergic rhinitis, ALK nevertheless expects  
to gain full paediatric coverage via the  
abovementioned Phase III trials in allergic  
rhinitis. This development is not expected  
to impact ALK’s long-term financial  
SLIT-tablet portfolio covers five of the most  
common respiratory allergies  
ALK’s SLIT-tablet pipeline  
Phase I Phase II Phase III Filing  
Marketed  
GRAZAX® Europe  
Adults and children – Allergic rhinitis (grass)  
Adults and children – Allergic rhinitis (grass)  
Adults and children – Allergic rhinitis (grass)  
2007  
2014  
2017  
GRASTEK® North America  
GRAZAX® International markets*  
RAGWITEK® North America  
Adults and children – Allergic rhinitis (ragweed)  
Adults and children – Allergic rhinitis (ragweed)  
2014/21  
2020  
ambitions and ALK remains committed  
to exploring the full potential of AIT in the  
treatment of allergic disease.  
RAGWIZAX® Europe & Int'l markets  
Adults – Allergic rhinitis and allergic asthma (HDM)  
Adolescents – Allergic rhinitis (HDM)  
ACARIZAX® Europe  
2016/17  
ACARIZAX®/ODACTRA®  
North America  
Adults – Allergic rhinitis (HDM)  
2017/18  
2015/18  
***  
Elsewhere, the Phase III registration trial  
in China of the house dust mite tablet in  
adult allergic rhinitis remains paused due  
to COVID, and ALK is in discussions with the  
relevant authorities on possible next steps.  
MITICURE™ Japan**  
Adults and children – Allergic rhinitis (HDM)  
Adults - Allergic rhinitis and allergic asthma (HDM)  
Adults – Allergic rhinitis (HDM)  
ACARIZAX® International markets*  
ACARIZAX® China  
ACARIZAX®/ODACTRA®  
Europe & North America  
Children – Allergic asthma (HDM)  
ACARIZAX®/ODACTRA®  
Europe & North America  
In 2022, ALK’s goal is to further grow  
global tablet sales by approximately 20%,  
with double-digit growth across its three  
sales regions.  
Children – Allergic rhinitis (HDM)  
ODACTRA® North America  
Adolescents – Allergic rhinitis (HDM)  
Adults and children – Allergic rhinitis  
(Japanese cedar)  
CEDARCURE™ Japan**  
2018  
ITULAZAX®/ITULATEK™  
Europe & Canada  
Adults – Allergic rhinitis (tree: birch family)  
Children – Allergic rhinitis (tree: birch family)  
2019/20  
Progress on increasing consumer  
engagement continued, and Q2 saw the  
launch of ALK’s klarify digital engagement  
platform in Canada, bringing the total  
Continues  
ITULAZAX®/ITULATEK™  
Europe & Canada  
*
Licensed to Abbott for south-east Asia and Seqirus for Australia/New Zealand  
** Licensed to Torii for Japan  
*** Already marketed in selected markets  
 
Management’s review  
Annual report 2021  
ALK  
28  
number of klarify countries to six. Metrics  
on the success of this platform remain  
encouraging and, during 2021, ALK  
mobilised more than 375,000 consumers  
worldwide via klarify, including more  
than 40,000 in the USA, versus targets of  
250,000 and 20,000, respectively. ALK  
will continue this work in 2022 with a focus  
on converting mobilised consumers into  
allergy immunotherapy patients, so that  
this truly becomes an ‘end-to-end’ journey  
for people with allergy.  
Also in 2021, ALK signed an exclusive  
agreement with the China-based  
pharmaceutical company, Grandpharma,  
that will see its existing AAI, Jext®, become  
the first to be registered and launched in  
China.  
Work on the food allergy treatment  
initiative progressed well. In Q2, ALK  
concluded a development and licensing  
agreement with Catalent for the use of its  
ZydisTM fast-dissolving tablet technology  
– the same technology used in ALK’s  
existing respiratory tablet portfolio – for  
use in future food allergy products. This  
was followed, in Q4, by the successful  
completion of a formulation feasibility  
study confirming the suitability of ZydisTM  
for use in a peanut allergy product, and  
supporting ALK’s 2022 goal of initiating  
Phase I development in the first half of the  
year.  
An entry into food allergy  
treatment  
ALK’s ‘new horizons’ priority covers  
initiatives with the ability to accelerate the  
company’s long-term growth, including an  
expanded offering in anaphylaxis and an  
entry into food allergy treatment. On the  
first of these, ALK continued to advance  
two parallel adrenaline auto-injector  
(AAI) projects – one in-house, and one in  
partnership with Windgap – with the aim  
of a submission to the US FDA in 2024. In  
2022, these programmes will progress  
further with the device development and  
chemistry, manufacturing and controls  
(CMC) work needed to produce initial  
batches for use in stability and reliability  
testing. These steps will generate  
Food allergies can be life-threatening,  
and are often detected in early  
use of this technology in the food allergy  
programme, and in Q4 completed a  
feasibility study confirming its suitability  
for use in the clinical development of a  
peanut allergy product. This paves the  
way for the initiation of Phase I clinical  
development in the first half of 2022,  
which will draw upon ALK’s extensive  
knowledge and experience from the  
development of the respiratory tablets.  
It will also build upon evidence from  
earlier, clinical proof of concept work, by  
leading academic researchers, which  
has demonstrated that peanut sublingual  
AIT is efficacious, and may provide a safe  
and practical treatment for people living  
with peanut allergy.  
childhood. They affect around 2.5%  
of people worldwide and are on the  
increase. In early 2021, ALK announced  
its intention to establish a presence in this  
area, initially covering allergy to peanut,  
which is one of the most common food  
allergies, and can last a lifetime.  
The priority ‘optimise for excellence’  
covers ALK’s product and site strategy  
programme (PASS), amongst other  
initiatives. This aims to safeguard ALK’s  
core portfolio of legacy products by  
ensuring it remains viable in the long-  
term, which, in part, means upgrading  
Continues  
Since that initial announcement, progress  
has been both swift and encouraging.  
ALK’s approach is to adapt the fast-  
dissolving sublingual tablet technology  
already used in its respiratory tablet  
portfolio.  
In Q2, ALK finalised a development and  
licensing agreement with Catalent on the  
essential data for the planned regulatory  
submissions.  
 
Management’s review  
Annual report 2021  
ALK  
29  
legacy production processes so that  
they continue to meet the very latest  
regulatory standards. A key element in  
this programme is the simplification of  
ALK’s production setup by reducing the  
number of different drug substances used  
for similar products. In October, this work  
took another important step towards  
completion when ALK received an EU  
regulatory approval opening the door to  
the necessary changes for its SCIT product  
line ALUTARD SQ®. In 2021, as part of  
this ongoing work, ALK submitted a total  
of 1,859 regulatory variations covering  
129 products to 40 authorities around the  
world.  
agility, employee engagement and  
retention, and its sustainability agenda.  
Through a series of organisational agility  
initiatives, ALK aims to ensure its future  
growth ambitions can be delivered by the  
necessary range and depth of engaged  
and motivated employees, each of whom  
benefits from a strong framework and  
culture of support when it comes to both  
talent and leadership development. ALK’s  
approach is rooted in its cultural values,  
which encourage open dialogue, honest  
feedback, and strong cross-organisational  
cooperation.  
Market expansion by  
activating doctors and patients  
Market expansion is a key part of ALK’s  
growth strategy, especially in more  
mature allergy immunotherapy markets.  
The tablet portfolio is particularly  
important here because, in many cases,  
it brings growth that is additional to sales  
from the legacy portfolio.  
Further impetus can come from  
In 2022, ALK’s goal is to maintain or  
improve upon the high engagement score  
achieved in the previous year. In addition,  
ALK will continue to take steps to prioritise  
sustainability within its business model  
with the aim of improving access to allergy  
care and addressing environmental  
impact across the value chain. A more  
in-depth summary of progress to date on  
the people and planet platform, as well  
as future goals, can be found in ALK’s  
sustainability report.  
patients themselves, and ALK’s digital  
engagement strategy is designed to  
motivate new patients to take action on  
their allergies by connecting them with  
specialist doctors who can understand  
their needs, diagnose their condition and  
prescribe a relevant treatment that can  
improve their quality of life.  
In 2022, ALK’s goal is to further progress  
the PASS programme as well as ensuring  
there are no quality-related major  
interruptions to product supply.  
ALK’s experience, especially in the  
Nordic countries, has shown that existing  
prescribers of the tablets can become  
powerful advocates for their use, helping  
to expand the prescriber base among  
their peers and, in turn, driving increased  
prescription rates. In addition, the  
tablets are an attractive proposition to  
healthcare professionals in specialisms  
adjacent to allergy, such as paediatrics,  
ear, nose and throat, and to selected  
general practitioners.  
People and planet  
Underpinning ALK’s efforts in each of  
the four focus areas is a business-wide  
commitment to people and planet, which  
addresses ALK’s future organisational  
This model – of registering new  
products, building advocacy and market  
access, expanding the prescriber  
base, and mobilising patients – while  
predominantly applicable to Europe  
today, has shown increasing success  
each time ALK has launched a new tablet,  
from grass, to house dust mite, and most  
recently, to tree.  
 
Management’s review  
Annual report 2021  
ALK  
30  
ALK’s business model  
Becoming relevant for more  
people with allergy  
As a global allergy solutions  
company with a century of  
scientific knowledge and expertise,  
ALK’s business model is designed to  
help people to take control of their  
allergies and their lives.  
Deep understanding of  
natural allergens  
Resources  
Diverse  
talent  
Raw  
materials,  
water and  
energy  
Expertise  
from academic  
institutions  
~2,600  
employees, a net  
addition of 100  
employees  
Efficient large-scale  
production of AIT  
Financial  
resources  
2.1 million  
Standardising,  
A profound  
understanding  
of allergy  
patients in  
treatment with  
ALK products  
formulating, developing  
and documenting AIT  
treatments in large-scale  
clinical programmes  
ALK share  
price up 364%  
since  
31 December  
2017  
>24,000  
Global commercial  
reach and leader in  
severe allergy care  
participants in  
clinical trials* for  
the tablets  
Value created  
*
22 Phase III trials  
 
 
Management’s review  
Annual report 2021  
ALK  
31  
Corporate  
matters  
High-performance liquid  
chromatography (HPLC) is just  
one of the pharmaceutical-grade  
analytical processes used to  
monitor the quality and consistency  
of ALK’s peanut product.  
32 Governance and ownership  
40 Risk management  
42 Board of Directors  
44 Board of Management  
 
 
Management’s review  
Annual report 2021  
ALK  
32  
Governance and ownership
Board of Director’s  
annual cycle  
Corporate governance
structure, including the Board of
Board composition
ALK’s statutory corporate governance
statement for 2021, pursuant to section
107b of the Danish Financial Statements
Act, is available at https://ir.alk.net/
financial-reporting/risk-management
Directors’ composition, competencies,
activities, self-assessment process,
and remuneration. The statement also
describes key elements of ALK’s internal
control and risk management systems
related to financial reporting processes.
At the Annual General Meeting
(AGM) in 2021, Anders Hedegaard
(Chairman), Lene Skole (Vice Chairman),
Lars Holmqvist, Jakob Riis, and Vincent
Warnery were all re-elected to the Board
of Directors. Furthermore, Gitte Aabo, CEO
of GN Hearing, and Bertil Lindmark, Chief
The statement provides a detailed
account of ALK’s two-tier management
Continues  
Attendance at meetings  
Attended  
Absent  
Board  
meetings  
Audit Committee  
meetings  
Remuneration & Nomination  
Committee meetings  
Scientific Committee  
Name (male/female)  
meetings  
Board meetings  
Monthly reports  
Annual General Meeting  
Strategy work  
Anders Hedegaard (m)  
Lene Skole (f)  
Gitte Aabo (f)*  
Lars Holmqvist (m)  
Bertil Lindmark (m)*  
Jakob Riis (m)  
Review of finacial performance  
Evaluation of collaboration between  
the Board of Directors and Board of  
Management  
Vincent Warnery (m)**  
Katja Barnkob (f)***  
Nanna Rassov Carlson (f)***  
Johan Smedsrud (m)***  
Organisational performance review and  
succession planning  
Next year’s budget  
*
elected at the AGM on 18 March 2021  
** stepped down on 5 August 2021  
*** employee-elected  
 
 
Management’s review  
Annual report 2021  
ALK  
33  
Medical Officer of Galecto, were elected as
new, independent members of the Board.
Competency matrix for the Board of Directors  
Based on its long-term strategy, ALK has  
identified the core competencies which must  
be represented in the Board of Directors for  
the Board to be able to support the strategy.  
To assess whether all core competencies are  
adequately represented, each shareholder-  
elected member of the Board has been  
asked to identify a maximum of four primary  
Employee-elected members are not part of  
the competency self-assessment. For the  
Chairman and Vice Chairman, two additional  
competencies, specific to these roles, have  
been identified.  
At the next AGM on 16 March 2022, the
Board of Directors will propose the election
as a new Board member of Alan Main,
previously head of Consumer Healthcare
and Executive Committee member at
Sanofi. His nomination follows the decision
of Vincent Warnery to step down in August
2021 after his appointment as CEO of
Beiersdorf.
competencies they bring to the Board,  
considering ALK’s long-term strategy. They  
may also have knowledge or experience  
in areas other than the four primary  
competencies. The matrix shows the  
responses to the self-assessment process.  
Role competencies:  
Chairman &  
Vice Chairman  
Core competencies  
Executive  
Board  
If the nomination of Alan Main is
experience  
in a global  
company  
Life  
science  
industry  
Consumer  
healthcare / Financial  
OTC / Risk  
Experience Research  
experience  
Experience from other  
at CEO level companies  
Commer-  
cial  
Digitalisa-  
tion  
with  
& Devel-  
opment  
approved at the AGM, four out of seven
shareholder-elected members will
again be independent, according to the
definitions set by the Danish Committee on
Corporate Governance. This reflects the
Board’s efforts to provide an adequate
balance between independent and non-
independent members.
US market  
Anders Hedegaard  
Chairman  
Lene Skole  
Vice Chairman  
Gitte Aabo  
Member  
Lars Holmqvist  
Member  
No other changes to the Board of Directors
will be proposed at the next AGM, as the
Board’s annual self-evaluation process
validated the skills and competencies of
the current Board. As such, the Board is
considered to have the right competencies
Bertil Lindmark  
Member  
Jakob Riis  
Member  
Continues  
 
Management’s review  
Annual report 2021  
ALK  
34  
to support ALK’s long-term value creation
and strategic progress.
Governance recommendations
The Danish Committee on Corporate
Governance has set out a series
recommendations took place in 2020 and
came into effect from 2021. To ensure its
continued compliance, ALK has made the
following amendments to procedures and
policies:
New policies were adopted covering
stakeholder communications and
investor relations.
All shareholder-elected Board members
are elected for a term of one year. In
addition, the Board includes three
of recommendations on corporate
governance which has been adopted
by Nasdaq Copenhagen. ALK’s Board
of Directors actively applies these
recommendations as inspiration for setting
up structures, tasks and procedures, and
ALK accounts for its compliance with the
recommendations in an annual ‘comply-
or-explain’ review.
New guidelines were introduced to
govern the principles and procedures in
the event of a proposed takeover.
employee-elected members, all elected
for a term of four years. All Board members
are presented on pages 42-43 of this
annual report, with details of their specific
competencies, directorships, and other
relevant background information. The
Board of Management is presented on
page 44. There were no changes to the
Board of Management in 2021.
The election of new independent Board
members in 2021-22 to achieve an
overweight of independent members on
the Board of Directors and its three sub-
committees: The Audit Committee, the
Remuneration & Nomination Committee,
as well as the Scientific Committee.
The review of all updated 40 guidelines is
available at https://ir.alk.net/corporate-
governance
The most recent update to the Danish
Committee on Corporate Governance’s
Continues  
Board of Directors  
Find out more  
ALK’s statutory corporate  
Nationality  
Gender diversity  
Independence  
governance statement: https://  
ir.alk.net/corporate-governance  
Danish  
Other  
Male  
Female  
Independent  
Non-independent  
33%  
Find out more  
33%  
The Board of Directors’ ‘comply  
or explain’ review: https://ir.alk.  
net/corporate-governance  
50%  
50%  
67%  
67%  
 
Management’s review  
Annual report 2021  
ALK  
35  
Remuneration  
The remuneration policy was approved by  
the AGM in March 2021.  
Remuneration 2017-21  
Remuneration for the Board of Directors  
and the Board of Management is  
determined in accordance with ALK’s  
remuneration policy as adopted by the  
AGM. The policy is prepared in accordance  
with sections 139 and 139a of the Danish  
Companies Act as well as items 4.1.1-  
4.1.6 of the latest Danish Corporate  
Governance Recommendations.  
DKKt  
2021  
2020  
2019  
2018  
2017  
Summary of remuneration report  
Remuneration for the Board of Directors  
and Board of Management is reported  
separately in ALK’s remuneration report.  
The report is prepared in accordance with  
section 139b of the Danish Companies Act.  
Board of Directors  
Base fees  
Committee fees  
3,650  
998  
3,359  
885  
3,245  
850  
3,080  
850  
3,300  
850  
Total  
4,648  
4,244  
4,095  
3,930  
4,150  
Board of Management  
Base salary  
Short-term incentives (cash bonus)  
Sign-on bonus (cash)  
Pension incl. social security  
Other benefits  
Termination benefits  
17,276  
11,924  
-
1,396  
703  
16,804  
9,906  
-
1,345  
741  
15,104  
8,535  
-
1,298  
803  
14,229  
7,342  
686  
1,151  
814  
16,775  
7,835  
1,500  
1,584  
932  
The report provides an overview of the  
components in the remuneration for  
the Board of Directors and Board of  
Management, including an overview  
of the actual remuneration in 2021, its  
development during the past three years,  
as well as the shareholdings of Board  
of Directors and Board of Management  
members.  
The policy outlines the overall framework  
for remuneration. The objectives of the  
policy are to:  
-
-
-
-
2,332  
13,228  
Long-term incentives (grant value)  
6,371  
6,204  
6,863  
12,376  
Total  
37,670  
35,000  
32,603  
36,598  
44,186  
Attract, motivate, and retain qualified  
members of the Board of Directors and  
Board of Management.  
serving on the Board’s committees. The  
Board and committee fees remained  
unchanged from 2020 to 2021. For  
members serving on the Scientific  
Committee, a fee was set as outlined in  
ALK’s remuneration policy. Members of  
the Board are not offered share options,  
performance shares or other incentives  
as payment for their work on the Board or  
committees.  
strong financial results and solid progress  
on ALK’s strategic agenda. Both the short-  
term and long-term incentive plans were  
settled above target, while the base salary  
for members of the Board of Management  
was increased by 1.75%, in line with  
the general increase for ALK employees  
Continues  
Align the remuneration components to  
the interests of shareholders.  
All remuneration for the Board of Directors  
and Board of Management followed the  
principles and framework outlined in ALK’s  
remuneration policy.  
Contribute to promoting value creation  
at ALK and support ALK’s business  
strategy.  
Members of the Board of Directors each  
received a fixed annual fee for serving on  
the Board, with the Vice Chairman and  
Chairman receiving double and triple  
the annual fee, respectively. In addition,  
members received an additional fee for  
Ensure that the remuneration of individual  
members of the Board of Management  
reflects the overall performance as well  
as individual results.  
Find out more  
The remuneration policy is  
available at https://ir.alk.  
net/corporate-governance  
The remuneration of the Board of  
Management reflects a good year with  
 
Management’s review  
Annual report 2021  
ALK  
36  
in Denmark – except for the CFO, who  
received an increase above the general  
level to bring his base salary closer to the  
market level.  
Foundation, while all B shares are listed  
on Nasdaq Copenhagen and freely  
negotiable.  
Of the largest registered shareholders,  
the vast majority were institutional  
investors, particularly from Europe  
and North America. The international  
registered ownership was estimated at  
approximately 31% (23%), representing  
52% of the free float of the B share capital,  
excluding the Lundbeck Foundation’s  
holding and treasury shares.  
Core data for the share  
Share capital  
Nominal value  
No of A shares  
DKK 111,411,960  
10 DKK per share  
On 31 December 2021, ALK had 20,434  
registered shareholders versus 17,697  
at the end of 2020. The registered  
shareholders owned 98% of the share  
capital (98%).  
The remuneration report for 2021 will be  
presented for an advisory vote at the AGM  
on 16 March 2022. The remuneration  
report is available at https://ir.alk.net/  
corporate-governance  
920,760 units with  
10 votes per share  
No of AA shares  
No of B shares  
92,760 units with  
10 votes per share  
Two shareholders have reported to ALK  
that they held 5% or more of the shares on  
31 December 2021:  
To meet obligations to deliver shares under  
management incentive programmes, ALK  
held 148,528 of its own shares, or 1.3% of  
the share capital, versus 1.9% at the end of  
2020. The holding was reduced during the  
year following the settlement of share option  
and performance share programmes. The  
Continues  
Investor relations objectives  
10,128,360 units with  
1 vote per share  
It is ALK’s objective to have a diversified  
shareholder base in terms of geography,  
investment profile and time horizon that  
shares the company’s vision and supports  
its long-term strategy. Accordingly, ALK’s  
investor relations (IR) activities aim to  
support the perception of ALK as an  
accessible, trustworthy, and professional  
company that provides relevant, accurate,  
balanced, and timely information to capital  
markets in order to enable both a fair  
valuation and regular trading of its shares.  
The Lundbeck Foundation (Denmark):  
40.3% incl. A and AA shares  
ATP (Denmark): 5.8%  
Stock exchange  
Ticker symbol  
Indices  
Nasdaq Copenhagen  
ALK B  
X4500 (healthcare),  
OMXCLCPI (LargeCap)  
and OMXCPI (all)  
ISIN  
DK0060027142  
ALKB.DC  
Major shareholders’ and treasury shares  
Shareholder  
Registered office  
No of shares  
Interest  
Votes  
Blomberg code  
Reuters code  
ADR ticker symbol  
Lundbeck Foundation  
Copenhagen,  
Denmark  
920,720 A shares  
92,072 AA shares  
3,474,827 B shares  
40.3%  
67.2%  
ALKB_CO  
AKABY  
Growing shareholder base  
ALK’s share capital is divided into A  
shares, AA shares and B shares. The  
A and AA shares are not listed and are  
predominantly held by the Lundbeck  
ATP  
Hillerød,  
Denmark  
642,314 B shares  
5.8%  
1.3%  
3.2%  
-
LEI code  
529900SGCREUZCZ7P020  
ALK (treasury shares)  
Hørsholm,  
Denmark  
148,528 B shares  
 
Management’s review  
Annual report 2021  
ALK  
37  
current holding is considered sufficient to  
cover current obligations under long-term  
incentive programmes.  
Return to shareholders  
yielded an average, annual return of 47%  
to shareholders.  
recommendation that dividend payments  
be suspended until ALK’s profitability  
further improves. Accordingly, the Board  
of Directors will propose to the AGM, that  
no dividends are declared for 2021. The  
Board of Directors revisits the dividend  
policy and ALK’s capital structure on an  
ongoing basis.  
At year-end, the closing price of ALK B  
shares on Nasdaq Copenhagen was  
DKK 3,430, up 37% since 31 December  
2020. During the same period, the Danish  
OMXC25 increased by 17% and the  
Nasdaq Biotechnology Index decreased  
by 1%.  
Dividend and capital structure  
The Board of Directors considers that  
ALK’s financial resources, including credit  
facilities, continue to form a sufficient  
basis for executing ALK’s strategy and  
to fund investments. At the end of 2021,  
net interest-bearing debt amounted to  
DKK 516 million and leverage stood at 1.0  
EBITDA (1.6).  
The Board of Directors and Board of  
Management held a total of 12,963 shares  
at year-end, corresponding to 0.1% of the  
share capital (0.1%).  
Liquidity  
The total market value of ALK’s B shares,  
excluding treasury shares, was DKK 34  
billion at year-end versus DKK 25 billion  
at the end of 2020. Since end of 2017,  
shortly after the announcement of ALK’s  
new strategy, share price increases have  
Up to and including 11 March 2023,  
the Board of Directors is authorised to  
increase the share capital by up to DKK  
11,141,196 (AA shares with a nominal  
value of up to DKK 1,012,836, and B  
shares with a nominal value of up to DKK  
The daily trading liquidity during 2021 was  
largely unchanged and averaged DKK 30  
million (31) per day in value.  
In support of ALK’s growth strategy,  
the Board of Directors is extending its  
Shareholders as at 31 December 2021  
The ALK share in 2021  
The Lundbeck Foundation  
ALK  
ATP  
ALK  
Other  
OMXC25 (indexed)  
Pharma, biotech and life sciences (NBI-NAS, indexed)  
Index  
140  
130  
120  
110  
100  
90  
40.3%  
52.6%  
5.8%  
1.3%  
80  
Jan  
Feb  
Mar  
Apr  
May  
Jun  
Jul  
Aug  
Sep  
Oct  
Nov  
Dec  
Continues  
 
Management’s review  
Annual report 2021  
ALK  
38  
10,128,360). Capital increases may either  
be at a price below market price with pre-  
emption rights for existing shareholders, or  
at market price without pre-emption rights  
for B shareholders.  
Working to strengthen its dialogue with  
all financial stakeholders, in accordance  
with good IR practice and the applicable  
rules and regulations for companies  
listed on Nasdaq Copenhagen, by  
providing equal and sufficient access to  
potentially price-sensitive information.  
The Board of Directors is authorised for  
the period until 12 March 2024 to let  
the company acquire own B shares on a  
regular basis for a nominal value of up to  
DKK 11,141,196 (equivalent to 10% of the  
share capital). Such shares may only be  
acquired for an amount that, together with  
the treasury shares already held by the  
company, at no time exceeds a nominal  
value of 10% of the share capital. The  
consideration for such shares may not  
deviate by more than 10% from the official  
quoted price of the B shares on Nasdaq  
Copenhagen on the date of acquisition.  
Sharing key feedback from investors  
and analysts with the Board of  
Management and Board of Directors;  
and facilitating the ability of all  
shareholders to easily exercise their  
voting rights.  
During 2021, besides hosting  
regular telephone conferences, ALK  
representatives participated in many  
individual meetings and briefing calls with  
analysts and investors. ALK also presented  
at investor conferences and seminars  
targeting various audiences. As in-person  
meetings continued to be limited due to  
COVID, the engagement with investors and  
analysts was predominantly virtual.  
Investor relations  
According to ALK’s IR policy, the IR  
department is committed to:  
Providing information on strategy,  
operations, performance, expectations,  
goals, pipeline, market development,  
and other matters of importance to the  
assessment of the share.  
A total of 26 announcements were  
published in 2021 (2020: 17), including  
investor news and reports on transactions  
by managerial staff. All announcements  
Continues  
 
Management’s review  
Annual report 2021  
ALK  
39  
are available on ALK’s main corporate  
website, together with reports,  
presentations, recordings of telephone  
conferences, share price information,  
analysts’ estimates, and related  
information. Registered shareholders  
are encouraged to sign up at the  
InvestorPortal.  
Ownership structure  
The Lundbeck  
Foundation  
Institutional and  
private investors  
(20,433)  
40.3% 59.7%  
of capital  
of capital  
Find out more  
67.2% 32.8%  
Visit Investor Relations at  
https://ir.alk.net/investors  
of votes  
of votes  
Contact Investor Relations  
e Lundbeck Foundation  
Per Plotnikof, Head of IR  
Tel. +45 4574 7527  
A + AA shares  
(The Lundbeck Foundation):  
A + AA shares (Other):  
1,012,792  
The Lundbeck Foundation, one of Denmark’s largest commercial  
44  
foundations, is the controlling shareholder of ALK, owning 67% of the  
votes and 40% of the capital. The Foundation grants a minimum of  
DKK 500 million each year to public biomedical and health science  
research with a particular focus on neuroscience. Its business  
activities encompass majority shareholdings in two other healthcare  
companies, H. Lundbeck and Falck, an international portfolio of life  
science venture companies, a portfolio of biotech start-ups based on  
research from primarily Danish universities, as well as management  
of securities of around DKK 24 billion.  
A + AA shares total:  
1,012,836  
B-shares  
(The Lundbeck Foundation):  
B-shares (ATP):  
Financial calendar for 2022  
3,474,827  
642,314  
5,862,691  
Annual General Meeting  
16 March  
B-shares (Other):  
Three-month interim report (Q1)  
Six-month interim report (Q2)  
Nine-month interim report (Q3)  
12 May  
11 August  
B-shares total:  
10,128,360  
10 November  
 
Management’s review  
Annual report 2021  
ALK  
40  
Commercial risks  
Risk management  
Description  
The degree of market acceptance for a new product or drug candidate depends on several factors,  
including the demonstration of clinical efficacy and safety, cost-effectiveness, convenience and  
ease of administration, potential advantages over alternative treatment methods, competition, and  
marketing and distribution support. If ALK’s new products, primarily tablets, fail to achieve market  
acceptance, this could have a significant influence on the company’s ability to generate revenue.  
Even if market acceptance of the tablets is successfully achieved, the extent of their acceptance could  
influence the company’s ability to fully deliver on its sales-growth targets for these products. While  
acceptance of tablets continues to increase in most markets, market acceptance remains a risk for  
ALK primarily in the USA.  
ALK’s Board of Management  
is responsible for the ongoing  
management of risks throughout  
the value chain, including risk  
mapping, the assessment of  
probabilities and potential  
consequences, and the  
relevant to ALK’s risk profile. It meets twice  
a year or more, as required, to perform its  
tasks. Risks are systematically assessed  
according to a two-dimensional matrix,  
rating the impact and probability of each  
risk. A risk management report with  
key enterprise risks and recommended  
mitigation plans is presented to Board of  
Management before it is submitted to the  
Board of Directors on an annual basis for  
their review and approval.  
Price pressures mandated by authorities can have a significant impact on the company’s earnings  
capacity. In most of the countries in which ALK operates, prescription drugs are subject to  
reimbursement from, and price controls by, national authorities and healthcare providers. This  
often results in significant price differences between individual markets. Exceptionally, governments  
and national authorities may introduce economic measures that also affect the pricing and  
reimbursement of medicines, for example, because of the impact of COVID on healthcare budgets or  
because of a major economic downturn.  
introduction of risk-reducing  
measures.  
Risk mitigation  
The following is a description of ALK’s key  
enterprise risks, and the main initiatives  
taken to mitigate these risks. The risk  
movements compared to the previous year  
are indicated.  
ALK closely monitors economic, market and regulatory developments as they relate to product  
pricing, along with the competitive situation and initiatives in all important markets, with the aim of  
appropriate risk mitigation.  
The Board of Management has established  
a risk committee to assist it in meeting its  
overall responsibility for risk management.  
The Risk Committee comprises  
ALK regularly conducts extensive surveys of market conditions and similar factors and commits  
significant resources to providing information on its products to doctors and patients. Sales growth  
targets are set with a full understanding of the potential risks involved in successfully marketing  
any product and these are anticipated and managed so far as is possible. ALK continues its focus  
on market access strategy, especially in the USA, to make tablets a more attractive alternative for  
patients.  
representatives from each functional area  
ALK is strongly committed to evidenced-based medicine, based on strong clinical and health  
economic evidence as the basis for pricing and reimbursement. ALK actively engages in dialogue  
with authorities with the aim of securing fair pricing and reimbursement agreements and maintains  
a strong focus on its market access strategy.  
2021 movement  
The impact of the risk has increased  
compared to the year before  
The impact of the risk is stable and  
has not changed from the year before  
The impact of the risk has decreased  
compared to the year before  
2021 movement:  
 
 
Management’s review  
Annual report 2021  
ALK  
41  
Production and quality issues impacting  
product supply and patient safety  
Failures or delays in  
product development  
Breaches of legal or  
ethical standards  
Severe IT security breaches  
impacting business continuity  
Description  
Description  
Description  
Description  
ALK’s products are subject to many statutory and regulatory requirements with respect to  
issues such as safety, efficacy, and production. The products may, in unexpected situations,  
be associated with allergic reactions of varying extents, durations and severities. Meeting  
high product quality standards is a prerequisite for the company’s ability to supply products  
and hence its competitive strength, and for the company’s earnings and sales.  
The future success of ALK depends on the  
Non-compliance with applicable regulations,  
legislation, or ALK’s Code of Conduct could  
negatively impact the company’s good  
reputation which is essential for operating  
within the pharmaceutical industry.  
The threat of cyberattacks continues to grow  
significantly for ALK, as it does for most  
major companies. Disruption to IT systems,  
such as severe breaches of data security,  
may occur across the global value chain,  
where well-functioning IT systems and  
infrastructure are critical for the company’s  
ability to operate effectively.  
company’s ability to maintain current products and  
to successfully identify, develop and market new,  
innovative drugs, which involves significant risks.  
A pharmaceutical drug must be subjected to  
extensive and lengthy clinical trials to document  
qualities such as safety and efficacy before it can be  
approved for marketing. During the development  
process, the outcomes of these trials are subject to  
significant risks. Even though substantial resources  
are invested in the development process, the trials  
may produce negative results.  
ALK has concentrated its key in-house production capacity at plants in Denmark, France,  
Spain and the USA. Although the plants are in areas that have not historically been hit by  
natural disasters, this geographical spread calls for risk planning to avoid emergencies,  
such as lack of, or poor access to, raw materials: for instance, pollen.  
Patents and other intellectual property rights  
are important for developing and retaining  
ALK’s competitive strength.  
As ALK works to rationalise its product portfolio, there may be risks associated with the  
discontinuation of its products. Among others, these may include potential disruption at  
manufacturing sites during decommissioning work, the loss of sales from products for which  
no suitable ALK substitute product exists, or the inability to meet sudden spikes in demand  
for other products due to patients switching from discontinued products. Dependency on  
third parties for supplying input for key production processes and commercialising the  
company’s products in several markets entails risks that ALK would not be subject to if the  
company possessed the necessary in-house capabilities.  
Risk mitigation  
Risk mitigation  
ALK strives to act professionally, honestly,  
and with high integrity throughout the  
company in relation to stakeholders. ALK’s  
Code of Conduct defines ALK’s high standard  
of ethical behaviour in relation to customers,  
employees, shareholders, society, suppliers,  
and partners. Immediate action is taken on  
substantiated non-compliance. Annually,  
all employees are asked to sign and confirm  
their knowledge of the Code of Conduct and  
to take an online test.  
ALK continuously manages this risk, among  
other ways, by having a security strategy  
in place to prevent intruders from causing  
damage to systems or gaining access  
to critical data and systems. Awareness  
campaigns, access controls, intrusion  
detection and prevention systems have  
all been implemented, further initiatives  
are planned, and systems are regularly  
upgraded to increase network security.  
Failures or delays in the development process or in  
obtaining regulatory approvals may have a major  
impact for the patients not able to benefit from the  
products, and on the ability of ALK to achieve its  
long-term goals.  
Risk mitigation  
Risk mitigation  
ALK stringently monitors product quality and safety, both in clinical development and in  
sales and marketing activities. If, despite the high levels of quality and safety, a situation  
should occur in which it is necessary to recall a product, ALK has procedures in place to  
ensure that this can be managed swiftly and effectively and in accordance with regulatory  
requirements. Production and manufacturing processes are subject to periodic and routine  
inspections by regulatory authorities as a regular part of their monitoring processes to  
ensure that ALK observes the prescribed requirements and standards.  
ALK and its collaborative partners perform thorough  
risk assessments of their research and development  
programmes throughout the development and  
registration processes with the objective of risk  
mitigation to optimise the likelihood of the products  
reaching the market.  
Internal controls and policies are in place to  
safeguard ALK’s intellectual property rights.  
The risk that ALK might infringe patents or  
trademark rights held by other companies,  
as well as the risk that other companies  
may attempt to infringe the patents and/or  
trademark rights of ALK are monitored and, if  
necessary, suitable measures are taken.  
ALK’s Scientific Committee is responsible for other  
patient-/product-related innovation activities.  
The committee advises on matters relating to R&D  
activities and other patient-/product-related  
innovation activities, including reviewing R&D  
programmes and the overall R&D pipeline.  
ALK’s production processes and quality standards have been developed and optimised over  
many years. ALK has invested significantly to increase the robustness and compliance of the  
legacy business by reducing manufacturing complexity, and all possible steps are taken during  
portfolio rationalisation work to mitigate any potential impact on other areas of manufacturing  
or the wider business. ALK conducts risk planning including for the prevention of unwanted  
events, and preventative inventory management. ALK manages third party dependency risks  
through contractual stipulations, planning, monitoring, and joint steering committees.  
2021 movement:  
2021 movement:  
2021 movement:  
2021 movement:  
 
Management’s review  
Annual report 2021  
ALK  
42  
Board of Directors  
Anders Hedegaard  
Lene Skole1  
(1959, Danish)  
Gitte Aabo  
(1967, Danish)  
Lars Holmqvist1  
(1959, Swedish)  
(1960, Danish)  
Rodenstock Group, CEO  
The Lundbeck Foundation, CEO  
and directorships at two other subsidiaries  
GN Hearing, CEO  
Professional board member  
Board member since 20152  
Chairman  
Board member since 20202  
Board member since 20212  
Vice Chairman  
Board member since 20142  
Member of the Audit Committee  
Member of the Audit Committee  
Chairman of the Remuneration & Nomination  
Committee  
Member of the Remuneration & Nomination  
Committee  
Member of the Scientific Committee  
Member of the Scientific Committee  
Competencies  
Competencies  
Competencies  
Competencies  
Specific expertise within management and sales  
& marketing in international life science and  
consumer care companies.  
Experience in management, financial and  
economic expertise, experience in strategy and  
communication in international companies.  
Extensive global leadership experience and deep  
understanding of international management,  
finance, IT, and sales & marketing, as well  
as considerable insights into building digital  
communities.  
Experience in management, finance and sales &  
marketing in international life science companies,  
including med-tech and pharmaceutical  
companies.  
Directorships3  
Directorships3  
Directorships3  
Falck A/S, Vice Chairman  
H. Lundbeck A/S, Vice Chairman  
Tryg Forsikring A/S  
Tryg A/S  
Ørsted A/S, Vice Chairman  
Danmarks Nationalbank  
HIMPP A/S (Hearing Instrument Manufacturers  
Patent Partnership)  
UNION therapeutics A/S  
The Danish Chamber of Commerce  
Biovica International AB, Chairman  
H. Lundbeck A/S  
The Lundbeck Foundation  
Naga UK Topco Limited, UK  
Vitrolife AB, Sweden  
1
These board members are not regarded as independent in the sense of the definition contained in the Danish Corporate Governance Recommendations due to their affiliations with the Lundbeck Foundation, which owns 40.3% of ALK’s shares.  
Members elected by the Annual General Meeting are up for re-election each year.  
2
3
Directorships do not include those for companies that are privately owned, in whole or in part, by members of the Board of Directors.  
 
 
Management’s review  
Annual report 2021  
ALK  
43  
Bertil Lindmark  
(1955, Swedish)  
Jakob Riis1  
(1966, Danish)  
Katja Barnkob  
(1969, Danish)  
Nanna Rassov Carlson  
Johan Smedsrud  
(1976, Danish)  
(1972, Danish)  
Galecto A/S, Chief Medical Officer  
Board member since 20212  
Falck A/S, President & CEO  
Board member since 20132  
Chairman of the Audit Committee  
Project Director, Global CMC  
Development, ALK-Abello A/S  
Manager, QA Release, ALK-Abelló A/S  
Board member since 2019  
Employee-elected  
Maintenance Supporter, Process &  
Production Support, ALK-Abelló A/S  
Board member since 2011  
Employee-elected  
Board member since 2019  
Employee-elected  
Chairman of the Scientific Committee  
Competencies  
Competencies  
Competencies  
Competencies  
Competencies  
More than 30 years’ experience  
of global R&D leadership in  
Experience in management and  
sales & marketing in the international  
healthcare industry.  
Experience in project management of  
global drug development projects in the  
pharmaceutical industry.  
Expertise in production and release of  
ALK’s active pharmaceutical ingredients  
for sublingual immunotherapy products.  
Experience in HVAC systems, cleanroom  
testing, utensil washing and sterilisation  
for the pharmaceutical industry.  
pharmaceuticals and biotech. Brings  
board-level experience from Almirall  
and Medicon Valley Alliance, and served  
on the Research Board of AstraZeneca.  
Has also participated in a range of  
IPOs, acquisitions and debt-financing  
activities.  
Directorships3  
Danish Board of Business Development,  
Chairman  
1
These board members are not regarded as independent in the sense of the definition contained in the Danish Corporate Governance Recommendations due to their affiliations with the Lundbeck Foundation, which owns 40.3% of ALK’s shares.  
Members elected by the Annual General Meeting are up for re-election each year.  
2
3
Directorships do not include those for companies that are privately owned, in whole or in part, by members of the Board of Directors.  
 
Management’s review  
Annual report 2021  
ALK  
44  
Board of Management  
Carsten Hellmann  
Henrik Jacobi  
Søren Jelert  
Søren Niegel  
(1964)  
(1965)  
(1972)  
(1971)  
President & CEO  
Executive Vice President,  
Research & Development  
Executive Vice President & CFO  
Executive Vice President,  
Commercial Operations  
Competencies  
Competencies  
Competencies  
Competencies  
Executive management experience  
in global healthcare and  
biopharmaceutical companies.  
Experience in management, innovation,  
and research & development in the  
pharmaceutical industry.  
Experience in management, financial  
and economic expertise in the  
pharmaceutical industry and other  
sectors.  
Experience in management as well as  
global production and sales & marketing  
within the pharmaceutical industry.  
Henrik Jacobi holds a degree in  
Medicine from 1993.  
Directorships1  
Coloplast A/S  
Copenhagen Capacity  
The Danish Chamber of Commerce  
1
Directorships do not include those for companies that are privately owned, in whole or in part, by members of the Board of Management.  
 
 
Financial statements  
Annual report 2021  
ALK  
45  
Financial  
statements  
Statements  
46 Statement by Management on the annual report  
47 Independent Auditor’s reports  
Consolidated financial statements  
52 Income statement  
52 Statement of comprehensive income  
53 Cash flow statement  
54 Balance sheet  
55 Statement of changes in equity  
56 Notes  
The peanut drug  
Parent company financial statements  
92 Income statement  
substance is processed  
into a lyophilised tablet  
as the drug product that  
is visually inspected for  
e.g. colour.  
93 Balance sheet  
94 Statement of changes in equity  
95 Notes  
 
 
Financial statements  
Annual report 2021  
ALK  
46  
Statement by Management on the annual report
The Board of Directors and the Board of
Management have today considered
and adopted the annual report of
ALK-Abelló A/S for the financial year
1 January to 31 December 2021.
consolidated cash flows for the financial
year 1 January to 31 December 2021.
Board of Management  
In our opinion, Management's review
includes a true and fair account of the
development in the operations and
financial circumstances of the group and
the parent company, of the results for the
year and of the financial position of the
group and the parent company as well as
a description of the most significant risks
and elements of uncertainty facing the
group and the parent company.
Carsten Hellmann
President & CEO
The consolidated financial statements
have been prepared in accordance
with International Financial Reporting
Standards as adopted by the EU and
further requirements in the Danish
Financial Statements Act. The parent
company financial statements have been
prepared in accordance with the Danish
Financial Statements Act. Management's
review has been prepared in accordance
with the Danish Financial Statements Act.
Henrik Jacobi
Søren Jelert
Executive Vice President
& CFO
Søren Daniel Niegel
Executive Vice President,
Research & Development
Executive Vice President,
Commercial Operations
In our opinion, the annual report of ALK-
Abelló A/S for the financial year 1 January
to 31 December 2021 identified as “ALK-
2021-12-31-en.zip” is prepared, in all
material respects, in compliance with the
ESEF Regulation.
Board of Directors  
Anders Hedegaard
Lene Skole
Gitte Aabo
In our opinion, the consolidated financial
statements and the parent company
financial statements give a true and
fair view of the financial position at
31 December 2021 of the group and the
parent company and of the results of the
group and parent company operations and
Chairman
Vice Chairman
We recommend that the annual report be
adopted at the annual general meeting.
Katja Barnkob
Bertil Lindmark
Nanna Rassov Carlson
Jakob Riis
Lars Holmqvist
Hørsholm, 8 February 2022
Johan Smedsrud
 
 
Statements  
Annual report 2021  
ALK  
47  
Independent Auditor’s Reports
To the shareholders of ALK-Abelló A/S
Our opinion is consistent with our Auditor’s
Long-form Report to the Audit Committee
and the Board of Directors.
under those standards and requirements
are further described in the Auditor’s
responsibilities for the audit of the
Appointment
We were first appointed auditors of
ALK-Abelló A/S on 11 March 2020 for
the financial year 2020. We have been
reappointed annually by shareholder
resolution for a total period of
Report on the audit of the
Financial Statements
Financial Statements section of our report.
What we have audited
The Consolidated Financial Statements
(pp 51-90) and the Parent Company
Financial Statements (pp 91-102) of ALK-
Abelló A/S for the financial year 1 January
to 31 December 2021 comprise income
statement, balance sheet, statement of
changes in equity and notes, including
summary of significant accounting policies
for the Group as well as for the Parent
Company and statement of comprehensive
income and cash flow statement for the
Group.
We believe that the audit evidence we have
obtained is sufficient and appropriate to
provide a basis for our opinion.
Our opinion
uninterrupted engagement of two years
including the financial year 2021.
In our opinion, the Consolidated Financial
Statements give a true and fair view of the
Group’s financial position at 31 December
2021 and of the results of the Group’s
operations and cash flows for the financial
year 1 January to 31 December 2021 in
accordance with International Financial
Reporting Standards as adopted by the
EU and further requirements in the Danish
Financial Statements Act.
Independence
We are independent of the Group in
accordance with the International Ethics
Standards Board for Accountants’
International Code of Ethics for
Professional Accountants (IESBA Code)
and the additional ethical requirements
applicable in Denmark. We have also
fulfilled our other ethical responsibilities in
accordance with these requirements and
the IESBA Code.
Moreover, in our opinion, the Parent
Collectively referred to as the “Financial
Statements”.
Company Financial Statements give a true
and fair view of the Parent Company’s
financial position at 31 December 2021
and of the results of the Parent Company’s
operations for the financial year 1 January
to 31 December 2021 in accordance with
the Danish Financial Statements Act.
Basis for opinion
To the best of our knowledge and belief,
prohibited non-audit services referred
to in Article 5(1) of Regulation (EU) No
537/2014 were not provided.
We conducted our audit in accordance
with International Standards on Auditing
(ISAs) and the additional requirements
applicable in Denmark. Our responsibilities
 
 
Statements  
Annual report 2021  
ALK  
48  
Key audit matters
Statement on Management’s Review
Management is responsible for
Management’s Review (pp 1-44 and p
103).
Statements Act. We did not identify any
material misstatement in Management’s
Review.
Key audit matters are those matters that, in our professional judgement, were of most
significance in our audit of the Financial Statements for 2021. These matters were
addressed in the context of our audit of the Financial Statements as a whole, and in
forming our opinion thereon, and we do not provide a separate opinion on these matters.
Management’s responsibilities for the
Financial Statements
Our opinion on the Financial Statements
does not cover Management’s Review,
and we do not express any form of
assurance conclusion thereon.
Management is responsible for the
preparation of consolidated financial
statements that give a true and fair view
in accordance with International Financial
Reporting Standards as adopted by the
EU and further requirements in the Danish
Financial Statements Act and for the
preparation of parent company financial
statements that give a true and fair view
in accordance with the Danish Financial
Statements Act, and for such internal
control as Management determines is
necessary to enable the preparation of
financial statements that are free from
material misstatement, whether due to
fraud or error.
Key audit matter
How our audit addressed the key audit matter
Valuation of deferred tax assets
A significant part of the recognised deferred tax
assets relates to tax losses carried forward in
Denmark.
We assessed the method applied by Management
for calculating the deferred tax assets and
assessing their valuation.
In connection with our audit of the Financial
Statements, our responsibility is to read
Management’s Review and, in doing so,
consider whether Management’s Review
is materially inconsistent with the Financial
Statements or our knowledge obtained
in the audit, or otherwise appears to be
materially misstated.
We tested the calculation of the deferred tax
assets prepared by Management and involved
our internal tax specialist in assessing the tax
calculation to ensure compliance with relevant tax
legislation.
Utilisation of the recognised deferred tax assets is
depending on the expected future taxable income
within the Danish joint taxation group with the
Lundbeck Foundation and its other subsidiaries.
We focused on this area as the amounts involved
are material and as the valuation of deferred tax
assets is associated with significant accounting
estimates and judgements. This includes the
estimation uncertainty regarding assessing the
future taxable profits of ALK-Abelló A/S and within
the Danish joint taxation group.
We evaluated and challenged the documentation
prepared by Management regarding the deferred
tax assets, including Management’s best
estimate of the probability of realising the future
taxable profits in Denmark and within the Danish
joint taxation group. We furthermore evaluated
Management’s sensitivity and risk analysis.
Moreover, we considered whether
Management’s Review includes the
disclosures required by the Danish
Financial Statements Act.
We refer to note 2.8 in the consolidated financial
statements.
We assessed the appropriateness of the related
disclosure provided in the consolidated financial
statements.
In preparing the Financial Statements,
Management is responsible for assessing
the Group’s and the Parent Company’s
ability to continue as a going concern,
disclosing, as applicable, matters related
to going concern and using the going
concern basis of accounting unless
Based on the work we have performed,
in our view, Management’s Review is
in accordance with the Consolidated
Financial Statements and the Parent
Company Financial Statements and has
been prepared in accordance with the
requirements of the Danish Financial
Management either intends to liquidate
 
Statements  
Annual report 2021  
ALK  
49  
Identify and assess the risks of
material misstatement of the Financial
Statements, whether due to fraud
or error, design and perform audit
procedures responsive to those risks,
and obtain audit evidence that is
sufficient and appropriate to provide
a basis for our opinion. The risk of not
detecting a material misstatement
resulting from fraud is higher than for
one resulting from error, as fraud may
involve collusion, forgery, intentional
omissions, misrepresentations, or the
override of internal control.
basis of accounting and based on the
audit evidence obtained, whether a
material uncertainty exists related to
events or conditions that may cast
significant doubt on the Group’s and the
Parent Company’s ability to continue
as a going concern. If we conclude
that a material uncertainty exists,
opinion on the Consolidated Financial
the Group or the Parent Company or to
cease operations, or has no realistic
alternative but to do so.
Statements. We are responsible for the
direction, supervision and performance
of the group audit. We remain solely
responsible for our audit opinion.
Auditor’s responsibilities for the audit
of the Financial Statements
We communicate with those charged
with governance regarding, among other
matters, the planned scope and timing of
the audit and significant audit findings,
including any significant deficiencies in
internal control that we identify during our
audit.
Our objectives are to obtain reasonable
assurance about whether the Financial
Statements as a whole are free from
material misstatement, whether due to
fraud or error, and to issue an auditor’s
report that includes our opinion.
Reasonable assurance is a high level of
assurance, but is not a guarantee that
an audit conducted in accordance with
ISAs and the additional requirements
applicable in Denmark will always detect
a material misstatement when it exists.
Misstatements can arise from fraud or
error and are considered material if,
individually or in the aggregate, they could
reasonably be expected to influence the
economic decisions of users taken on the
basis of these Financial Statements.
we are required to draw attention in
our auditor’s report to the related
disclosures in the Financial Statements
or, if such disclosures are inadequate, to
modify our opinion. Our conclusions are
based on the audit evidence obtained
up to the date of our auditor’s report.
However, future events or conditions may
cause the Group or the Parent Company
to cease to continue as a going concern.
We also provide those charged with
governance with a statement that we
have complied with relevant ethical
requirements regarding independence,
and to communicate with them all
relationships and other matters that may
reasonably be thought to bear on our
independence, and where applicable,
actions taken to eliminate threats or
safeguards applied.
Obtain an understanding of internal
control relevant to the audit in order
to design audit procedures that are
appropriate in the circumstances, but not
for the purpose of expressing an opinion
on the effectiveness of the Group’s and
the Parent Company’s internal control.
Evaluate the overall presentation,
structure and content of the Financial
Statements, including the disclosures,
and whether the Financial Statements
represent the underlying transactions
and events in a manner that gives a true
and fair view.
Evaluate the appropriateness of
accounting policies used and the
reasonableness of accounting
estimates and related disclosures made
by Management.
From the matters communicated with
those charged with governance, we
determine those matters that were of most
significance in the audit of the Financial
Statements of the current period and
are therefore the key audit matters. We
As part of an audit in accordance with
ISAs and the additional requirements
applicable in Denmark, we exercise
professional judgement and maintain
professional scepticism throughout the
audit. We also:
Obtain sufficient appropriate audit
evidence regarding the financial
Conclude on the appropriateness of
Management’s use of the going concern
information of the entities or business
activities within the Group to express an
 
Statements  
Annual report 2021  
ALK  
50  
Management is responsible for preparing
an annual report that complies with the ESEF
Regulation. This responsibility includes:
and to issue a report that includes our
opinion. The nature, timing and extent
of procedures selected depend on
the auditor’s judgement, including the
assessment of the risks of material
departures from the requirements set out
in the ESEF Regulation, whether due to
fraud or error. The procedures include:
Reconciling the iXBRL tagged data with
the audited Consolidated Financial
Statements.
describe these matters in our auditor’s
report unless law or regulation precludes
public disclosure about the matter or
when, in extremely rare circumstances,
we determine that a matter should not be
communicated in our report because the
adverse consequences of doing so would
reasonably be expected to outweigh
the public interest benefits of such
communication.
The preparing of the annual report in
XHTML format;
In our opinion, the annual report of ALK-
Abelló A/S for the financial year 1 January
to 31 December 2021 with the file name
ALK-2021-12-31-en.zip is prepared, in all
material respects, in compliance with the
ESEF Regulation.
The selection and application of
appropriate iXBRL tags, including
extensions to the ESEF taxonomy and
the anchoring thereof to elements in the
taxonomy, for all financial information
required to be tagged using judgement
where necessary;
Testing whether the annual report is
prepared in XHTML format;
Obtaining an understanding of the
company’s iXBRL tagging process and
of internal control over the tagging
process;
Hellerup, 8 February 2022
Report on compliance with
the ESEF Regulation
PricewaterhouseCoopers
Statsautoriseret Revisionspartnerselskab
CVR No 3377 1231
As part of our audit of the Financial
Statements we performed procedures to
express an opinion on whether the annual
report of ALK-Abelló A/S for the financial
year 1 January to 31 December 2021
with the filename ALK-2021-12-31-en.
zip is prepared, in all material respects,
in compliance with the Commission
Delegated Regulation (EU) 2019/815 on
the European Single Electronic Format
(ESEF Regulation) which includes
Ensuring consistency between iXBRL
tagged data and the Consolidated
Financial Statements presented in
human-readable format; and
Evaluating the completeness of the
iXBRL tagging of the Consolidated
Financial Statements;
Lars Baungaard
For such internal control as Management
determines necessary to enable the
preparation of an annual report that is
compliant with the ESEF Regulation.
State Authorised Public Accountant
mne23331
Evaluating the appropriateness of
the company’s use of iXBRL elements
selected from the ESEF taxonomy and
the creation of extension elements
where no suitable element in the ESEF
taxonomy has been identified;
Kim Tromholt
State Authorised Public Accountant
mne33251
Our responsibility is to obtain reasonable
assurance on whether the annual report
is prepared, in all material respects, in
compliance with the ESEF Regulation
based on the evidence we have obtained,
requirements related to the preparation
of the annual report in XHTML format
and iXBRL tagging of the Consolidated
Financial Statements.
Evaluating the use of anchoring of
extension elements to elements in the
ESEF taxonomy; and
 
Consolidated financial statements  
Annual report 2021  
ALK  
51  
Consolidated  
financial statements  
Financial statements  
Notes  
Income statement  
52  
52  
53  
54  
55  
56  
Section 1  
Basis of reporting  
Section 3  
Operating assets and liabilities  
Section 5  
Other disclosures  
Statement of comprehensive income  
Cash flow statement  
Balance sheet  
1.1 General accounting policies  
56  
58  
3.1 Intangible assets  
3.2 Property, plant and equipment  
3.3 Leases  
66  
68  
70  
72  
73  
73  
74  
76  
76  
5.1 Share-based payments  
5.2 Cash flow  
84  
87  
88  
1.2 Significant accounting  
estimates and judgements  
5.3 Related parties  
Statement of changes in equity  
Notes  
3.4 Inventories  
5.4 Events after the reporting period 88  
5.5 Approval of financial statements 88  
5.6 List of companies in  
Section 2  
Results for the year  
3.5 Trade receivables  
3.6 Prepayments  
Definitions  
90  
2.1 Revenue and segment  
information  
the ALK Group  
89  
3.7 Pensions and similar liabilities  
3.8 Provisions  
59  
60  
2.2 Expenses  
3.9 Other payables  
2.3 Depreciation, amortisation  
and impairment  
3.10 Contingent liabilities  
and commitments  
61  
61  
77  
2.4 Staff costs  
2.5 Fees to the ALK Group’s auditors 62  
Section 4  
Capital structure and financing  
2.6 Other operating items, net  
2.7 Financial income and expenses  
2.8 Income taxes and deferred tax  
62  
62  
63  
4.1 Share capital and earnings  
per share  
78  
79  
4.2 Financial risks and  
financial instruments  
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
52  
Income statement  
Statement of comprehensive income  
Amounts in DKKm  
Note  
2021  
2020  
Amounts in DKKm  
Note  
2021  
2020  
Revenue  
Cost of sales  
2.1  
3,916
1,520
3,491
1,463
Net profit  
219
25
2.2-2.4, 3.4, 5.1  
Items that will subsequently not be reclassified  
to the income statement:  
Gross profit  
2,396
2,028
Actuarial gains/(losses) on pension plans  
Tax related to actuarial gains/(losses) on pension plans  
3.7  
2.8  
16
(5)
(3)
1
Research and development expenses  
Sales and marketing expenses  
Administrative expenses  
2.2-2.4, 5.1  
2.2-2.4, 5.1  
2.2-2.4, 5.1  
2.6  
631
1,234
240
1
515
1,125
237
11
(2)
Other operating items, net  
(1)
Items that will subsequently be reclassified to  
Operating profit (EBIT)  
292
150
the income statement, when specific conditions are met:  
Foreign currency translation adjustment of foreign affiliates  
Tax related to other comprehensive income, that will  
subsequently be reclassified to the income statement  
84
(106)
Financial income  
Financial expenses  
2.7  
2.7  
10
23
5
54
2.8  
(4)
1
Profit before tax (EBT)  
279
101
80
(105)
Tax on profit/(loss)  
2.8  
4.1  
60
76
Other comprehensive income/(loss)  
Total comprehensive income/(loss)  
91
(107)
(82)
Net profit  
219
25
310
Earnings per share (EPS)  
Earnings per share (EPS)  
Earnings per share (DEPS), diluted  
19.96
19.82
2.29
2.27
   
 
Consolidated financial statements  
Annual report 2021  
ALK  
53  
Cash flow statement  
Amounts in DKKm  
Note  
2021  
219
2020  
25
Net profit  
Adjustments  
Adjustments for non-cash items  
Changes in working capital  
Financial income, received  
Financial expenses, paid  
Income taxes, paid (net)  
5.2  
5.2  
400
(28)
-
(23)
(100)
462
(154)
4
(22)
(14)
Cash flow from operating activities  
468
301
Investments in intangible assets  
Investments in tangible assets  
Investments in other financial assets*  
3.1  
3.2  
(45)
(218)
(3)
(26)
(196)
(23)
Cash flow from investing activities  
Free cash flow  
(266)
202
(245)
56
Sale of treasury shares  
31
(72)
226
(32)
(464)
11
(24)
-
(30)
(19)
Exercised share options, paid  
Proceeds from borrowings  
Repayment of lease liabilities  
Repayment of borrowings  
5.1  
5.2  
5.2  
5.2  
Cash flow from financing activities  
Net cash flow  
(311)
(109)
298
(62)
(6)
Cash beginning of year  
316
Unrealised gain/(loss) on cash held in foreign currency and  
financial assets carried as cash  
Net cash flow  
5
(12)
(6)
(109)
Cash year end  
194
298
The consolidated statement of cash flow is compiled using the indirect method. As a result, the individual figures in the cash flow  
statement cannot be reconciled directly to the income statement and the balance sheet.  
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
54  
Balance sheet – Assets  
Balance sheet – Equity and liabilities  
31 Dec.  
2021  
31 Dec.  
2020  
31 Dec.  
2021  
31 Dec.  
2020  
Amounts in DKKm  
Note  
Amounts in DKKm  
Note  
Non-current assets  
Equity  
Share capital  
Currency translation adjustment  
Retained earnings  
4.1  
111
(41)
3,410
111
(125)
3,167
Intangible assets  
Goodwill  
Other intangible assets  
3.1  
3.1  
457
165
452
172
Total equity  
3,480
3,153
622
624
Tangible assets  
Land and buildings  
Plant and machinery  
Other fixtures and equipment  
Property, plant and equipment in progress  
3.2-3.3  
3.2  
3.2-3.3  
3.2  
958
451
80
921
442
72
Liabilities  
Non-current liabilities  
Mortgage debt  
Bank loans  
Pensions and similar liabilities  
Lease liabilities  
Deferred income  
4.2  
4.2  
3.7  
4.2  
222
-
324
207
42
240
446
345
207
-
325
269
1,814
1,704
Other non-current assets  
Receivables  
Deferred tax assets  
Income tax receivables  
29
790
172
30
697
168
2.8  
Deferred tax liabilities  
Income tax payables  
2.8  
1
-
169
143
991
895
965
1,381
Current liabilities  
Mortgage debt  
Bank loans  
Trade payables  
Lease liabilities  
Deferred income  
Provisions  
Total non-current assets  
Current assets  
3,427
3,223
4.2  
4.2  
18
226
115
37
4
12
18
-
74
32
1
3
21
880
4.2  
3.8  
3.9  
Inventories  
3.4  
3.5  
5.3  
1,204
583
12
14
82
314
194
1,093
544
20
24
96
265
298
Trade receivables  
Receivables from group companies  
Income tax receivables  
Other receivables  
Prepayments  
Income tax payables  
Other payables  
23
950
1,385
1,029
3.6  
Cash  
Total liabilities  
2,350
2,410
Total current assets  
2,403
2,340
Total equity and liabilities  
5,830
5,563
Total assets  
5,830
5,563
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
55  
Statement of changes in equity  
Currency  
translation  
adjust-  
Currency  
translation  
adjust-  
ment  
Share  
capital  
Retained  
earnings  
Total  
equity  
Share  
capital  
Retained  
earnings  
Total  
equity  
Amounts in DKKm  
ment  
Amounts in DKKm  
2021  
2020  
Equity at 1 January  
111
(125)
3,167
3,153
Equity at 1 January  
111
(19)
3,084
3,176
Net profit  
Other comprehensive income  
-
-
-
84
219
7
219
91
Net profit  
Other comprehensive income/(loss)  
-
-
-
25
(1)
25
(107)
(106)
Total comprehensive income  
-
84
226
310
Total comprehensive income/(loss)  
-
(106)
24
(82)
Share-based payments  
Share options settled  
Sale of treasury shares  
Tax related to items recognised  
directly in equity  
-
-
-
-
-
-
36
(72)
31
36
(72)
31
Share-based payments  
Share options settled  
Sale of treasury shares  
Tax related to items recognised  
directly in equity  
-
-
-
-
-
-
29
(24)
11
29
(24)
11
-
-
-
-
10
12
10
12
-
-
43
43
Other adjustments  
Other transactions  
-
-
59
59
Other transactions  
-
-
17
17
Equity at 31 December  
111
(125)
3,167
3,153
Equity at 31 December  
111
(41)
3,410
3,480
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
56  
Section 1 – Basis of reporting  
1.1 General accounting policies  
overall description of accounting  
policies.  
and companies (subsidiaries)  
at the transaction date. Receivables  
and debt and other monetary items not  
settled at the balance sheet date are  
translated at the closing rate.  
at the exchange rate at the balance  
sheet date.  
The consolidated financial statements  
for the period 1 January to 31  
controlled by the parent company.  
The parent company is considered  
to control a subsidiary when it holds,  
directly or indirectly, more than 50%  
of the voting rights, or is otherwise  
able to exercise or actually exercises a  
controlling influence and has the right  
to variable returns from the entity.  
December 2021 have been prepared  
in accordance with the International  
Financial Reporting Standards (IFRS)  
as adopted by the EU and in accordance  
with Danish disclosure requirements  
for listed companies. Additional Danish  
disclosure requirements for annual  
reports are imposed by the Statutory  
Order on Adoption of IFRS issued under  
the Danish Financial Statements Act.  
Exchange rate differences arising on  
The accounting policies are unchanged  
from last year except for the below  
mentioned impacts of new standards.  
the translation of foreign subsidiaries’  
opening balance sheet items to the  
exchange rates at the balance sheet  
date and on the translation of the  
income statements from average  
exchange rates to exchange rates at  
the balance sheet date are recognised  
in other comprehensive income.  
Exchange rate differences between  
the exchange rate at the date of  
New standards effective from  
1 January 2021  
the transaction and the exchange  
rate at the date of payment or the  
balance sheet date, respectively, are  
recognised in the income statement  
under financial items. Tangible assets  
and intangible assets, inventories and  
other nonmonetary assets acquired in  
foreign currency and measured based  
on historical cost are translated at the  
exchange rates at the transaction date.  
The ALK Group has implemented all  
new and amended standards and  
interpretations (IFRIC) which are  
effective for the financial year 2021.  
This has not resulted in any changes  
to the accounting policies of the ALK  
Group.  
Basis of consolidation  
The consolidated financial statements  
are prepared based on the financial  
statements of ALK-Abelló A/S and  
its subsidiaries. The consolidated  
financial statements are prepared as  
a consolidation of items of a uniform  
nature. The financial statements  
used for consolidation are prepared  
in accordance with the ALK Group’s  
accounting policies.  
Foreign exchange rate adjustment of  
receivables or debt to subsidiaries  
which are considered part of the  
parent company’s overall investment  
in the subsidiary in question are also  
recognised in other comprehensive  
income in the consolidated financial  
statements.  
The consolidated financial statements  
are presented in Danish kroner (DKK),  
which is considered the primary  
currency of the ALK Group’s activities  
and the functional currency of the  
parent company.  
New standards effective on or after  
1 January 2022  
On recognition in the consolidated  
financial statements of subsidiaries  
whose financial statements are  
A number of IFRS standards, amended  
standards and IFRIC interpretations,  
which are effective on or after 1 January  
2022, have not been implemented.  
Based on a preliminary assessment it  
is estimated that these standards and  
interpretations will have no material  
impact on the consolidated financial  
statements.  
The consolidated financial statements  
are presented on a historical cost  
basis, apart from certain financial  
instruments, which are measured at  
fair value.  
presented in a functional currency  
other than DKK, the income statements  
are translated at average exchange  
rates for the respective months, unless  
these deviate materially from the actual  
exchange rates at the transaction  
dates. In that case, the actual exchange  
rates are used. Balance sheet items  
are translated at the exchange rates  
at the balance sheet date. Goodwill is  
considered to belong to the acquired  
company in question and is translated  
On consolidation, intra-group income  
and expenses, intra-group balances  
and dividends, and gains and losses  
arising on intra-group transactions are  
eliminated.  
Definitions and ratios  
The key ratios have been calculated in  
accordance with generally accepted  
financial ratios applied by financial  
analysts. Definitions are shown on  
page 90.  
The general accounting policies  
described below apply to the  
consolidated financial statements as  
a whole. To enhance understanding,  
specific accounting policies are  
described in the notes to which they  
relate. The description of accounting  
policies in the notes form part of the  
Foreign currency translation  
On initial recognition, transactions  
denominated in currencies other  
than DKK are translated at average  
exchange rates, which are an  
Reporting under the ESEF regulation  
The Commission Delegated Regulation  
(EU) 2019/815 on the European  
Single Electronic Format (ESEF) (ESEF  
Regulation) has introduced a single  
The consolidated financial  
statements  
The consolidated financial statements  
comprise the financial statements of  
ALK-Abelló A/S (the parent company)  
approximation of the exchange rates  
   
 
Consolidated financial statements  
Annual report 2021  
ALK  
57  
Section 1 – Basis of reporting  
1.1 Accounting policies – continued  
electronic reporting format for the  
annual financial reports of issuers with  
securities listed on the EU regulated  
markets.  
As part of the tagging process financial  
XBRL 1.1 specification, which enables  
the conversion of XHTML-formatted  
information into a machine-readable  
XBRL data record by appropriate  
software.  
ESEF data  
statement line items are marked up  
to elements in the ESEF taxonomy.  
If a financial statement line item is  
not defined in the ESEF taxonomy, an  
extension to the taxonomy is created.  
Extensions have to be anchored  
to elements in the ESEF taxonomy,  
except for elements corresponding to  
subtotals.  
Name of reporting entity or other  
means of identification  
ALK-Abelló A/S
The ESEF Regulation sets out the  
following main requirements: (1)  
Issuers shall draw up and disclose  
their annual financial reports using  
the XHTML format; and (2) issuers that  
draw-up their primary consolidated  
financial statements in accordance  
with IFRS as endorsed by the EU shall  
tag those consolidated financial  
statements using inline eXtensible  
Business Reporting Language (iXBRL)  
and with effect from the 2022 annual  
report block-tag the notes to the  
consolidated financial statements.  
Domicile of entity  
Denmark
The tagging process is a process where  
iXBRL tags are applied to financial  
statement line items, etc.  
Legal form of entity  
A/S
Country of incorporation  
Denmark
Taxonomy is an electronic dictionary  
of business reporting elements used  
to report business data. A taxonomy  
element is an element defined in a  
taxonomy that is used for the machine-  
readable labeling of information in an  
XBRL data record.  
The annual report 2021 for the ALK  
Group submitted to the Danish Financial  
Supervisory Authority (The Officially  
Appointed Mechanisms) consists of the  
XHTML document together with some  
technical files all included in a ZIP file  
named “ALK-2021-12-31-en.zip”.  
Address of entity’s registered office  
Bøge Allé 6-8, DK-2970 Hørsholm
Principal place of business  
Global
Description of nature of entity’s  
operations and principal activities  
ALK is a global allergy solutions
company
Key definitions  
The combination of the XHTML  
XHTML (eXtensible HyperText Markup  
Language) is a text-based markup  
language used to structure and mark  
up content such as text, images, and  
hyperlinks in documents that are  
displayed as Web pages in an updated  
standard Web browser like Chrome,  
Internet Explorer or Safari.  
format with the iXBRL tags makes the  
annual financial reports both human-  
readable and machine-readable,  
thus enhancing accessibility, analysis  
and comparability of the information  
included in the annual financial reports.  
Name of parent entity  
Lundbeck Foundation
(Lundbeckfond Invest A/S)
Name of ultimate parent of group  
Lundbeck Foundation
(Lundbeckfond Invest A/S)
iXBRL tags shall comply with the ESEF  
taxonomy, which is included in the ESEF  
Regulation and developed based on the  
IFRS taxonomy published by the IFRS  
Foundation.  
iXBRL tags (or Inline XBRL tags) are  
hidden meta-information embedded  
in the source code of an XHTML  
document in accordance with the Inline  
 
Consolidated financial statements  
Annual report 2021  
ALK  
58  
Section 1 – Basis of reporting  
1.2 Significant accounting estimates and judgements  
In the preparation of the consolidated  
financial statements according to  
IFRS, Management is required to make  
certain estimates as many financial  
statement items cannot be reliably  
measured, but must be estimated.  
Such estimates comprise judgements  
made on the basis of the most recent  
information available at the reporting  
date.  
were based or due to supplementary  
information, additional experience or  
subsequent events. Similarly, the value  
of assets and liabilities often depends  
on future events that are somewhat  
uncertain. In that connection, it is  
necessary to set out e.g. a course of  
events that reflects Management’s  
assessment of the most probable  
course of events.  
the preparation of the consolidated  
financial statements.  
A description of significant accounting  
estimates and judgements as well as  
assumptions applied is included in the  
relevant notes.  
It may be necessary to change previous  
estimates as a result of changes to the  
assumptions on which the estimates  
Management considers those listed  
below as the key accounting estimates  
and related judgements used in  
Estimate/  
judgement  
Note  
Key accounting estimates and judgements  
2.2 Expenses  
Recognition of costs for outsourced clinical trials  
Estimate  
2.8 Income taxes and deferred tax  
Provision for uncertain tax positions and measurement of  
deferred tax assets  
Estimate/  
judgement  
3.1 Intangible assets  
3.4 Inventories  
Recoverable amount of goodwill  
Estimate  
Estimate  
Valuation of inventories and capitalisation of indirect  
production costs  
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
59  
Section 2 – Results for the year  
2.1 Revenue and segment information  
Europe  
North America  
International markets  
Total  
2021  
Accounting policies  
Segment information  
Amounts in DKKm  
2021  
2020  
2021  
2020  
2021  
2020  
2020  
Based on the internal reporting used by the  
SCIT/SLIT-drops  
SLIT-tablets  
Other products and services  
1,273  
1,340  
196  
1,320  
1,019  
211  
302  
120  
261  
275  
85  
213  
80  
314  
30  
78  
266  
24  
1,655  
1,774  
487  
1,673  
1,370  
448  
Board of Management to assess the results of  
operations and allocation of resources, the ALK  
Group has identified one operating segment  
‘Allergy treatment’, which is in accordance  
with the way the activities are organised and  
managed. Even though revenue within the  
operating segment “Allergy treatment” can be  
divided by product lines and market, the main  
part of the activities within production, research  
and development, sales and marketing and  
administration are shared by the ALK Group  
as a whole. The disclosures in the financial  
statements include a breakdown of revenue by  
product line and a geographical breakdown  
of revenue and non-current assets. The  
Total revenue  
2,809  
2,550  
683  
573  
424  
368  
3,916  
3,491  
Sale of goods  
Royalties  
Services  
3,835  
3,429  
58  
81  
-
4
Total revenue  
3,916  
3,491  
Of total revenue, DKK 101 million (2020: DKK 83 million) is derived from Denmark.  
The ALK Group’s non-current tangible and intangible assets are distributed among the following geographical markets:  
geographical information on markets is based  
on customer and asset location.  
Europe  
2021  
North America  
International markets  
Total  
Amounts in DKKm  
2020  
2021  
2020  
2021  
2020  
2021  
2020  
Revenue  
The primary performance obligation of the  
ALK Group is the sale and delivery of own-  
manufactured goods and goods for resale for  
allergy treatment. Revenue from the sale of  
goods is recognised in the income statement  
upon the control of the goods being transferred  
to the customer, i.e. when goods are delivered.  
Revenue is recognised by the ALK Group at a  
point in time.  
Non-current tangible and  
intangible assets  
1,671  
1,629  
763  
695  
2
4
2,436  
2,328  
Of total non-current tangible and intangible assets, DKK 1,283 million relates to assets in Denmark (2020: DKK 1,257 million).  
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
60  
Section 2 – Results for the year  
2.1 Revenue and segment information – continued  
2.2 Expenses – continued  
The ALK Group’s customers have payment terms that reflect the customer type and the market in which  
sales take place, which typically varies from 0 to 180 days.  
income statement when incurred. Due to the long development periods and significant uncertainties  
in relation to the development of new products, including risks regarding clinical trials and regulatory  
approvals, it is the assessment that most of the ALK Group’s development expenses do not meet the  
Revenue is measured as the fair value of the consideration received or receivable.  
capitalisation criteria in IAS 38, Intangible Assets. Consequently, development expenses are generally  
recognised in the income statement when incurred. Development expenses relating to individual minor  
development projects running for short-term periods and subject to limited risk are capitalised under  
other intangible assets.  
Revenue is measured exclusive of VAT, taxes etc. charged on behalf of third parties and less any  
commissions and discounts in connection with sales.  
Furthermore, revenue includes licence income and royalties from outlicensed products as well as up-  
front payments, milestone payments and services in connection with partnerships. These revenues  
are recognised in the income statement in accordance with the agreements and when the ALK Group  
obtains the right to the payments, which is when services have been delivered to the customer or at the  
point in time the subsequent sales occur.  
Sales and marketing expenses  
The item comprises selling and marketing expenses, including salaries and expenses relating to sales  
staff, advertising and exhibitions, depreciation, amortisation and impairment losses on tangible assets  
and intangible assets used in the sales and marketing process as well as other indirect costs.  
Administrative expenses  
When combined contracts are entered, the elements of the contracts are identified and assessed  
separately for accounting purposes.  
The item comprises expenses incurred for management and administration, including expenses for  
administrative staff and management, office expenses and depreciation, amortisation and impairment  
losses on tangible assets and intangible assets used in administration.  
2.2 Expenses  
Significant accounting estimates and judgements  
Accounting policies  
Clinical trials, which are outsourced to Clinical Research Organisations (“CROs”), take several years  
to complete. As such, Management is required to make estimates based on the progress and costs  
incurred to-date for the ongoing trials. Estimates are made in determining the amount of costs to be  
expensed during the period or recognised as prepayments or accruals on the balance sheet.  
Cost of sales  
The item comprises cost of sales and production costs incurred in generating the revenue for the year.  
Costs for raw materials, consumables, goods for resale, production staff and a proportion of production  
overheads, including maintenance and depreciation, amortisation and impairment of tangible assets  
and intangible assets used in production as well as operation, administration and management of  
factories are recognised in cost of sales and production costs. In addition, the costs and write-down to  
net realisable value of obsolete and slow-moving goods are recognised.  
At 31 December 2021, DKK 179 million is recognised as accrued expenses (2020: DKK 135 million) and  
DKK 240 million as prepayments in the balance sheet (2020: DKK 218 million). In 2021, clinical trials  
expenses of DKK 242 million have been recognised in the income statement (2020: DKK 154 million).  
Research and development expenses  
The item comprises research and development expenses, including expenses incurred for wages  
and salaries, amortisation, impairment of capitalised development projects in progress, and other  
overheads as well as costs relating to research partnerships. Research expenses are recognised in the  
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
61  
Section 2 – Results for the year  
2.3 Depreciation, amortisation and impairment  
2.4 Staff costs  
Amounts in DKKm  
2021  
2020  
Amounts in DKKm  
2021  
2020  
Wages and salaries  
Pensions, cf. note 3.7  
Other social security costs, etc.  
1,425  
115  
193  
35  
1,342  
110  
197  
28  
Depreciation, amortisation and impairment allocation:  
Cost of sales  
Research and development expenses  
Sales and marketing expenses  
Administrative expenses  
158  
8
36  
40  
152  
26  
29  
Share-based payments, cf. note 5.1  
Total  
1,768  
1,677  
38  
Staff costs are allocated as follows:  
Cost of sales  
Research and development expenses  
Sales and marketing expenses  
Administrative expenses  
Total  
242  
245  
682  
254  
604  
170  
58  
668  
233  
557  
164  
55  
Impairment amounts to DKK 20 million (2020: DKK 38 million), of which DKK 8 million relate to tangible  
assets (2020: DKK 16 million) and DKK 12 million relate to intangible assets (2020: DKK 22 million).  
Included in the cost of assets  
Total  
1,768  
1,677  
The impairment of tangible assets is related to impairment of equipment with no recoverable amount  
after impairment of which DKK 7 million relate to production equipment and DKK 1 million relate to  
research and development equipment. The impairment is recognised as cost of sales and research and  
development expenses, respectively.  
Remuneration to Management:  
Remuneration to Board of Management:*  
Salaries  
Short-term incentive (cash bonus)  
Pensions  
Long-term incentives (share-based) based on  
expensed accounting value, cf. note 5.1  
18  
12  
1
18  
10  
1
The impairment of intangible assets is related to impairment of acquired intellectual property rights of DKK  
1 million and to impairment of sales and marketing software solution of DKK 11 million with no recoverable  
amount after impairment. The impairment is recognised as sales and marketing expenses.  
11  
42  
5
11  
40  
4
Total remuneration to Board of Management  
Remuneration to Board of Directors**  
Total remuneration to Board of Management and Board of Directors  
47  
44  
Employees  
Average number (FTE)  
Number year end (FTE)  
2,492  
2,537  
2,419  
2,447  
*
The expensed costs include DKK 5 million (2020: DKK 3 million) related to adjustment in the share options and performance share  
units expected to vest.  
**The total remuneration to the Board of Directors includes remuneration for participation in the Audit Committee DKK 385,000  
(2020: DKK 385,000), the Remuneration and Nomination Committee DKK 310,000 (2020: DKK 350,000) and the Scientific  
Committee DKK 303,000 (2020: DKK 150,000). The remaining remuneration relates to regular Board of Directors activities.  
   
 
Consolidated financial statements  
Annual report 2021  
ALK  
62  
Section 2 – Results for the year  
2.5 Fees to the ALK Group’s auditors  
2.7 Financial income and expenses  
Amounts in DKKm  
2021  
2020  
Amounts in DKKm  
2021  
2020  
Fees to the auditors appointed at the annual general meeting:  
Audit services  
Other opinions  
Tax advisory services  
Other services  
Interest income  
1
1
5
5
3
-
1
-
3
-
-
Financial income from financial assets measured at amortised cost  
Currency gains, net  
9
-
-
Total financial income  
10  
5
Total  
4
3
Interest expenses*  
23  
23  
30  
30  
Financial expenses from financial liabilities measured  
at amortised cost  
The fee for non-audit services provided by PricewaterhouseCoopers Statsautoriseret  
Revisionspartnerselskab (Denmark) of DKK 1 million (2020: DKK 0.4 million) relates to tax advisory and  
other general financial accounting matters.  
Interest expenses on uncertain tax positions, net  
Currency losses, net  
-
-
4
20  
For information on ALK entities intended to be exempt from local audits of the 2021 accounts, see  
note 5.6.  
Total financial expenses  
23  
54  
*
Includes interest expenses related to leasing of DKK 7 million (2020: DKK 8 million).  
2.6 Other operating items, net  
Accounting policies  
In 2021, other operating items, net includes other operating income of DKK 1 million related to  
numerous minor components.  
Financial items comprise interest receivable and interest payable, the interest element of lease  
payments, realised and unrealised gains and losses on securities, cash, liabilities and foreign currency  
transactions, mortgage amortisation premium/allowance etc. and provisions for uncertain tax  
positions.  
In 2020, other operating items, net included other operating expenses of DKK 1 million related to sale of  
production equipment.  
Interest expenses and income related to uncertain tax positions are recognised on the balance sheet  
as tax liabilities and tax assets respectively upon the receipt of ruling from the tax authorities and  
correspondingly reflected in the income statement as financial items net.  
Accounting policies  
Other operating items comprise income and expenses of a secondary nature relative to the principal  
activities of the ALK Group.  
Interest income and expenses are accrued based on the principal and the effective rate of interest.  
The effective rate of interest is the discount rate to be used on discounting expected future payments  
in relation to the financial asset or the financial liability so that their present value corresponds to the  
carrying amount of the asset or liability, respectively.  
     
 
Consolidated financial statements  
Annual report 2021  
ALK  
63  
Section 2 – Results for the year  
2.8 Income taxes and deferred tax  
Amounts in DKKm  
2021  
2020  
Tax on profit  
Current income tax  
Adjustment of deferred tax  
Prior year adjustments, income tax  
154  
(97)  
3
117  
(38)  
(3)  
Tax on profit for the year  
60  
76  
Profit before tax  
279  
61  
101  
22  
Income tax, tax rate of 22% (2020: 22%)  
Effect of deviation of foreign subsidiaries’ tax rate  
relative to Danish tax rate  
Permanent differences  
Other taxes and adjustments  
11  
(14)  
1
15  
(2)  
46  
Change in valuation of net tax assets  
Prior year adjustments, income tax  
(2)  
3
(2)  
(3)  
Tax on profit for the year  
60  
76  
Tax related to equity comprises an income of DKK 10 million (2020: income of DKK 43 million) and other  
comprehensive income comprises an expense of DKK 9 million (2020: income of DKK 2 million).  
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
64  
Section 2 – Results for the year  
2.8 Income taxes and deferred tax – continued  
Intangible  
assets  
Tangible  
assets  
Current and  
other assets  
Tax losses  
carried forward  
Amounts in DKKm  
Liabilities  
Total  
2021  
Deferred tax  
Carrying amount beginning of year  
Adjustment to prior years’ deferred tax  
Adjustment of receivables from group companies  
Currency adjustments  
Recognised in the income statement, net  
Change in valuation of net tax assets  
Recognised in other comprehensive income, net  
Recognised in equity, net (share-based payments)  
(7)  
3
-
-
(103)  
340  
(4)  
135  
332  
-
(6)  
1
(16)  
-
(4)  
33  
697  
-
(6)  
-
95  
2
(9)  
10  
1
-
(2)  
6
-
-
-
-
1
-
-
125  
-
(16)  
(4)  
-
-
-
2
(5)  
-
-
-
(23)  
Carrying amount year end  
(20)  
(98)  
438  
129  
340  
789  
2020  
Deferred tax  
Carrying amount beginning of year  
Adjustment to prior years’ deferred tax  
Adjustment of receivables from group companies  
Currency adjustments  
Recognised in the income statement, net  
Change in valuation of net tax assets  
Recognised in other comprehensive income, net  
Recognised in equity, net (share-based payments)  
11  
-
-
1
(100)  
(1)  
-
3
(5)  
-
206  
(17)  
-
(1)  
117  
-
117  
19  
-
(2)  
(2)  
2
382  
(1)  
(2)  
(1)  
(55)  
-
616  
-
(2)  
-
36  
2
(19)  
-
-
-
-
-
1
1
2
-
35  
-
8
43  
Carrying amount year end  
(7)  
(103)  
340  
135  
332  
697  
Deferred tax consists of deferred tax assets of DKK 790 million (2020: DKK 697 million) and deferred tax liabilities of DKK 1 million (2020: DKK 0).  
Unrecognised deferred tax assets comprising tax losses carried forward amount to DKK 14 million and primarily relate to US entities (2020: DKK 16 million). The tax losses have no expiry date.  
 
Consolidated financial statements  
Annual report 2021  
ALK  
65  
Section 2 – Results for the year  
2.8 Income taxes and deferred tax – continued  
Accounting policies  
income within a foreseeable future. This includes an assessment of the possibilities to utilise tax losses in  
the joint Danish taxation scheme with the Lundbeck Foundation (Lundbeckfond Invest A/S).  
Tax on the profit for the year comprises the year’s current tax and changes in deferred tax. The  
tax expense relating to the profit/loss for the year is recognised in the income statement, and the  
tax expense relating to items recognised in other comprehensive income and directly in equity,  
respectively, is recognised in other comprehensive income or directly in equity. Exchange rate  
adjustments of deferred tax are recognised as part of the adjustment of deferred tax for the year.  
At each balance sheet date, it is reassessed whether it is likely that there will be sufficient future taxable  
income for the deferred tax asset to be utilised.  
The parent company is included in a joint Danish taxation scheme with the Lundbeck Foundation  
(Lundbeckfond Invest A/S) and its Danish subsidiaries. The tax charge for the year is allocated among  
the jointly taxed companies in proportion to the taxable incomes of individual companies, taking into  
account taxes paid.  
Current tax payable and receivable is recognised in the balance sheet as the expected tax on the  
taxable income for the year, adjusted for tax paid on account.  
The current tax charge for the year is calculated based on the tax rates and rules enacted at the balance  
sheet date.  
Significant accounting estimates and judgements  
Uncertain tax position is recognised for those matters for which the tax determination is uncertain but it  
is considered probable that there will be a future outflow of funds to a tax authority (and a future inflow  
of funds from a tax authority). The uncertain tax positions are measured at the best estimate of the  
amount expected to become payable (and receivable).  
Management is required to make an estimate in the recognition of deferred tax assets. This assessment  
includes estimates of future taxable income in ALK and other members of the joint Danish taxation scheme  
with the Lundbeck Foundation. The forecasts for ALK-Abelló A/S with increased positive results (EBT) is  
based on growth in revenue and earnings driven by SLIT-tablets.  
Deferred tax is measured using the balance sheet liability method on all temporary differences between  
the carrying amount and the tax base of assets and liabilities. However, deferred tax is not recognised  
on temporary differences relating to the initial recognition of goodwill or the initial recognition of a  
transaction, apart from business combinations, and where the temporary difference existing at the date  
of initial recognition affects neither profit/loss for the year nor taxable income.  
At 31 December 2021, the value of the total net deferred tax asset is DKK 789 million (2020: DKK 697  
million). It includes a net deferred tax asset in Denmark related to tax losses carried forward of DKK 328  
million (2020: DKK 322 million).  
Complying with tax rules, when conducting business globally, can be complex as the interpretation of  
legislation and case law may change over time or may not always be clear. Management’s judgements  
are applied to assess the possible effect of exposures and the possible outcome of disputes or  
interpretational uncertainties when transfer pricing disputes with local tax authorities may occur.  
Dialogue with local tax authorities, tax advisors, business plans and knowledge of the business are key  
parameters for Management to estimate the tax assets and liabilities.  
Deferred tax is calculated based on the planned use of each asset and settlement of each liability,  
respectively. Deferred tax is measured using the tax rates and tax rules that, based on legislation  
enacted or in reality enacted at the balance sheet date, are expected to apply in the respective  
countries when the deferred tax is expected to crystallise as current tax. Changes in deferred tax as a  
result of changed tax rates or rules are recognised in the income statement, in other comprehensive  
income or in equity, depending on where the deferred tax was originally recognised. Deferred tax  
related to equity transactions is recognised in equity.  
At 31 December 2021, the ALK Group recognises uncertain tax positions as part of non-current tax and  
deferred tax. The actual outcome may deviate and depends on the result of litigation and settlements  
with the relevant local tax authorities.  
Deferred tax assets, including the tax value of tax loss carry-forwards, are recognised in the balance sheet  
at the value at which the asset is expected to be realised, either through a set-off against deferred tax  
liabilities or as net assets to be offset against future positive taxable income. Deferred tax assets including  
the tax value of tax losses are recognised if it is probable that it can be utilised against future taxable  
 
Consolidated financial statements  
Annual report 2021  
ALK  
66  
Section 3 – Operating assets and liabilities  
3.1 Intangible assets  
Patents,  
Patents,  
trademarks  
Software and rights  
trademarks  
Software and rights  
Amounts in DKKm  
Goodwill  
Other  
Total  
Amounts in DKKm  
Goodwill  
Other  
Total  
2021  
2020  
Cost beginning of year  
Currency adjustments  
Additions  
Disposals  
Transfer to/from other groups  
475  
4
-
396  
1
8
(17)  
32  
231  
5
1
(1)  
-
245  
1
36  
(1)  
(32)  
1,347  
11  
45  
(19)  
-
Cost beginning of year  
Currency adjustments  
Additions  
Disposals  
Transfer to/from other groups  
483  
(8)  
400  
(1)  
3
(7)  
1
240  
(9)  
251  
(2)  
23  
(26)  
(1)  
1,374  
(20)  
26  
(33)  
-
-
-
-
-
-
-
-
-
Cost year end  
479  
420  
236  
249  
1,384  
Cost year end  
475  
396  
231  
245  
1,347  
Amortisation and impairment  
beginning of year  
Currency adjustments  
Amortisation for the year  
Amortisation on disposals  
Impairment for the year, cf. note 2.3  
Amortisation and impairment  
beginning of year  
Currency adjustments  
Amortisation for the year  
Amortisation on disposals  
Impairment for the year, cf. note 2.3  
23  
(1)  
-
-
-
313  
-
25  
(17)  
11  
214  
4
7
(1)  
1
173  
723  
4
41  
(18)  
12  
22  
1
-
-
-
299  
(2)  
23  
(7)  
-
208  
(7)  
13  
-
-
163  
(1)  
11  
(22)  
22  
692  
(9)  
47  
(29)  
22  
1
9
-
-
Amortisation and impairment  
year end  
Amortisation and impairment  
year end  
22  
332  
88  
225  
11  
183  
66  
762  
622  
23  
313  
83  
214  
17  
173  
72  
723  
624  
Carrying amount year end  
457  
Carrying amount year end  
452  
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
67  
Section 3 – Operating assets and liabilities  
3.1 Intangible assets – continued  
Goodwill  
Acquired intellectual property rights  
Goodwill is related to acquisition of companies in previous years and has been subject to an impairment  
test, which has been submitted to the Audit Committee for subsequent approval by the Board of  
Directors. The impairment test performed in 2021 revealed no need for impairment of goodwill.  
Acquired intellectual property rights in the form of patents, brands, licenses, software, customer base  
and similar rights are measured at cost less accumulated amortisation and impairment.  
The cost of software includes costs of instalment and direct salaries.  
Goodwill has been tested at an aggregated level for ALK as one cash-generating unit. In the calculation  
of the value in use of the cash-generating unit, future free net cash flow is estimated based on Board  
of Directors-approved budget (2022) and financial forecasts (2023-2025) in line with the ALK Group’s  
strategy.  
Intangible assets with determinable useful lives are amortised on a straight-line basis over the  
expected useful lives of the assets, typically not exceeding 10 years. If the actual useful life is shorter  
than either the remaining life or the contract period, the asset is amortised over this shorter useful  
life. The carrying amounts are reviewed at the balance sheet date to determine whether there are  
any indications of impairment. If such indications are found, the recoverable amount of the asset is  
calculated to determine any need for an impairment write-down and, if so, the amount of the write-  
down.  
The budget and the forecast plans are based on specific future business initiatives for which the risks  
relating to key parameters have been assessed and recognised in estimated future free cash flows.  
The key parameters in the calculation of the value in use are revenue, earnings, working capital,  
capital expenditure, discount rate and the preconditions for the terminal value. Estimates are based on  
historical data and expectations on future changes in the markets and products. These expectations  
are based on a number of assumptions including expected product launches, volume forecasts, price  
information and profitability of both the ALK Group’s business as well as geographical expansions.  
Intangible assets with indeterminable useful lives are not amortised, but are tested for impairment at  
least once a year. To the extent that the carrying amount of the assets exceeds the recoverable amount,  
the assets are written down to this lower amount.  
See note 3.2 for moreinformation on assessment, recognition and reversal of impairment.  
For financial years after the four year budget and forecast period (2022-2025), the cash flows in the  
most recent period have been extrapolated adjusted for a growth factor of 1.5% (2020: 1.5%) during the  
terminal period. The discount rate used is 9% pre-tax and 7% after tax (2020: 10% pre-tax and 7.5%  
after tax).  
Other intangible assets  
Other intangible assets includes individual minor development projects running for short-term periods,  
including software development projects, which fulfil the requirements in IFRS. The measurement  
follows the same rules as described above for acquired intellectual property rights.  
The calculated value in use shows that future earnings and cash flows fully support the carrying amount  
of total net assets, including goodwill.  
Significant accounting estimates and judgements  
Accounting policies  
The assessment of whether goodwill is impaired requires a determination of the value in use of the  
cash-generating unit. The determination of the value in use requires estimates of the expected future  
cash flow of the cash-generating unit and a reasonable discount rate.  
Goodwill  
On initial recognition, goodwill is measured and recognised as the excess of the cost of the acquired  
company over the fair value of the acquired assets, liabilities and contingent liabilities.  
At 31 December 2021, the carrying amount of goodwill is DKK 457 million (2020: DKK 452 million).  
On recognition of goodwill, the goodwill amount is allocated to the ALK Group’s cash-generating  
unit. The ALK Group is considered as one cash-generating unit as the individual companies and  
business units in the ALK Group cannot be evaluated separately due to the value-adding processes are  
generated across corporations and entities.  
Goodwill is not amortised, but is tested for impairment at least once a year. To the extent that the  
carrying amount of goodwill exceeds the recoverable amount, goodwill is written down to this lower  
amount. Impairment of goodwill is not reversed.  
 
Consolidated financial statements  
Annual report 2021  
ALK  
68  
Section 3 – Operating assets and liabilities  
3.2 Property, plant and equipment  
Property,  
plant and  
Property,  
plant and  
Other  
Other  
Land and  
Plant and fixtures and equipment  
Land and  
Plant and fixtures and equipment  
Amounts in DKKm  
buildings* machinery equipment in progress  
Total  
Amounts in DKKm  
buildings* machinery equipment in progress  
Total  
2021  
2020  
Cost beginning of year  
Currency adjustments  
Additions  
Disposals  
Transfer to/from other groups  
1,493  
41  
942  
21  
18  
(25)  
67  
256  
2
12  
(13)  
15  
360  
7
176  
(1)  
(126)  
3,051  
71  
252  
(40)  
-
Cost beginning of year  
Currency adjustments  
Additions  
Lease contract modifications  
Disposals  
1,533  
(58)  
15  
807  
(23)  
15  
244  
(4)  
9
-
(14)  
21  
421  
(9)  
167  
-
(18)  
(201)  
3,005  
(94)  
206  
1
(67)  
-
46  
(1)  
44  
1
(1)  
3
-
(34)  
177  
Transfer to/from other groups  
Cost year end  
1,623  
1,023  
272  
416  
3,334  
Cost year end  
1,493  
942  
256  
360  
3,051  
Depreciation and impairment  
beginning of year  
Currency adjustments  
Depreciation for the year  
Depreciation of disposals  
Impairment for the year, cf. note 2.3  
572  
9
85  
(1)  
-
500  
12  
77  
(24)  
7
184  
2
19  
(13)  
-
91  
-
-
(1)  
1
1,347  
23  
181  
(39)  
8
Depreciation and impairment  
beginning of year  
Currency adjustments  
Depreciation for the year  
Depreciation of disposals  
Impairment for the year, cf. note 2.3  
510  
(13)  
76  
(1)  
-
482  
(15)  
66  
(33)  
-
183  
(3)  
18  
(14)  
-
91  
-
-
(16)  
16  
1,266  
(31)  
160  
(64)  
16  
Depreciation and impairment  
year end  
665  
958  
572  
451  
192  
80  
91  
1,520  
1,814  
Depreciation and impairment  
year end  
572  
921  
500  
442  
184  
72  
91  
1,347  
1,704  
Carrying amount year end  
325  
Carrying amount year end  
269  
of which financing costs  
Value of land and buildings  
subject to mortgages  
-
of which financing costs  
Value of land and buildings  
subject to mortgages  
-
186  
197  
*
Land and buildings include buildings on land leased from Scion DTU A/S, Hørsholm in Denmark. The leases are open-ended and  
the estimated lease terms are 15 years. See also note 3.3.  
*
Land and buildings include buildings on land leased from Scion DTU A/S, Hørsholm in Denmark. The leases are open-ended and  
the estimated lease terms are 15 years. See also note 3.3.  
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
69  
Section 3 – Operating assets and liabilities  
3.2 Property, plant and equipment – continued  
Accounting policies  
If the asset does not generate any cash flows independently of other assets, the recoverable amount is  
calculated for the smallest cash-generating unit that includes the asset.  
Land and buildings, plant and machinery and other fixtures and equipment are measured at cost less  
accumulated depreciation and impairment. Land is not depreciated.  
The recoverable amount is calculated as the higher of the fair value less costs to sell and the value in  
use of the asset or the cash-generating unit, respectively. In determining the value in use, the estimated  
future cash flows are discounted to their present value, using a discount rate reflecting current market  
assessments of the time value of money as well as risks that are specific to the asset or the cash-  
generating unit and which have not been taken into account in the estimated future cash flows.  
Cost comprises the purchase price and any costs directly attributable to the acquisition and any  
preparation costs incurred until the date when the asset is available for use.  
The depreciation base is cost less the estimated residual value at the end of the useful life. The residual  
value is determined as the amount the company expects to obtain for the asset less costs of disposal.  
If the recoverable amount of the asset or the cash-generating unit is lower than the carrying amount, the  
carrying amount is written down to the recoverable amount. For the cash-generating unit, the write-  
down is allocated in such a way that goodwill amounts are written down first, and any remaining need  
for write-down is allocated to other assets in the unit, although no individual assets are written down to  
a value lower than their fair value less costs to sell.  
The cost of an asset is divided into smaller components that are depreciated separately if such  
components have different useful lives.  
Tangible assets are depreciated on a straight-line basis over their estimated useful lives as follows:  
Buildings  
Plant and machinery  
Other fixtures and equipment  
25-50 years  
5-10 years  
5-10 years  
Impairment write-downs are recognised in the income statement. If write-downs are subsequently  
reversed as a result of changes in the assumptions on which the calculation of the recoverable amount  
is based, the carrying amount of the asset or the cash-generating unit is increased to the adjusted  
recoverable amount, not, however, exceeding the carrying amount that the asset or cash-generating  
unit would have had, had the write-down not been made.  
Depreciation methods, useful lives and residual values are reassessed once a year.  
Impairment  
The carrying amounts of tangible assets are reviewed at the balance sheet date to determine whether  
there are any indications of impairment. If such indications are found, the recoverable amount of the  
asset is calculated to determine any need for an impairment write-down and, if so, the amount of the  
write-down.  
 
Consolidated financial statements  
Annual report 2021  
ALK  
70  
Section 3 – Operating assets and liabilities  
3.3 Leases  
Specification of right-of-use assets:  
Specification of right-of-use assets:  
Other  
Land and fixtures and  
Other  
Land and fixtures and  
Amounts in DKKm  
buildings*  
equipment  
Total  
Amounts in DKKm  
buildings*  
equipment  
Total  
2021  
2020  
Cost beginning of year  
Currency adjustments  
Additions  
295  
6
34  
2
-
-
297  
6
34  
Cost beginning of year  
Currency adjustments  
Additions  
293  
(9)  
10  
1
2
-
-
295  
(9)  
10  
1
Lease contract modifications  
-
Cost year end  
335  
2
-
337  
Cost year end  
295  
2
297  
Depreciation beginning of year  
Currency adjustments  
Depreciation for the year  
69  
2
38  
1
-
-
70  
2
38  
Depreciation beginning of year  
Currency adjustments  
35  
(2)  
1
-
36  
(2)  
Depreciation for the year  
36  
-
36  
Depreciation year end  
109  
1
110  
Depreciation year end  
69  
1
70  
Carrying amount year end  
226  
1
227  
Carrying amount year end  
226  
1
227  
*
Land and buildings include buildings on land leased from Scion DTU A/S, Hørsholm in Denmark. The leases are open-ended and  
the estimated lease terms are 15 years.  
*
Land and buildings include buildings on land leased from Scion DTU A/S, Hørsholm in Denmark. The leases are open-ended and  
the estimated lease terms are 15 years.  
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
71  
Section 3 – Operating assets and liabilities  
3.3 Leases – continued  
Leases in the income statement  
Amounts in DKKm  
Accounting policies  
2021  
2020  
Lease liabilities  
Lease assets are recognised at the commencement date of the contract if it is or contains a lease.  
Lease assets are recognised at cost less accumulated depreciation and impairment. Cost is defined as  
the lease liability adjusted for any lease payments made at or before the commencement date. Lease  
assets are depreciated on a straight-line basis over the lease term.  
Expenses from short-term leases  
1
19  
38  
7
1
19  
36  
8
Expenses from low-value assets (including cars)  
Depreciation of right-of-use assets  
Interest expenses on lease liabilities  
On initial recognition, lease liabilities are measured as the present value of future payments. The lease  
payments contain fixed payments less any lease incentives receivable and variable lease payments  
that depend on an index or a rate.  
Total  
65  
64  
Cash outflow related to lease agreements was DKK 41 million (2020: DKK 38 million).  
On subsequent recognition, lease liabilities are measured at amortised cost. The difference between  
the present value and the nominal value of lease payments is recognised in the income statement over  
the term of the lease as a finance charge.  
If the interest rate cannot be determined in the agreement, the lease payments are discounted using  
the ALK Group’s incremental borrowing rate adjusted for the functional currency and length of the lease  
term. The lease liability is remeasured if or when the future payment or lease term changes.  
Short term lease expenses and low value assets are not recognised as part of lease liabilities. They are  
recognised in the income statement when incurred as an operating expense.  
 
Consolidated financial statements  
Annual report 2021  
ALK  
72  
Section 3 – Operating assets and liabilities  
3.4 Inventories  
Amounts in DKKm  
2021  
2020  
The net realisable value of inventories is calculated as the expected selling price less completion costs  
and costs incurred in making the sale.  
Raw materials  
Work in progress  
Manufactured goods and goods for resale  
245  
432  
527  
209  
438  
446  
A minor part of ALK’s raw materials inventory contains biological assets from agricultural activities. Due  
to missing market on which a fair value can be established these products are not valuated.  
Total  
1,204  
1,093  
Significant accounting estimates and judgements  
Amount of write-down of inventories during the year  
Amount of reversal of write-down of inventories during the year*  
40  
15  
45  
10  
The valuation of inventories includes Management’s assessment of the saleability of the finished goods,  
and the quality of raw materials to be used in the production process. If the expected sales price less  
any completion costs and costs to execute sales (net realisable value) of inventories is lower than the  
carrying amount, the inventories are written down to net realisable value. When assessing salability  
and net realisable value, Management uses estimates for future sales and related costs.  
Total cost of materials included in cost of sales  
Net carrying amount of inventory not expected to be sold in following year  
396  
209  
357  
225  
*
Reversal of provision for slow moving items, sold in 2021.  
End of 2021, the write-down of inventories to net realisable value amounted to DKK 97 million (2020:  
DKK 70 million).  
Accounting policies  
Further, work in progress and manufactured goods and goods for resale are measured at cost including  
indirect production costs. The indirect production costs are measured using a standard cost method.  
This is reviewed regularly to ensure reliable measurement of employee costs, capacity utilisation, cost  
drivers and other relevant factors. When including the indirect productions costs for capitalisation,  
Management makes estimates about cost of production, standard cost variances, cost drivers and  
capacity utilisation. Changes in these parameters may have a significant impact on the gross margin  
and the overall valuation of work in progress and manufactured goods and goods for resale.  
Inventories are measured at cost determined under the FIFO method or net realisable value where this  
is lower.  
Cost comprises raw materials, goods for resale, and direct payroll costs as well as fixed and  
variable production overheads. Variable production overheads comprise indirect materials and  
payroll costs and are allocated based on predetermined costs of the goods actually produced. Fixed  
production overheads comprise maintenance of and depreciation on the machines, factory buildings  
and equipment used in the manufacturing process as well as the cost of factory management and  
administration. Fixed production overheads are allocated based on the normal capacity of the  
production plant.  
End of 2021, the indirect production costs capitalised under inventories amounted to DKK 406 million  
(2020: DKK 377 million).  
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
73  
Section 3 – Operating assets and liabilities  
3.5 Trade receivables  
Days past due  
Not due <180 days 180-360 >360 days  
Accounting policies  
On initial recognition, receivables are measured at fair value, subsequently at amortised cost.  
Amounts in DKKm  
Total  
Expected credit losses are measured based on historical data adjusted by forward-looking information.  
Forward-looking information includes assessment of the probability of default as well as consideration  
of various external sources of actual and economic information that is reasonable and supportable  
without undue cost or effort.  
2021  
Average expected credit loss rate  
Trade receivables (gross)  
Loss allowance  
1%  
519  
5
6%  
68  
4
20%  
5
50%  
2
594  
11  
1
1
ALK recognises expected credit losses that result from default events possible within the whole asset  
life. Risk related to trade receivables is managed in ALK locally by entities, based on an individual  
assessment. Loss allowance for doubtful trade receivables is also based on an individual assessment  
of the receivables. ALK has not implemented a global provision matrix due to different characteristics  
related to receivables across the ALK Group. Loss allowance are calculated based on variables, e.g.  
probability-weighted amount (based on historical realised losses), the time value of money, additional  
supportable information, including an individual assessment of each customer/customer group.  
Trade receivables (net)  
514  
64  
4
1
583  
Loss allowance:  
Balance beginning of year  
Change in allowances during the year  
Realised losses during the year  
15  
(1)  
(3)  
An impairment gain or loss is recognised in the income statement.  
Loss allowance, year end  
11  
Receivables are written down when information indicates severe financial difficulties and that there is  
no reasonable expectation of recovery. Financial assets written off may still be subject to enforcement  
activities. Any recoveries made are recognised in the income statement.  
2020  
Average expected credit loss rate  
Trade receivables (gross)  
Loss allowance  
1%  
475  
5
8%  
71  
6
14%  
7
50%  
6
559  
15  
1
3
3.6 Prepayments  
Trade receivables (net)  
470  
65  
6
3
544  
Amounts in DKKm  
2021  
2020  
Loss allowance:  
Balance beginning of year  
Change in allowances during the year  
Realised losses during the year  
12  
6
(3)  
Clinical trials, cf. note 2.2  
Other  
240  
74  
218  
47  
Total  
314  
265  
Loss allowance, year end  
15  
Accounting policies  
Prepayments are recognised as an asset and comprise incurred costs relating to subsequent financial  
years. Prepayments are measured at cost.  
   
 
Consolidated financial statements  
Annual report 2021  
ALK  
74  
Section 3 – Operating assets and liabilities  
3.7 Pensions and similar liabilities  
The ALK Group has entered into defined contribution plans as well as defined benefit plans.  
Amounts in DKKm  
2021  
2020  
In defined contribution plans, the ALK Group is obliged to pay a certain contribution to a pension fund  
or the like but bears no risks regarding the future development in interest, inflation, mortality, disability  
rates etc. regarding the amount to be paid to the employee.  
The principal assumptions used for the actuarial valuations  
Discount rate range of 0.4% - 1.1% (weighted average rate)  
Expected future rate of salary increase range of 1% - 2.5%  
(weighted average rate)  
1.0%  
2.4%  
0.7%  
2.4%  
The ALK Group sponsors defined benefit plans for qualifying employees of its subsidiaries in Germany,  
France and Switzerland. The defined benefit plans guarantee employees a certain level of pension  
benefits for life. The pension is based on seniority and salary at the time of retirement. The ALK Group  
bears the risks regarding the future development in interest, inflation, mortality, disability rates etc.  
regarding the amount to be paid to the employee.  
Assumed life expectations on retirement age for current pensioners  
(years based on weighted average)*:  
Males  
Females  
21.1  
24.4  
21.1  
24.8  
Assumed life expectations on retirement age for current employees  
(future pensioners) (years based on weighted average)*:  
Amounts in DKKm  
2021  
2020  
Males  
Females  
22.4  
26.3  
22.3  
26.2  
Costs related to defined contribution plans  
Costs related to defined benefit plans  
91  
24  
86  
24  
Sensitivity analysis:  
Significant actuarial assumptions for determining the  
defined benefit obligation  
Discount rate, effect in case of increase in range of 0.25% - 1%**  
Discount rate, effect in case of decrease in range of 0.25% - 1%**  
Salary, effect in case of 0.25% - 0.5% increase**  
Salary, effect in case of 0.25% - 0.5% decrease**  
Life expectancy, effect in case of increase by 1 year*  
Life expectancy, effect in case of decrease by 1 year*  
Total  
115  
110  
Present value of funded pension obligations  
Fair value of plan assets  
25  
(17)  
20  
(13)  
(42)  
50  
(43)  
56  
Funded pension obligations, net  
8
7
4
5
(4)  
11  
(5)  
12  
Present value of unfunded pension obligations  
246  
268  
Pension obligations  
254  
275  
(11)  
(12)  
Anniversary liabilities  
Other liabilities*  
11  
59  
12  
58  
Movements in the present value of the defined benefit obligation  
in the current year  
Opening defined benefit obligation  
Current service costs  
Actuarial (gains)/losses arising from experience adjustments  
Benefits paid  
20  
2
-
2
1
20  
2
(1)  
(1)  
-
Pension obligations and similar liabilities, year end  
324  
345  
*
Other liabilities include liability related to the transition period for the Danish Holiday Act of DKK 59 million (2020: DKK 58 million).  
Plan assets consist of assets placed in pension companies. Assets are placed in investments classified  
as other assets than shares, bonds and property by the pension companies, and are not measured at  
quoted prices.  
Currency translation adjustment  
Closing defined benefit obligation  
25  
20  
*
Based on national statistics for mortality.  
The weighted average duration of the pension obligations is 19.24 years (2020: 19.64 years).  
**Based on actuarial reports with different rates.  
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
75  
Section 3 – Operating assets and liabilities  
3.7 Pensions and similar liabilities – continued  
Amounts in DKKm  
2021  
2020  
The expected contribution for 2022 for the defined benefit plans is DKK 12 million (2021: DKK 12  
million).  
Movements in the fair value of the plan assets in the current year  
Opening fair value of plan assets  
Contribution from plan participants  
Benefits paid  
The most recent actuarial valuations of the defined benefit liability were carried out by external  
independent actuary agents at 31 December 2021.  
13  
2
2
13  
1
(1)  
Accounting policies  
Closing fair value of plan assets (fully invested in insurance contracts)  
17  
13  
The ALK Group has entered into pension agreements and similar agreements with some of the ALK  
Group’s employees.  
Movements in present value of unfunded pension obligations  
in the current year  
Opening present value of unfunded pension obligations  
Other adjustments  
Current service costs  
268  
(12)  
7
257  
-
8
In respect of defined contribution plans, the ALK Group pays in fixed contributions to independent pension  
funds etc. The contributions are recognised in the income statement during the period in which the  
employee renders the related service. Payments due are recognised as a liability in the balance sheet.  
Interest costs  
2
2
7
(1)  
(2)  
(3)  
In respect of defined benefit plans, the ALK Group is required to pay an agreed benefit in connection  
with the retirement of the employees covered by the plan, e.g. in the form of a fixed amount or a  
percentage of the salary at retirement.  
Actuarial (gains)/losses from changes in financial assumptions  
Actuarial (gains)/losses arising from experience adjustments  
Actuarial (gains)/losses arising from demographic adjustments  
Benefits paid  
(15)  
(1)  
-
(3)  
For defined benefit plans, an annual actuarial assessment is made of the net present value of future  
benefits to which the employees have earned the right through their past service for the ALK Group and  
which will have to be paid under the plan. The Projected Unit Credit Method is applied to determine net  
present value.  
Closing present value of unfunded pension obligations  
246  
268  
Amount recognised as staff expenses in the income statement  
Current service costs  
Net interest expense  
10  
2
10  
2
The net present value is calculated based on assumptions of the future development of salary, interest,  
inflation, mortality and disability rates.  
Total  
12  
12  
The net present value of pension liabilities is recognised in the balance sheet, after deduction of the  
fair value of any assets attached to the plan, as either plan assets or pension liabilities, depending on  
whether the net amount is an asset or a liability, as described below.  
Amount recognised in comprehensive income in respect  
of defined benefit plans  
If the assumptions made with respect to discount factor, inflation, mortality and disability are changed,  
or if there is a discrepancy between the expected and realised return on plan assets, actuarial gains  
or losses occur. These gains and losses concerning previous financial years are recognised in other  
comprehensive income.  
Actuarial (gains)/losses  
(16)  
3
Total  
(16)  
3
 
Consolidated financial statements  
Annual report 2021  
ALK  
76  
Section 3 – Operating assets and liabilities  
3.8 Provisions  
3.9 Other payables  
Restructuring  
Other  
Amounts in DKKm  
2021  
2020  
Amounts in DKKm  
programs*  
provisions**  
Total  
Rebates and commissions  
Salaries, holiday payments etc.  
Clinical trials, cf. note 2.2  
VAT and other taxes  
Other  
294  
239  
179  
85  
243  
242  
135  
109  
151  
2021  
Provisions beginning of year  
Provisions made during the year  
Used during the year  
-
10  
-
3
-
(1)  
3
10  
(1)  
153  
Total  
950  
880  
Provisions, year end  
10  
2
12  
Provisions are recognised as follows:  
Current liabilities  
Accounting policies  
10  
2
12  
Other payables are recognised as a current liability and comprise costs due in the subsequent financial  
year. Other payables are measured at amortised cost.  
Provisions, year end  
10  
2
12  
2020  
Provisions beginning of year  
Used during the year  
19  
(19)  
4
(1)  
23  
(20)  
Provisions, year end  
-
3
3
Provisions are recognised as follows:  
Current liabilities  
-
3
3
Provisions, year end  
-
3
3
*
Provision made during 2021 for restructuring programs of DKK 10 million relates to restructuring of ALK’s Spanish entity ALK-  
Abelló S.A. Provision for restructuring programs of DKK 19 million used during 2020 related to restructuring of ALK’s Italian  
entity ALK-Abelló S.p.A (DKK 16 million) and restructuring of production in Denmark (DKK 3 million).  
** Other provisions include a provision for sales in Italy of DKK 2 million (2020: DKK 3 million).  
Accounting policies  
Provisions are recognised when, as a consequence of a past event during the financial year or previous  
years, the ALK Group has a legal or constructive obligation, and it is likely that settlement of the  
obligation will require an outflow of the ALK Group’s financial resources. Provisions are measured as the  
best estimate of the costs required to settle the obligations at the balance sheet date. Provisions with an  
expected term of more than a year after the balance sheet date are measured at present value.  
   
 
Consolidated financial statements  
Annual report 2021  
ALK  
77  
Section 3 – Operating assets and liabilities  
3.10 Contingent liabilities and commitments  
Contingent liabilities  
In the ordinary course of business, the ALK Group is involved in certain claims, disputes etc. In the  
opinion of Management, settlement or continuation of pending claims and other disputes will have no  
material impact on the ALK Group’s financial position.  
The ALK Group operates in a wide variety of jurisdictions, in some of which the tax law is subject to  
varying interpretations and potentially inconsistent enforcement. As a result, there can be practical  
uncertainties in applying tax legislation to the ALK Group’s activities. Whilst the ALK Group considers  
that it operates in accordance with applicable tax law, there are potential tax exposures in respect of its  
operations, the impact of which cannot be reliably estimated, but could be material.  
Joint taxation scheme  
ALK-Abelló A/S is included in a joint Danish taxation scheme with the Lundbeck Foundation  
(Lundbeckfond Invest A/S) and its Danish subsidiaries. The Danish companies are joint and several  
liable for the joint taxation liability. The joint taxation liability covers income taxes and withholding taxes  
on dividends, royalties and interest. The joint taxation liability is capped at an amount equal to the share  
of the capital of the company directly or indirectly owned by the ultimate parent company. The total tax  
obligation under the joint Danish taxation scheme is shown in the financial statements of the Lundbeck  
Foundation (Lundbeckfond Invest A/S).  
Commitments  
Land and buildings provided as security vis-à-vis for mortgage debt amount to DKK 186 million  
(2020: DKK 197 million) out of mortgage debt of DKK 240 million (2020: DKK 258 million).  
Change of control  
The ALK Group’s credit facilities are subject to standard change of control clauses according to which  
the lender has the right to cancel the commitment and demand repayment of outstandings.  
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
78  
Section 4 – Capital structure and financing  
4.1 Share capital and earnings per share  
2021  
Nominal  
2020  
Nominal  
2021  
2020  
value  
value  
Treasury shares  
Units  
(DKKm)  
Units  
(DKKm)  
Treasury shares beginning of year (B-shares), units  
Sale of treasury shares, units  
212,873  
(64,345)  
240,694  
(27,821)  
Treasury shares year end (B-shares), units  
148,528  
212,873  
Share capital  
The share capital consists of:  
A shares (nominal value of DKK 10)  
AA shares (nominal value of DKK 10)  
B shares (nominal value of DKK 10)  
920,760  
92,076  
10,128,360  
9
1
101  
920,760  
92,076  
10,128,360  
9
1
101  
Proportion of share capital year end  
Nominal value year end  
Market value year end  
1.3%  
1.5  
509  
1.9%  
2.1  
532  
Total  
11,141,196  
111  
11,141,196  
111  
Earnings per share  
The calculation of earnings per share is based on the following:  
Net profit (DKKm)  
Number in units:  
Average number of issued shares  
Average number of treasury shares  
219  
25  
Each A and AA share carries 10 votes, whereas each B share carries 1 vote. AA shares no longer held by  
individuals or legal entities other than the Lundbeck Foundation (Lundbeckfond Invest A/S) or companies  
which are group affiliated with the Lundbeck Foundation, cf. the definition of groups in section 6 of the  
Danish Companies Act, or in the event that a company which holds AA shares is no longer group affiliated  
with the Lundbeck Foundation, such AA shares shall be transferred to the B share capital.  
11,141,196 11,141,196  
(171,509) (225,139)  
Average number of shares used for calculation of  
earnings per share  
10,969,687 10,916,057  
79,810 78,328  
According to a resolution passed by the parent company at the annual general meeting, the parent  
company is allowed to purchase treasury shares, up to 10% of the share capital. The parent company  
has purchased treasury shares in connection with the issuance of share-based incentive plans. All  
shares are paid in.  
Average dilutive effect of outstanding share options  
Average number of shares used for calculation  
of diluted earnings per share  
11,049,497 10,994,385  
Earnings per share (EPS) (DKK)  
19.96  
19.82  
2.29  
2.27  
Earnings per share, diluted (DEPS) (DKK)  
Accounting policies  
Acquisition and sales sums arising on the purchase and sale of treasury shares and dividends on  
treasury shares are recognised directly in retained earnings under equity.  
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
79  
Section 4 – Capital structure and financing  
4.2 Financial risks and financial instruments  
Financial risk management policy  
fluctuations. The greatest exposure is to USD and in 2021, 15% (2020: 15%) of the revenue was  
As a result of operations, investments and financing, the ALK Group is exposed to exchange and interest  
rate changes. ALK-Abelló A/S manages the ALK Group’s financial risks centrally and coordinates the  
ALK Group’s cash management, including the raising of capital and investment of excess cash. The  
ALK Group complies with a policy, approved by the Board of Directors, to maintain a low risk profile,  
ensuring that the ALK Group is only exposed to foreign exchange rate risk, liquidity risk, interest rate  
risk, and credit risk in connection with its commercial activities.  
denominated in USD. The sales are not deemed to be exposed to EUR due to Denmark’s participation in  
the European Exchange Rate Mechanism.  
The ALK Group is exposed to exchange rate risks when intercompany balances and net assets of foreign  
subsidiaries are translated into DKK. In accordance with the ALK Group’s accounting policies, such  
currency translation adjustments are recognised in the income statement and in other comprehensive  
income, respectively.  
Capital structure  
The ALK Group manages its capital to ensure that all entities will be able to continue as going concern  
while maximising the return to stakeholders through the optimisation of the debt and equity balances.  
The capital structure of the ALK Group consists of net debt and equity. The dividend policy of the ALK  
Group is to distribute maximum possible dividend to ALK-Abelló A/S.  
No exchange rate hedge contracts were open at 31 December 2021 or 31 December 2020.  
Sensitivity to a 10% increase in USD exchange rate  
The table below shows the estimated effect of a 10% increase in the USD exchange rate on revenue,  
EBITDA and equity levels, respectively. A decrease in the exchange rates will have a corresponding  
adverse effect. In the sensitivity analysis, data for revenue and EBITDA are based on current short-term  
expectations and data for equity are based on actual equity at 31 December 2021.  
The ALK Group’s Risk Committee reviews the capital structure annually. As a part of this review, the  
committee considers the cost of capital and the risks associated with each class of capital.  
Foreign exchange rate risk  
Foreign exchange rate risk arises due to imbalances between revenue and expenses in each individual  
currency. Foreign exchange rate exposure relating to future transactions and assets and liabilities is  
evaluated and hedged through matching of payments received and paid in the same currency. This  
serves to limit the impact on the financial results of any exchange rate fluctuations. The exchange  
rate exposure relating to net investments in foreign subsidiaries is not hedged by forward exchange  
contracts. In case it is evaluated to be relevant, the ALK Group hedges significant exchange rate  
exposures regarding future sales and purchase of goods in the coming six months in accordance with  
the ALK Group’s policy.  
Amounts in DKKm  
Revenue  
EBITDA  
Equity  
31 December 2021  
USD  
approx. +65  
approx. +60  
approx. 0  
approx. 0  
approx. +110  
approx. +90  
31 December 2020  
The general objective of the ALK Group’s foreign exchange risk management is to limit and delay  
any adverse impact of exchange rate fluctuations on earnings and cash flows and thus increase  
the predictability of the financial results. The most significant financial risk relates to exchange rate  
USD  
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
80  
Section 4 – Capital structure and financing  
4.2 Financial risks and financial instruments – continued  
Net positions  
Liquidity risk  
In connection with the ALK Group’s ongoing financing of operations, including refinancing, efforts are  
made to ensure adequate and flexible liquidity. This is guaranteed by placing free funds in credit-  
worthy, liquid, interest bearing instruments of relatively short durations in accordance with the ALK  
Group’s policy.  
Amount  
hedged  
Net  
position  
Amounts in DKKm  
Cash Receivables Liabilities  
31 December 2021  
The liquidity risk is considered to be minimal due to the ALK Group’s current capital structure.  
DKK  
USD  
EUR  
GBP  
SEK  
(9)  
67  
75  
4
3
54  
69  
123  
342  
12  
39  
135  
(957)  
(176)  
(1,093)  
(21)  
-
-
-
-
-
-
(897)  
14  
(676)  
(5)  
23  
105  
Liquidity exposure  
Revaluation/payment date  
Carrying  
amount  
Total  
cash flow*  
Within  
1 year  
From  
1-5 years  
After  
5 years  
(19)  
(84)  
Amounts in DKKm  
Other  
Total  
194  
720  
(2,350)  
-
(1,436)  
31 December 2021  
31 December 2020  
Mortgage debt and bank loans  
Trade payables  
Lease liabilities  
466  
115  
244  
973  
472  
115  
269  
973  
245  
115  
43  
76  
-
134  
-
151  
-
92  
-
DKK  
USD  
EUR  
GBP  
SEK  
18  
65  
150  
5
7
53  
124  
88  
345  
20  
28  
109  
(936)  
(144)  
(1,243)  
(16)  
-
-
-
-
-
-
(794)  
9
(748)  
9
21  
105  
Other financial liabilities  
973  
Financial liabilities  
1,798  
1,829  
1,376  
210  
243  
(14)  
(57)  
Other  
31 December 2020  
Total  
298  
714  
(2,410)  
-
(1,398)  
Mortgage debt and bank loans  
Trade payables  
704  
74  
746  
74  
29  
74  
535  
-
182  
-
Lease liabilities  
Other financial liabilities  
239  
901  
270  
901  
38  
901  
126  
-
106  
-
Financial liabilities  
1,918  
1,991  
1,042  
661  
288  
*
Total cash flow includes interests.  
 
Consolidated financial statements  
Annual report 2021  
ALK  
81  
Section 4 – Capital structure and financing  
4.2 Financial risks and financial instruments – continued  
Interest rate risk  
An increase in the interest rate of 1 percentage point on mortgage debt and bank loans would decrease  
net profit and equity by approximately DKK 4 million (2020: decrease of DKK 5 million). An increase in  
the interest of 1 percentage point on cash would increase net profit and equity by approximately DKK 2  
million (2020: increase of DKK 3 million).  
The ALK Group does not hedge its interest rate exposure, as this is not considered to be financially viable.  
Concerning the ALK Group’s financial assets and financial liabilities, the earlier of the contractual  
revaluation and redemption date is applied. Effective interest rates are stated on the basis of the  
current level of interest rates on the balance sheet date.  
Credit risk  
The ALK Group’s primary credit exposure is related to trade receivables and cash. The ALK Group has  
no major exposure relating to one single customer or business partner. According to the ALK Group’s  
policy for assuming credit exposure, all customers and business partners are credit rated regularly.  
Trade receivables are monitored at the local level and are distributed across a number of markets and  
customers. Therefore, the credit risk is considered to be low. For more information, see note 3.5.  
Interest rate exposure  
Carrying  
amount  
Fixed/  
floatinginterest rate  
Effective  
Amounts in DKKm  
Currency Expiry date  
31 December 2021  
Embedded derivative financial instruments  
The ALK Group has made a systematic review of contracts that might contain terms that would make  
the contract or parts thereof a derivative financial instrument. The review did not lead to recognition of  
derivative financial instruments relating to the contracts.  
Cash  
194  
Various  
Floating (1.09)-(0.10)  
Interestbearing assets  
194  
Mortgage debt  
Lease liabilities  
Bank loans  
240  
244  
226  
DKK  
2035  
Floating  
Fixed  
0.2  
2.0  
0.4-0.5  
Various 2022-2033  
EUR  
2022  
Fixed  
Interestbearing liabilities  
710  
31 December 2020  
Cash  
298  
Various  
DKK  
Various 2021-2033  
EUR 2022  
Floating (1.40)-(0.05)  
Interestbearing assets  
298  
Mortgage debt  
Lease liabilities  
Bank loans  
258  
239  
446  
2035  
Floating  
Fixed  
0.2  
2.0  
1.8  
Fixed  
Interestbearing liabilities  
943  
 
Consolidated financial statements  
Annual report 2021  
ALK  
82  
Section 4 – Capital structure and financing  
4.2 Financial risks and financial instruments – continued  
Categories of financial instruments  
Measurement and fair value hierarchy  
Revaluation/payment date  
Amounts in DKKm  
2021  
2020  
Fair  
value  
Within  
1 year  
From  
1-5 years  
After  
5 years  
Amounts in DKKm  
Financial assets  
31 December 2021  
Financial assets measured  
at amortised cost  
Receivables from group companies  
Receivables  
Trade receivables  
Other receivables  
Cash  
Impairment method  
12m ECL  
12m ECL  
Lifetime ECL (simplified approach)  
12m ECL  
Mortgage debt  
Bank loans  
243  
226  
18  
226  
73  
-
152  
-
12  
29  
583  
82  
20  
30  
544  
96  
Total  
469  
244  
73  
152  
31 December 2020  
194  
298  
Total  
900  
988  
Mortgage debt  
Bank loans  
263  
446  
18  
-
73  
446  
172  
-
Financial liabilities  
Total  
709  
18  
519  
172  
Financial liabilities measured at amortised cost  
All financial assets and liabilities are measured at cost or amortised cost. The carrying amounts for  
these approximate fair value.  
Mortgage debt  
Bank loans  
Lease liabilities  
Trade payables  
Other payables  
240  
226  
244  
115  
950  
258  
446  
239  
74  
Fair value for mortgage debt is measured by level 1 input (quoted prices in active markets) from the  
fair value hierarchy and fair value for bank loans is measured by level 2 input (inputs other than quoted  
markets that are observable) from the fair value hierarchy.  
880  
Total  
1,775  
1,897  
No financial derivatives were used in 2021 or 2020.  
Financial resources  
In 2021, the ALK Group extended its financial resources with a DKK 1,500 million credit facility which  
runs until the end of 2024. By the end of 2021, DKK 223 million was drawn.  
 
Consolidated financial statements  
Annual report 2021  
ALK  
83  
Section 4 – Capital structure and financing  
4.2 Financial risks and financial instruments – continued  
Accounting policies  
Financial assets  
On initial recognition, investments and other financial assets are measured at cost, corresponding  
to fair value. They are subsequently measured at fair value either through the income statement or  
through comprehensive income.  
Financial liabilities  
Other financial liabilities, including bank loans and trade and other payables, are on initial recognition  
measured at fair value. The liabilities are subsequently measured at amortised cost.  
Debt  
Trade payables, other payables, including sales discounts and rebates as well as debt to public  
authorities etc., are measured at amortised cost.  
Mortgage debt  
Mortgage debt is recognised on the raising of a loan at cost, equalling fair value of the proceeds  
received, and net of transaction costs incurred. Subsequently, mortgage debt is measured at amortised  
cost.  
 
Consolidated financial statements  
Annual report 2021  
ALK  
84  
Section 5 – Other disclosures  
5.1 Share-based payments  
The ALK Group has established long-term equity-based incentive plans linked to the creation of  
shareholder value and the fulfilment of strategic goals. The plans are established for the members of  
Board of Management and other key employees, reward long-term value creation and align to interests  
of the shareholders.  
on the grant date. The plan was conditional upon strategic key performance indicators being attained.  
Based on the financial results for 2020, the KPI achievements exceeded their targets increasing the  
granted number of performance shares and share options by 100%. However, the overall payout of the  
plan on the vesting date for the performance shares and on the exercise date for the share options can  
never exceed a total value of 300% of the recipient’s 2018 annual base salary.  
The incentive plans consist of share options and performance share units that are considered  
sufficiently covered by treasury shares.  
Expensed in the income statement:  
Amounts in DKKm  
2021  
2020  
Ordinary incentive plans  
The share options entitle the holder to acquire one existing B share of DKK 10 nominal value in the  
company per share option and the performance share units entitle the holder to receive one existing B  
share per performance share unit free of charge.  
Cost for the year regarding share-based payments is recognised as follows:  
Cost of sales  
Research and development expenses  
Sales and marketing expenses  
Administrative expenses  
5
7
11  
12  
1
3
6
9
10  
1
The vesting period for both share options and performance share units is three years after grant.  
Vesting is conditional upon certain targets being met and upon the participant not having resigned.  
Target achievement is met upon fulfilment of strategic key performance indicators. In case performance  
is below the threshold there will be no units vesting, and if above target, a multiplier is applied that can  
increase the vesting by up to 100%.  
Financial expenses  
Total  
36  
29  
In 2021, the total cost of share-based payments included a financial expense of DKK 1 million due to  
the exercise and cash settlement of share options (2020: DKK 1 million). The total cost included DKK 11  
million related to adjustment in the share options and performance share units expected to vest (2020:  
DKK 5 million).  
The exercise of share options is possible in the trading windows following the release of annual and  
interim reports conditional upon the share option holder not having resigned at the time of exercise.  
For performance share units, the final transfer of ownership takes place at vesting three years after the  
grant.  
Special incentive plan 2018  
ALK’s special incentive plan was a one-time scheme designed to implement ALK’s growth strategy and  
consisted of both share options and performance share units with a vesting period of three years.  
The special incentive plan was adopted at the annual general meeting in March 2018 and vested in  
March 2021. The grant value of the plan did not exceed 50% of the Executive’s 2018 annual base salary  
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
85  
Section 5 – Other disclosures  
5.1 Share-based payments – continued  
Specification of outstanding share options and performance share units:  
Share options  
Other key  
employees  
units  
Performance share units  
Board of  
Management  
units  
Weighted average  
exercise price  
DKK  
Board of  
Management  
units  
Other key  
employees  
units  
Total  
units  
Total  
units  
2021  
Outstanding at 1 January  
Additions  
Exercised/settled  
Expired  
89,758  
29,811  
(55,279)  
0
59,338  
25,494  
(46,323)  
(100)  
149,096  
55,305  
(101,602)  
(100)  
972  
1,129  
844  
13,444  
6,250  
(13,183)  
0
35,426  
10,799  
(20,316)  
0
48,870  
17,049  
(33,499)  
0
795  
Outstanding at 31 December  
64,290  
38,409  
102,699  
1,187  
6,511  
25,909  
32,420  
Total number of vested share options  
Average remaining life at year end (years)  
Exercise prices at year end (DKK)  
49,247  
2.1  
802-2,320  
2020  
Outstanding at 1 January  
Additions  
Exercised/settled  
Cancellations  
98,263  
13,253  
(21,758)  
-
62,293  
12,130  
(15,085)  
-
160,556  
25,383  
(36,843)  
-
904  
1,332  
954  
-
13,569  
3,024  
(3,149)  
-
36,257  
12,528  
(12,774)  
(585)  
49,826  
15,552  
(15,923)  
(585)  
Outstanding at 31 December  
89,758  
59,338  
149,096  
972  
13,444  
35,426  
48,870  
Total number of vested share options  
Average remaining life at year end (years)  
Exercise prices at year end (DKK)  
32,467  
2.6  
783-1,372  
The Board of Directors decided for one trading window in 2021 to settle share options by cash and a total of 66,986 share options were exercised and total cash payments amounted to DKK 62 million. For three trading  
windows the Board of Directors decided to settle share options by shares and a total of 34,616 share options were exercised.  
The Board of Directors decided for two trading windows in 2020 to settle share options by cash and a total of 24,945 share options were exercised and total cash payments amounted to DKK 24 million. For two trading  
windows the Board of Directors decided to settle share options by shares and a total of 11,898 share options were exercised.  
 
Consolidated financial statements  
Annual report 2021  
ALK  
86  
Section 5 – Other disclosures  
5.1 Share-based payments – continued  
Outstanding share options and performance share units have the following characteristics:  
Fair value of share options and performance share units granted:  
Share options  
Share options  
Average  
Performance share units  
Fair value at grant date is measured in accordance with the Black & Scholes model for valuation of share  
options, using the following assumptions:  
exercise  
price  
Exercise  
period  
(years)  
2021  
Plan  
2020  
Plan  
Vested  
as per  
Vested  
as per  
Plan  
Units  
DKK  
Units  
Average share price (DKK)  
Expected exercise price (DKK)  
Expected volatility rate, based on the historical volatility  
Expected option life  
Expected dividend per share  
2,320  
2,498  
36% p.a.  
4 years  
-
1,372  
1,477  
34% p.a.  
4 years  
-
2016 Plan  
2018 Plan  
2018 Plan – special plan*  
2019 Plan  
2020 Plan  
3,660  
5,789  
39,798  
23,738  
18,677  
11,037  
1,113  
802  
802  
1,141  
1,460  
2,439  
1 Mar 2019  
1 Mar 2021  
1 Mar 2021  
1 Mar 2022  
1 Mar 2023  
1 Mar 2024  
4
2
2
2
2
2
13,241 1 Mar 2022  
11,314 1 Mar 2023  
7,865 1 Mar 2024  
Risk-free interest rate  
Calculated fair value of granted share options (DKK)  
-0.49% p.a. -0.01% p.a.  
576 328  
2021 Plan  
Outstanding at  
31 December  
102,699  
32,420  
Performance share units  
Performance share units have been granted at DKK 2,320 per share (2020: DKK 1,372 per share).  
* The payout upon exercise of the outstanding options cannot exceed DKK 18 million according to the conditions of the plan.  
Accounting policies  
Share-based incentive plans (equity-settled share-based payments), which comprise share options  
and performance share units, are measured at the grant date at fair value and recognised in the income  
statement under the respective functions over the vesting period and offset in equity.  
The fair value of share options is determined using the Black & Scholes model. The exercise price is  
equivalent to the average market price of the share for the five trading days immediately preceeding the  
date of grant and is increased by 2.5% p.a. and reduced by dividends paid. The fair value of performance  
share units is determined using the average share price (closing) five days after annual general meeting.  
The ALK Group settles the equity-settled share-based incentive plans in shares. However, the share  
option agreement entitles the ALK Group to demand cash settlement of the options. The ALK Group  
recognises share options, in case of cash settlement, as other liabilities and adjusts to fair value as from  
the time when the ALK Group has an obligation to settle in cash. The ALK Group recognises subsequent  
adjustment to fair value in the income statement under financial income or financial expenses.  
 
Consolidated financial statements  
Annual report 2021  
ALK  
87  
Section 5 – Other disclosures  
5.2 Cash flow  
Adjustment for non-cash items  
Financial reserves  
Amounts in DKKm  
2021  
2020  
Amounts in DKKm  
2021  
2020  
Cash  
Undrawn facilities  
194  
1,277  
298  
600  
Tax on profit  
Financial income and expenses  
Share-based payments  
60  
13  
36  
76  
49  
29  
Total  
1,471  
898  
Depreciation, amortisation and impairment  
Other adjustments*  
242  
49  
245  
63  
In 2021 the ALK Group extended its financial resources with a DKK 1,500 million credit facility which runs  
until the end of 2024. By the end of 2021, DKK 223 million was drawn.  
Total  
400  
462  
*
Other adjustments include non-cash transactions related to the divestment of ALK’s part-share of a formulation production line  
for tablets to production partner Catalent of DKK 33 million (2020: DKK 37 million). In 2020, other adjustments further included  
provision for transition period for the Danish Holiday Act of DKK 39 million.  
Accounting policies  
Cash flow  
Changes in working capital  
The cash flow statement of the ALK Group is presented using the indirect method and shows cash flows  
from operating, investing and financing activities as well as cash at the beginning and at the end of the  
financial year.  
Amounts in DKKm  
2021  
2020  
Change in inventories  
Change in receivables and prepayments  
Change in short-term payables  
(84)  
(5)  
61  
(69)  
(159)  
74  
The cash effect of acquisitions and divestments is shown separately under cash flows from investing  
activities. In the cash flow statement, cash flows concerning acquired companies are recognised from  
the date of acquisition, while cash flows concerning divested companies are recognised until the date of  
divestment.  
Total  
(28)  
(154)  
Cash flows from operating activities are stated as net profit, adjusted for non-cash operating items and  
changes in working capital, less the income tax paid and plus net financial items.  
Reconciliation of liabilities arising from financing activities  
Amounts in DKKm  
2021  
2020  
Cash flows from investing activities comprise payments in connection with acquisition and divestment of  
companies and financial assets as well as purchase, development, improvement and sale of intangible  
and tangible assets.  
Liabilities from financing activities at 1 January  
Proceeds from borrowings  
Repayment of borrowings  
New leases  
Installments of lease liabilities  
Exchange rate adjustments  
943  
226  
(464)  
34  
(32)  
3
990  
-
(19)  
11  
(30)  
(9)  
Cash flows from financing activities comprise changes to the parent company’s share capital and  
related costs as well as the raising and repayment of loans, instalments on interest-bearing debt, lease  
liabilities, purchase of treasury shares, and settlement of share options and payment of dividends.  
Total  
710  
943  
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
88  
Section 5 – Other disclosures  
5.2 Cash flow – continued  
5.4 Events after the reporting period  
No events have occured after the reporting period, that influence the evaluation of the consolidated  
financial statements.  
Cash flows in currencies other than the functional currency are recognised in the cash flow statement  
using average exchange rates for the individual months if these are a reasonable approximation of the  
actual exchange rates at the transaction dates. If this is not the case, the actual exchange rates for the  
specific days in questions are used.  
5.5 Approval of financial statements  
Cash comprise cash subject to an insignificant risk of changes in value less any overdraft facilities that  
are an integral part of the ALK Group’s cash management.  
The financial statements were approved by the Board of Directors and authorised for issue on  
8 February 2022.  
5.3 Related parties  
Related party exercising control  
ALK-Abelló A/S is controlled by the Lundbeck Foundation (Lundbeckfond Invest A/S) domiciled  
in Copenhagen, Denmark, which holds 67.2% of the total number of votes in ALK Abelló A/S. The  
remaining shares are widely held. ALK-Abelló A/S is parent company, and ultimate parent for the ALK  
Group is the Lundbeck Foundation (Lundbeckfond Invest A/S, incorporated in Denmark).  
Other related parties comprise ALK’s Board of Management and Board of Directors, companies in  
which the majority shareholder exercises control, and such companies’ subsidiaries, in this case  
H. Lundbeck A/S and Falck A/S and their subsidiaries.  
Transactions and balances  
Transactions and balances with the parent company’s majority shareholder:  
ALK-Abelló A/S received DKK 26 million (2020: DKK 121 million) concerning outstanding company  
tax from the Lundbeck Foundation (Lundbeckfond Invest A/S). The company tax relates to ALK-  
Abelló A/S, ALK-Abelló Nordic A/S, and ALK e-com A/S.  
Receivables from group companies to ALK-Abelló A/S relate to outstanding company tax of DKK 12  
million (2020: DKK 20 million) covering ALK-Abelló A/S, ALK-Abelló Nordic A/S, and ALK e-com A/S.  
Transactions with key management personnel consist of remuneration and exercise of share options,  
see notes 2.4 and 5.1 of the consolidated financial statements.  
No other transactions have taken place during the year with Board of Directors, Board of Management,  
major shareholders or other related parties.  
     
 
Consolidated financial statements  
Annual report 2021  
ALK  
89  
Section 5 – Other disclosures  
5.6 List of companies in the ALK Group  
Activity  
Production  
Sales & Distribution  
Research & Development  
Services  
Percentage of  
Entity  
Country shares owned  
Activity  
Parent company  
ALK-Abelló A/S  
Denmark  
Subsidiaries by geographical area  
Europe  
ALK-Abelló Allergie-Service GmbH  
ALK-Abelló Nordic A/S  
ALK-Abelló Nordic A/S (branch)  
ALK-Abelló Nordic A/S (branch)  
ALK-Abelló Nordic A/S (branch)  
ALK e-com A/S  
ALK S.A.S.  
ALK-Abelló Arzneimittel GmbH  
ALK-Abelló B.V.*  
ALK-Abelló Sp. z o.o.  
ALK Slovakia s.r.o.  
ALK Slovakia s.r.o. – od šteˇpny´ zavod (branch)  
ALK-Abelló S.A.  
ALK-Abelló S.p.A.  
ALK AG (In liquidation)  
ALK-Abelló AG  
ALK-Abelló Ltd.  
Austria  
Denmark  
Finland  
Norway  
Sweden  
Denmark  
France  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
100%  
Percentage of  
Country shares owned  
Entity  
Activity  
North America  
ALK-Abelló Pharmaceuticals, Inc.  
ALK-Abelló, Inc.  
OKC Allergy Supplies Inc.  
ALK-Abelló, Source Materials, Inc.  
OKC Crystal Laboratory Inc.  
Canada  
USA  
100%  
100%  
100%  
100%  
100%  
Germany  
Netherlands  
Poland  
Slovakia  
Czech Republic  
Spain  
USA  
USA  
USA  
International markets  
Italy  
ALK-Abelló A/S (branch)  
ALK (Shanghai) Medical Technology Company Limited (Dormant) China  
ALK ilaç ve Alerji Ürünleri Ticaret Turkey  
China  
100%  
100%  
100%  
Switzerland  
Switzerland  
United Kingdom  
*
Exemption for local audit of the 2021 accounts under the ruling of the Article 2:403 of the Dutch Civil Code is intended –  
Btw-nr. NL005302766B01  
 
 
Consolidated financial statements  
Annual report 2021  
ALK  
90  
Definitions  
Term  
Definitions  
Alternative Performance Measures  
Gross margin – %  
Gross profit x 100 / Revenue  
Amounts in DKKm  
2021  
2020  
EBITDA margin – %  
Net asset value per share  
Invested capital  
EBITDA x 100 / Revenue  
EBITDA reconciliation to net profit  
Net profit  
Tax on profit/(loss)  
Financial income  
Financial expenses  
219  
60  
(10)  
23  
25  
76  
(5)  
54  
Net asset value / Number of shares end of period  
Intangible assets, tangible assets, inventories and current receivables  
reduced by liabilities except for mortgage debt and bank loans  
Depreciation, amortisation and impairment  
242  
245  
EBITDA  
534  
395  
Return on equity (ROE) – % Net profit/(loss) for the period x 100 / Average equity  
Net asset value  
Equity  
3,480  
3,153  
Pay-out ratio – %  
Proposed dividend x 100 / Net profit/(loss) for the year  
Net asset value  
3,480  
3,153  
Earnings/(loss) per share  
(EPS)  
Net profit/(loss) for the period / Average number of  
outstanding shares  
Invested capital reconciliation  
Intangible assets  
Tangible assets  
Inventories  
Trade receivables  
Receivables from group companies  
Income tax receivables  
Other receivables  
622  
1,814  
1,204  
583  
624  
1,704  
1,093  
544  
20  
Earnings/(loss) per share  
diluted (DEPS)  
Net profit/(loss) for the period / Average number of  
outstanding shares diluted  
12  
14  
82  
Cash flow per share (CFPS) Cash flow from operating activities / Average number of outstanding  
24  
96  
shares  
Prepayments  
314  
265  
(345)  
(207)  
-
(74)  
(32)  
(1)  
(3)  
(21)  
(880)  
ROIC incl. goodwill – %  
Price earnings ratio (PE)  
Markets  
Operating profit x 100 / Average invested capital incl. goodwill  
Share price / Earnings per share  
Pensions and similar liabilities  
Lease liabilities (non-current)  
Deferred income (non-current)  
Trade payables  
Lease liabilities (current)  
Deferred income (current)  
Provisions (current)  
(324)  
(207)  
(42)  
(115)  
(37)  
(4)  
(12)  
(23)  
(950)  
Geographical markets (based on customer location):  
Europe comprises the EU, UK, Norway and Switzerland  
North America comprises the USA and Canada  
International markets comprise Japan, China and all other countries  
Income tax payables (current)  
Other payables  
The definitions are aligned with generally accepted financial ratios applied by financial analysts.  
The definitions are part of the Management’s review.  
Invested capital  
2,931  
2,807  
 
 
Parent company financial statements  
Annual report 2021  
ALK  
91  
Parent company  
financial statements  
Financial statements  
Notes  
Income statement  
Balance sheet  
92  
93  
94  
95  
1
2
Accounting policies  
95  
12  
13  
14  
15  
Mortgage debt and bank loans 100  
Revenue and segment  
information  
Pensions and similar liabilities  
Lease liabilities  
101  
101  
96  
96  
Statement of changes in equity  
Notes  
3
4
Staff costs  
Income tax payables to  
group companies  
Special items  
97  
101  
5
Financial income and expenses  
Income taxes  
97  
16  
Contingent liabilities and  
commitments  
101  
101  
6
97  
17  
18  
19  
Related parties  
7
Intangible assets  
Property, plant and equipment  
Deferred tax  
98  
Fees to ALK-Abelló A/S’ auditors 102  
8
98  
Proposed appropriation of  
net profit  
9
99  
102  
10  
11  
Investments in subsidiaries  
Inventories  
100  
100  
20  
Events after the reporting period 102  
 
 
Parent company financial statements  
Annual report 2021  
ALK  
92  
Income statement  
Amounts in DKKm  
Note  
2021  
2020  
Revenue  
Cost of sales  
2
3,4  
2,296  
1,029  
2,015  
1,011  
Gross profit  
1,267  
1,004  
Research and development expenses  
Sales and marketing expenses  
Administrative expenses  
3,4  
3,4  
3,18  
577  
248  
113  
-
508  
195  
101  
Other operating items, net  
(2)  
Operating profit (EBIT)  
329  
198  
Income from investments in subsidiaries  
Financial income  
Financial expenses  
10  
5
5
15  
22  
23  
831  
14  
49  
Profit before tax (EBT)  
343  
994  
Tax on profit/(loss)  
6
30  
105  
Net profit  
19  
313  
889  
 
 
Parent company financial statements  
Annual report 2021  
ALK  
93  
Balance sheet – Assets  
Balance sheet – Equity and liabilities  
31 Dec.  
2021  
31 Dec.  
2020  
31 Dec.  
2021  
31 Dec.  
2020  
Amounts in DKKm  
Note  
Amounts in DKKm  
Note  
Non-current assets  
Equity  
Intangible assets  
Intangible assets  
Share capital  
Retained earnings  
Capitalised development costs  
111  
3,090  
3
111  
2,771  
4
7
127  
119  
127  
119  
Tangible assets  
Land and buildings  
Plant and machinery  
Other fixtures and equipment  
Property, plant and equipment in progress  
Total equity  
3,204  
2,886  
8
8
8
8
312  
244  
47  
324  
263  
35  
Liabilities  
194  
151  
Mortgage debt  
Bank loans  
Pensions and similar liabilities  
Lease liabilities  
Deferred income  
12  
12  
13  
14  
222  
-
58  
120  
42  
115  
240  
446  
57  
121  
-
797  
773  
Other non-current assets  
Investments in subsidiaries  
Receivables from group companies  
Receivables  
Deferred tax assets  
Income tax receivables  
10  
9
1,058  
1,987  
23  
298  
122  
1,062  
998  
27  
326  
109  
Income tax payables to group companies  
15  
111  
Non-current liabilities  
557  
975  
3,488  
4,412  
2,522  
3,414  
Mortgage debt  
Bank loans  
12  
12  
18  
223  
57  
1,154  
10  
18  
-
31  
841  
8
Total non-current assets  
Current assets  
Trade payables  
Payables to group companies  
Lease liabilities  
Deferred income  
Other payables  
14  
Inventories  
11  
420  
53  
338  
56  
361  
80  
770  
71  
2
367  
-
Trade receivables  
Receivables from group companies  
Other receivables  
Prepayments  
332  
Current liabilities  
1,831  
1,230  
271  
233  
Total liabilities  
2,388  
2,205  
1,138  
42  
1,515  
162  
Cash  
Total equity and liabilities  
5,592  
5,091  
Total current assets  
1,180  
1,677  
Total assets  
5,592  
5,091  
 
 
Parent company financial statements  
Annual report 2021  
ALK  
94  
Statement of changes in equity  
Reserve for  
capitalised  
Share  
capital  
Retained development  
Proposed  
dividend  
Total  
equity  
Amounts in DKKm  
earnings  
costs  
2021  
Equity at 1 January  
Appropriated from net profit  
Share-based payments  
Share options settled  
Sale of treasury shares  
111  
2,771  
313  
36  
(72)  
31  
4
-
-
-
-
-
-
-
-
-
-
-
2,886  
313  
36  
(72)  
31  
-
-
-
-
-
-
Transfer to/(from) legal reserves  
Tax related to items recognised directly in equity  
1
10  
(1)  
-
-
10  
Other transactions  
-
319  
(1)  
-
318  
Equity at 31 December  
111  
3,090  
3
-
3,204  
See note 4.1 in the consolidated financial statements for information on treasury shares.  
 
 
Parent company financial statements  
Annual report 2021  
ALK  
95  
Notes  
1
Accounting policies  
company’s approval in general  
meeting of the dividend of the company  
in question less any write-downs at the  
investments.  
Where the recoverable amount of the  
investments is lower than cost, the  
investments are written down to this  
lower value.  
General  
The financial statements of the parent  
company ALK-Abelló A/S for the period  
1 January to 31 December 2021 have  
been prepared in accordance with the  
Danish Financial Statements Act for  
large reporting class D enterprises.  
In addition, cost is written down to  
the extent that dividends distributed  
exceed the accumulated earnings in the  
company since the acquisition date. In  
the event of indications of impairment,  
an impairment test is performed of  
investments in subsidiaries.  
Balance sheet  
Acquisition of activities from  
subsidiaries  
The financial statements are presented  
in Danish kroner (DKK), which is also  
the functional currency of the company.  
Acquisition of activities from  
subsidiaries is accounted for using  
the purchase method. On initial  
recognition, goodwill is measured  
and recognised as the excess of the  
consideration transferred exceeding  
the fair value of the net assets acquired  
at the acquisition date.  
Capitalisation of development costs  
A reserve for capitalisation of  
The accounting policies are unchanged  
from last year.  
development costs less deferred tax is  
recognised in the statement of equity.  
The reserve contains development  
costs, less amortisation/impairment  
losses, and less deferred tax,  
The parent company’s accounting  
policies for recognition and  
measurement are in accordance with  
the ALK Group’s accounting policies  
with the following exceptions:  
Goodwill  
Goodwill is measured at cost less  
accumulated amortisation and  
impairment. Amortisation is calculated  
using the straight-line method over the  
expected useful life, estimated at 10  
years. This estimate was made on the  
basis of estimated useful lives of the  
assets acquired.  
capitalised since 1 January 2016.  
Other accounting  
information  
Income statement  
Results of investments in  
subsidiaries  
Cash flow statement  
As allowed under section 86 (4) of the  
Danish Financial Statements Act, no  
cash flow statement is presented, as  
this is included in the consolidated cash  
flow statement.  
Dividends from investments in  
subsidiaries are recognised in the  
parent company’s financial statements  
when the right to the dividend finally  
vests, typically at the date of the  
Investments in subsidiaries  
Investments in subsidiaries are  
measured at cost.  
   
 
Parent company financial statements  
Annual report 2021  
ALK  
96  
Notes  
2
Revenue and segment information  
3
Staff costs  
Amounts in DKKm  
2021  
2020  
Amounts in DKKm  
2021  
2020  
Sale of goods  
Royalties  
Services  
2,215  
1,953  
58  
Wages and salaries  
Pensions  
Other social security costs, etc.  
Share-based payments  
654  
59  
12  
609  
57  
22  
81  
-
4
24  
20  
Total revenue  
2,296  
2,015  
Total  
749  
708  
Europe  
International markets  
1,969  
327  
1,735  
280  
Staff costs are allocated as follows:  
Cost of sales  
Research and development expenses  
Sales and marketing expenses  
Administrative expenses  
295  
219  
94  
300  
198  
77  
Total revenue  
2,296  
2,015  
96  
89  
Included in the cost of assets  
45  
44  
Total  
749  
708  
Remuneration to Board of Management and Board of Directors:  
See note 2.4 and 5.1 in the consolidated financial statements  
Employees  
Average number (FTE)  
Number year end (FTE)  
913  
954  
855  
873  
   
 
Parent company financial statements  
Annual report 2021  
ALK  
97  
Notes  
4
Special items  
6
Income taxes  
Special items include impairment of assets of DKK 9 million (2020: DKK 24 million) of which DKK 2 million  
is related to intangible assets (2020: DKK 22 million) and DKK 7 million is related to tangible assets  
(2020: DKK 2 million). Further, special items include impairment of investments in subsidiaries of DKK 4  
million (2020: DKK 0).  
Amounts in DKKm  
2021  
2020  
Current income tax  
Adjustment of deferred tax  
Prior year adjustments, income tax  
Prior year adjustments, deferred tax  
(11)  
41  
3
28  
79  
(2)  
-
The impairment of intangible assets of DKK 2 million is related to impairment of software. In the income  
statement, the impairment of intangible assets is recognised as sales and marketing expenses. The  
impairment of tangible assets of DKK 7 million is related to impairment of plant and machinery. In  
the income statement, the impairment of tangible assets is recognised with DKK 6 million as cost of  
sales and DKK 1 million as research and development expenses. The impairment of investments in  
subsidiaries includes DKK 4 million impairment of ALK Abelló A/S’ investment in its subsidiary in Turkey.  
(3)  
Total  
30  
105  
Profit before tax  
343  
994  
In 2020, the impairment of intangible assets included DKK 13 million relating to impairment of acquired  
intellectual property rights and DKK 9 million relating to impairment of software projects in progress.  
In the income statement, the impairment of intangible assets was recognised with DKK 19 million in  
research and development expenses and DKK 3 million as cost of sales. The impairment of tangible  
assets included DKK 2 million related to impairment of production equipment in progress. In the income  
statement, the impairment of tangible assets was recognised as cost of sales.  
Income tax, tax rate of 22%  
Non-taxable income  
Non-deductible expenses  
Prior year adjustments, income tax  
Prior year adjustments, deferred tax  
Other taxes and adjustments  
75  
(22)  
9
3
(3)  
(32)  
219  
(199)  
9
(2)  
-
78  
For the assets where ALK estimates that there is a recoverable amount, such amount was determined  
based on the fair value less cost to sell or the value in use of the respective asset.  
Tax on profit for the year  
30  
105  
5
Financial income and expenses  
Amounts in DKKm  
2021  
2020  
Interest on receivables from group companies  
Other interest income  
12  
4
10  
4
Currency gain, net  
6
-
Total financial income  
22  
14  
Other interest expenses*  
Currency loss, net  
23  
-
29  
20  
Total financial expenses  
23  
49  
*
In 2021, other interest expenses include net interest related to uncertain tax positions of DKK 3 million (2020: income of DKK 7  
million) and DKK 3 million related to lease interest expenses (2020: expense of DKK 3 million).  
     
 
Parent company financial statements  
Annual report 2021  
ALK  
98  
Notes  
7
Intangible assets  
8
Property, plant and equipment  
Patents, Develop-  
trademarks ment  
cost* Software progress  
Property,  
plant and  
Plant and fixtures and equipment  
buildings machinery equipment in progress  
Assets in  
Other  
Amounts in DKKm Goodwill and rights  
2021  
2020  
Land and  
Amounts in DKKm  
2021  
2020  
Cost beginning  
of year  
Additions  
Disposals  
867  
69  
-
-
14  
9
-
280  
7
(2)  
40  
27  
(9)  
1,270  
43  
(11)  
1,267  
25  
(22)  
Cost beginning of year  
Additions  
Disposals  
611  
11  
(1)  
526  
12  
(18)  
42  
9
-
236  
71  
-
1,415  
103  
(19)  
1,326  
122  
(33)  
-
-
Transfer to/from  
other groups  
Transfer to/from  
other groups  
-
-
-
23  
(23)  
-
-
1
16  
11  
(28)  
-
-
Cost year end  
867  
69  
23  
308  
35  
1,302  
1,270  
Cost year end  
622  
536  
62  
279  
1,499  
1,415  
Amortisation and  
impairment  
beginning of year  
Amortisation  
for the year  
Amortisation  
on disposals  
Impairment for  
the year  
Depreciation and  
impairment beginning  
of year  
Depreciation for the year  
Depreciation of disposals  
Impairment for the year  
867  
67  
1
-
7
2
-
210  
21  
-
-
-
-
1,151  
24  
1,130  
21  
287  
24  
(1)  
263  
40  
(18)  
7
7
8
-
85  
-
-
642  
72  
(19)  
7
614  
57  
(31)  
2
-
-
-
-
-
-
(2)  
(2)  
2
(22)  
22  
Depreciation and  
impairment year end  
310  
292  
244  
15  
47  
85  
702  
797  
642  
773  
-
-
2
Carrying amount  
year end  
Amortisation  
and impairment  
year end  
312  
194  
867  
-
68  
1
9
231  
77  
-
1,175  
127  
1,151  
119  
of which assets held  
under leases*  
Carrying amount  
year end  
125  
-
-
-
125  
186  
127  
197  
14  
35  
Value of land and buildings subject to mortgages  
*
The capitalised development cost relates to development of medical device products where the individual minor development  
projects are running for short-term periods and are subject to limited risk. The development projects are generating economic  
benefits in the form of sale of goods. At 31 December 2021, the capitalised development cost relates to the historical  
development of the adrenaline auto-injector Jext® for the European market. Additions of DKK 9 million relate to development  
projects in progress.  
*
Land and buildings in Denmark include buildings on land leased from Scion DTU A/S, Hørsholm. The leases are open-ended and  
the estimated lease terms are 15 years.  
   
 
Parent company financial statements  
Annual report 2021  
ALK  
99  
Notes  
9
Deferred tax  
Intangible  
assets  
Tangible  
assets  
Current and  
other assets  
Tax losses  
carried forward  
Amounts in DKKm  
Liabilities  
Total  
2021  
Carrying amount beginning of year  
Adjustment to prior years  
Recognised in the income statement, net  
Recognised in equity, net (share-based payments)  
(3)  
(65)  
60  
-
(13)  
(23)  
30  
-
10  
-
304  
-
(22)  
33  
326  
3
(41)  
10  
3
(17)  
-
-
1
-
Carrying amount year end  
(17)  
(64)  
24  
40  
315  
298  
2020  
Carrying amount beginning of year  
16  
(59)  
17  
-
8
31  
-
(1)  
351  
6
(61)  
8
356  
6
(79)  
43  
Adjustment of receivables from group companies  
Recognised in the income statement, net  
Recognised in equity, net (share-based payments)  
-
(19)  
-
-
(6)  
-
35  
-
Carrying amount year end  
(3)  
(65)  
60  
30  
304  
326  
ALK-Abelló A/S is included in a joint Danish taxation scheme with the Lundbeck Foundation (Lundbeckfond Invest A/S) and its Danish subsidiaries.  
ALK-Abelló A/S recognises deferred tax assets including the tax value of tax losses if it is probable that it can be utilised against future taxable income within a foreseeable future. This includes an assessment of the  
possibilities to utilise tax losses in the joint Danish taxation scheme with the Lundbeck Foundation (Lundbeckfond Invest A/S).  
 
 
Parent company financial statements  
Annual report 2021  
ALK  
100  
Notes  
10 Investments in subsidiaries  
12 Mortgage debt and bank loans  
Amounts in DKKm  
2021  
2020  
Amounts in DKKm  
2021  
2020  
Cost beginning of year  
Capital contribution in subsidiaries during the year  
1,470  
-
1,466  
4
Debt to mortgage credit institutions secured by real property  
Mortgage debt is due as follows:  
Within 1 year  
18  
73  
18  
72  
Cost year end  
1,470  
1,470  
From 1-5 years  
After 5 years  
149  
168  
Write-down beginning of year  
Write-down during the year, cf. note 4  
408  
4
408  
-
Total  
240  
258  
Write-down year end  
412  
408  
Bank loans  
Bank loans are due as follows:  
Within 1 year  
From 1-5 years  
Carrying amount year end  
1,058  
1,062  
223  
-
446  
-
-
-
In the income statement, income from investments in subsidiaries amounting to DKK 15 million (2020:  
DKK 831 million) is net amount of DKK 19 million dividends received (2020: DKK 831 million) and DKK 4  
million write-down of investments in subsidiaries (2020: DKK 0).  
After 5 years  
Total  
223  
446  
For an overview of all subsidiaries see note 5.6 in the consolidated financial statements.  
11 Inventories  
Amounts in DKKm  
2021  
2020  
Raw materials  
Work in progress  
Manufactured goods and goods for resale  
102  
284  
34  
75  
255  
31  
Total  
420  
361  
Amount of write-down of inventories during the year  
Amount of reversal of write-down of inventories during the year  
13  
8
4
2
     
 
Parent company financial statements  
Annual report 2021  
ALK  
101  
Notes  
13 Pensions and similar liabilities  
16 Contingent liabilities and commitments  
In December 2021, ALK-Abelló A/S issued a hold-harmless letter to ALK -Abelló Arzneimittel GmbH  
regarding costs under the ongoing tax audits in Germany (unlimited guarantee). The hold-harmless  
letter replaces the letter issued in December 2020.  
Amounts in DKKm  
2021  
2020  
Pensions and similar liabilities expire as follows:*  
Within 1 year  
From 1-5 years  
After 5 years  
-
3
55  
1
2
55  
In January 2022, ALK-Abelló A/S issued a letter of financial support to ALK e-com A/S. The Letter affirms  
Financial support for ALK e-com A/S for a period of at least 12 months from the date of approval of the  
31 December 2021 financial statements.  
Total  
58  
58  
*
Pensions and similiar liabilities relate to the provision for transition period for the Danish Holiday Act.  
Provisions recognised as debt to affiliates have been made to cover such exposures and the mentioned  
possible uncertainties are in addition to what is already provided for.  
For more information on contingent liabilities and commitments, see note 3.10 in the consolidated  
financial statements.  
14 Lease liabilities  
Amounts in DKKm  
2021  
2020  
17 Related parties  
Lease liabilities expire as follows:  
Within 1 year  
From 1-5 years  
10  
41  
79  
8
35  
86  
ALK-Abelló A/S is included in the consolidated financial statements of the Lundbeck Foundation  
(Lundbeckfond Invest A/S, incorporated in Denmark).  
After 5 years  
Total  
130  
129  
ALK-Abelló A/S has had transactions with susidiaries during 2021. All subsidiaries are owned 100%.  
The transactions are eliminated in the consolidated financial statements.  
Transactions with the majority shareholder are disclosed in note 5.3 in the consolidated financial  
statements. Apart from remuneration, no other transactions have taken place during the year with  
Board of Directors, Board of Management, major shareholders or other related parties.  
15 Income tax payables to group companies  
Non-current income tax payables to group companies of DKK 115 million (2020: DKK 111 million) is  
expected to expire between 1 to 5 years.  
Remuneration etc. to Board of Directors and Board of Management  
For information on remuneration and exercise of share options for the ALK Group’s Board of Directors  
and Board of Management, see note 2.4 and 5.1 in the consolidated financial statements.  
         
 
Parent company financial statements  
Annual report 2021  
ALK  
102  
Notes  
18 Fees to ALK-Abelló A/S’ auditors  
19 Proposed appropriation of net profit  
Amounts in DKKm  
2021  
2020  
Amounts in DKKm  
2021  
2020  
Fees to the auditors appointed at the annual general meeting:  
Audit services  
Tax advisory services  
Other services  
Proposed dividend  
Retained earnings  
-
-
2
1
-
2
-
-
313  
889  
Net profit  
313  
889  
Total  
3
2
20 Events after the reporting period  
No events have occured after the reporting period, that influence the evaluation of the parent company  
financial statements.  
     
 
Management’s review  
Annual report 2021  
ALK  
103  
Financial highlights and key ratios by quarter for the ALK Group*(unaudited)  
Q4  
Q3  
Q2  
Q1  
Q4  
Q3  
Q2  
Q1  
Amounts in DKKm  
2021 unaudited unaudited unaudited unaudited  
Amounts in DKKm  
2021 unaudited unaudited unaudited unaudited  
Income statement  
Revenue  
Cost of sales  
Balance sheet  
Total assets  
Invested capital  
Equity  
3,916  
1,520  
631  
1,234  
240  
1
292  
(13)  
279  
219  
534  
1,099  
398  
179  
372  
71  
928  
369  
147  
294  
63  
-
55  
(1)  
54  
37  
868  
362  
172  
291  
52  
1
(8)  
(13)  
(21)  
(21)  
48  
1,021  
391  
133  
277  
54  
5,830  
2,931  
3,480  
5,830  
2,931  
3,480  
5,718  
2,908  
3,314  
5,575  
2,803  
3,249  
5,785  
2,859  
3,323  
Research and development expenses  
Sales and marketing expenses  
Administrative expenses  
Other operating items, net  
Operating profit (EBIT)  
Net financial items  
Profit before tax (EBT)  
Net profit  
Cash flow and investments  
Depreciation, amortisation and impairment  
Cash flow from operating activities  
Cash flow from investing activities  
– of which investment in intangible assets  
– of which investment in tangible assets  
Free cash flow  
-
79  
(5)  
74  
76  
-
242  
468  
(266)  
(45)  
(218)  
202  
57  
158  
(105)  
(23)  
(82)  
53  
69  
99  
(78)  
(11)  
(67)  
21  
56  
84  
(42)  
(4)  
(38)  
42  
60  
127  
(41)  
(7)  
(31)  
86  
166  
6
172  
127  
226  
EBITDA  
136  
124  
Average number of employees (FTE)  
2,492  
2,525  
2,502  
2,481  
2,459  
Information on shares  
Dividend  
Share capital  
Shares in thousands of DKK 10 each  
Share price, end period – DKK  
Net asset value per share – DKK  
-
111  
11,141  
3,430  
312  
-
111  
11,141  
3,430  
312  
-
111  
11,141  
2,698  
297  
-
111  
11,141  
2,992  
292  
-
111  
11,141  
2,410  
298  
Revenue  
(Growth in revenue in local currency %)  
Europe  
– SCIT/SLIT-drops  
– SLIT-tablets  
2,809 (10)  
1,273 (-4)  
1,340 (31)  
196 (-8)  
795 (7)  
366 (-7)  
400 (31)  
29 (-33)  
640 (15)  
293 (4)  
278 (32)  
69 (5)  
621 (14)  
267 (3)  
302 (27)  
52 (12)  
753 (5)  
347 (-11)  
360 (34)  
46 (-19)  
– Other products and services  
Key figures  
Gross margin – %  
EBITDA margin – %  
Earnings per share (EPS) – DKK  
Earnings per share diluted (DEPS) – DKK  
Cash flow per share (CFPS)– DKK  
Share price/Net asset value  
North America  
– SCIT/SLIT-drops  
– SLIT-tablets  
683 (23)  
302 (14)  
120 (42)  
261 (27)  
193 (20)  
86 (11)  
33 (40)  
74 (24)  
169 (23)  
74 (11)  
29 (67)  
66 (26)  
161 (33)  
71 (34)  
31 (59)  
59 (22)  
160 (16)  
71 (4)  
27 (12)  
62 (37)  
61  
14  
20.0  
19.8  
42.7  
11.0  
64  
12  
6.9  
6.9  
14.4  
11.0  
60  
13  
3.4  
3.4  
9.0  
9.1  
58  
6
(1.9)  
(1.9)  
7.7  
62  
22  
11.6  
11.5  
11.6  
8.1  
– Other products and services  
International markets  
– SCIT/SLIT-drops  
– SLIT-tablets  
424 (15)  
80 (1)  
314 (18)  
30 (27)  
111 (6)  
31 (153)  
76 (-11)  
4 (-28)  
119 (51)  
21 (7)  
91 (69)  
86 (-15)  
13 (-48)  
68 (-1)  
5 (-38)  
108 (29)  
15 (-29)  
79 (35)  
14 (200)  
10.3  
*
Management’s review comprises this page as well as pages 1-44 and Financial highlights and key ratios for the ALK Group on  
page 13.  
– Other products and services  
7 (22)  
Definitions: see page 90.  
Total revenue  
– SCIT/SLIT-drops  
– SLIT-tablets  
3,916 (12) 1,099 (9)  
928 (20)  
388 (5)  
398 (41)  
142 (15)  
868 (13) 1,021 (9)  
1,655 (-1)  
1,774 (29)  
487 (10)  
483 (0)  
509 (23)  
107 (-2)  
351 (4)  
401 (23)  
116 (13)  
433 (-10)  
466 (32)  
122 (15)  
– Other products and services  
 
 
ALK-Abelló A/S  
Bøge Allé 6-8  
DK-2970 Hørsholm, Denmark  
CVR no. 63 71 79 16  
Tel. +45 45 74 75 76  
www.alk.net